

Appendix E: Patient Data Listings of Vital Signs

	Page
329 DEP Appendix E.1 Listing of Vital Sign Values by Treatment Group and Patient Intent-to-Treat Population	2
329 DEP Appendix E.2 Listing of Clinically Significant Abnormal Vital Signs by Treatment Group and Parameter Acute Phase	87

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	----- Sitting -----			----- Standing -----			Weight (lbs)	Height (in)
					Systolic (mmHg)	Diastolic (mmHg)	Pulse (bpm)	Systolic (mmHg)	Diastolic (mmHg)	Pulse (bpm)		
329.001.00063	SC	02NOV94	-6, .	0	110	80	72	126	84	88	177.50	70.0
	BL	08NOV94	1, .	0	96	60	66	100	70	80	181.00	
	1	15NOV94	8, .	20	120	60	86	120	60	68	178.00	
	2	22NOV94	15, .	20	124	80	80	122	76	88	180.00	
	3	29NOV94	22, .	20	122	64	80	120	70	104	179.20	
	4	06DEC94	29, .	20	120	70	84	120	76	98	179.70	
	5	13DEC94	36, .	20	100	58	68	108	78	88	183.00	
329.001.00065	SC	07NOV94	-10, .	0	114	70	60	110	64	74	131.00	65.0
	BL	17NOV94	1, .	0	120	68	60	92	64	80	128.00	
	1	21NOV94	5, .	20	110	70	60	118	80	72	126.00	
329.001.00068	SC	01FEB95	-7, .	0	108	74	68	112	84	80	129.00	62.0
	BL	08FEB95	1, .	0	112	80	84	120	86	80	127.00	
	1	15FEB95	8, .	20	116	72	72	122	80	80	128.00	
	2	22FEB95	15, .	20	108	70	82	112	84	88	128.00	
	3	01MAR95	22, .	20	116	78	104	118	80	108	125.50	
	4	08MAR95	29, .	30	110	78	80	120	80	100	127.70	
	5	15MAR95	36, .	40	116	70	84	110	74	98	128.00	
	6	22MAR95	43, .	40	124	80	80	118	84	88	131.00	
	7	29MAR95	50, .	40	110	80	110	116	84	124 H	131.00	
	8	05APR95	57, .	40	120	80	104	114	82	120	131.00	
329.001.00072	SC	07MAR95	-13, .	0	104	70	72	100	70	88	152.00	73.5
	BL	20MAR95	1, .	0	108	68	72	98	60	88	153.50	
	1	27MAR95	8, .	20	90	60	66	88	60	84	151.00	
	2	03APR95	15, .	20	100	60	76	90	60	114	150.00	
	3	10APR95	22, .	20	104	60	72	94	62	88	150.50	
329.001.00121	SC	22MAR95	-13, -69	0	102	62	60	98	60	86	143.50	74.0
	BL	04APR95	1, -56	0	106	60	68	100	60	100	143.50	
	1	11APR95	8, -49	20	104	60	60	106	64	70	141.00	
	2	18APR95	15, -42	20	100	66	64	98	70	80	139.75	
	3	26APR95	23, -34	20	100	68	64	104	62	88	135.50	
	4	02MAY95	29, -28	30	100	60	64	100	64	80	139.00	
	5	09MAY95	36, -21	30	110	70	60	100	70	88	138.70	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.001.00121	6	16MAY95	43, -14	30	98	70	64	104	72	84	139.50	
	7	23MAY95	50, -7	30	100	60	66	108	64	68	138.00	
	8	30MAY95	57, 1	30	98	66	60	100	70	80	138.00	
	12	27JUN95	85, 29	30	108	62	80	110	60	112	143.70	
	16	24JUL95	112, 56	30	100	60	68	96	62	80	142.70	
	20	21AUG95	140, 84	30	108	66	72	100	62	92	144.00	
329.001.00205	SC	29JAN96	-9, .	0	100	70	68	98	68	88	132.30	60.3
	BL	07FEB96	1, .	0	100	66	82	96	70	90	131.00	
	1	14FEB96	8, .	20	100	70	80	100	70	92	132.00	
329.001.00206	SC	12FEB96	-9, .	0	122	80	68	124	86	76	158.00	70.5
	BL	21FEB96	1, .	0	118	76	72	122	86	80	157.50	
	1	28FEB96	8, .	20	112	70	68	118	78	84	155.00	
	2	06MAR96	15, .	20	118	74	66	120	80	72	157.00	
	3	13MAR96	22, .	20	104	70	68	100	68	74	155.50	
	4	20MAR96	29, .	30	108	70	68	112	74	76	160.00	
	5	26MAR96	35, .	40	110	70	80	110	68	96	156.50	
	6	03APR96	43, .	40	110	70	72	106	68	84	156.00	
	7	10APR96	50, .	40	114	68	76	120	70	84	161.00	
	8	17APR96	57, .	30	106	70	78	112	70	92	160.00	
329.002.00055	SC	09JUN94	-15, -70	0	110	70	85	110	75	88	175.00	65.0
	BL	23JUN94	-1, -56	0	115	75	80	120	70	85	174.00	
	1	30JUN94	7, -49	20	104	68	64	110	70	75	174.50	
	2	07JUL94	14, -42	20	105	68	86	90	75	92	175.00	
	3	14JUL94	21, -35	20	100	66	72	100	72	96	173.00	
	4	21JUL94	28, -28	30	102	50	92	98	68	112	171.00	
	5	28JUL94	35, -21	40	102	60	72	100	62	102	168.00	
	6	04AUG94	42, -14	40	98	68	80	94	60	102	169.50	
	7	11AUG94	49, -7	40	92	58	72	94	60	100	169.00	
	8	18AUG94	56, 1	40	90	60	54	90	68	72	166.00	
	12	15SEP94	84, 29	40	94	60	68	92	64	98	170.00	
	16	13OCT94	112, 57	40	100	60	60	104	54	80	171.50	
	20	10NOV94	140, 85	40	112	70	72	104	68	84	173.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00058	SC	08SEP94	-12, -70	0	102	70	88	104	70	92	203.50	62.6
	BL	20SEP94	1, -58	0	102	70	88	104	70	92	203.50	
	1	29SEP94	10, -49	20	100	74	88	94	66	94	198.50	
	2	07OCT94	18, -41	20	110	80	100	102	60	84	195.50	
	3	13OCT94	24, -35	20	102	84	88	100	82	80	196.00	
	4	20OCT94	31, -28	30	100	60	72	98	54	84	197.00	
	5	27OCT94	38, -21	40	104	86	88	100	84	80	199.00	
	6	03NOV94	45, -14	40	102	80	84	100	78	86	195.00	
	7	10NOV94	52, -7	40	100	60	92	102	78	102	194.50	
	8	17NOV94	59, 1	40	110	80	80	112	82	100	194.50	
	12	15DEC94	87, 29	40	100	70	84	100	70	88	194.00	
	16	13JAN95	116, 58	40	120	72	80	122	74	82	190.00	
329.002.00099	SC	23FEB95	-7, -62	0	110	68	70	108	68	80	192.25	67.0
	1	07MAR95	6, -50	20	122	70	70	118	70	90	190.50	
	2	14MAR95	13, -43	20	102	64	64	106	64	60	189.00	
	3	21MAR95	20, -36	20	110	70	80	106	70	80	189.25	
	4	28MAR95	27, -29	20	110	70	64	108	70	64	189.50	
	5	04APR95	34, -22	30	94	66	76	90	68	80	190.00	
	6	11APR95	41, -15	30	108	70	66	104	70	64	188.50	
	7	18APR95	48, -8	40	90	60	90	90	60	95	188.25	
	8	25APR95	55, -1	40	98	60	80	92	60	80	188.75	
	12	23MAY95	83, 28	40	96	60	88	96	60	82	192.00	
	16	27JUN95	118, 63	40	108	60	100	102	56	100	196.00	
	20	01AUG95	153, 98	40	102	68	87	104	70	80	200.00	
	24	31AUG95	183, 128	40	90	58	68	94	62	92	203.00	
	28	28SEP95	211, 156	40	112	70	66	110	72	68	208.00 H	
	32	26OCT95	239, 184	40	108	70	79	110	72	78	207.00 H	
329.002.00102	BL	13APR95	1, -54	0	88	70	80	92	70	84	102.50	60.0
	1	18APR95	6, -49	20	90	50	92	98	58	95	100.50	
	2	25APR95	13, -42	20	88	60	62	92	60	70	101.00	
	3	02MAY95	20, -35	20	102	70	88	98	68	86	100.00	
	4	09MAY95	27, -28	30	98	60	88	92	60	84	103.50	
	5	16MAY95	34, -21	40	94	60	92	98	60	80	102.50	
	6	23MAY95	41, -14	40	92	60	110	96	60	120	101.70	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00102	7	30MAY95	48, -7	40	90	58	86	88	56	90	103.00	
	8	06JUN95	55, 1	40	90	60	100	92	60	90	104.20	
	12	13JUL95	92, 38	40	110	60	86	106	64	100	103.50	
	16	10AUG95	120, 66	40	90	64	84	84	60	88	104.00	
	20	12SEP95	153, 99	40	84	60	80	86	62	74	105.50	
	24	10OCT95	181, 127	40	80	64	80	84	64	80	107.50	
	28	09NOV95	211, 157	40	92	60	100	88	60	92	109.50	
	32	05DEC95	237, 183	30	84	62	80	80	60	86	108.00	
329.002.00105	BL	27JUL95	1, .	0	110	78	62	112	80	84	162.00	69.3
	1	03AUG95	8, .	20	132	70	100	138	78	108	162.50	
	2	10AUG95	15, .	20	122	74	88	112	70	80	161.00	
	3	17AUG95	22, .	20	120	74	80	130	80	82	158.00	
329.002.00106	BL	27JUL95	1, .	0	86	68	72	84	62	90	148.00	68.0
	1	03AUG95	8, .	20	110	60	80	106	60	84	149.50	
	2	08AUG95	13, .	20	102	60	96	102	68	100	154.00	
	3	17AUG95	22, .	20	80	60	68	78	58	75	152.00	
	4	24AUG95	29, .	20	100	64	70	100	60	68	152.00	
	5	31AUG95	36, .	30	98	70	66	100	64	74	153.00	
	6	05SEP95	41, .	40	98	68	64	96	70	78	153.00	
	7	12SEP95	48, .	40	90	64	80	86	64	72	153.00	
329.002.00242	SC	26JAN96	-12, -70	0	130	80	92	120	70	88	166.48	65.0
	1	14FEB96	8, -51	20	100	70	88	105	65	92	162.07	
	2	21FEB96	15, -44	20	110	70	92	115	75	100	158.76	
	3	29FEB96	23, -36	20	110	70	96	115	75	100	161.41	
	4	06MAR96	29, -30	30	110	70	96	115	75	100	159.86	
	5	14MAR96	37, -22	30	105	70	76	110	80	80	156.56	
	6	20MAR96	43, -16	30	110	75	84	110	80	108	158.76	
	7	28MAR96	51, -8	40	110	70	88	120	80	100	159.86	
	8	05APR96	59, 1	40	110	70	88	120	80	100	159.86	
	12	08MAY96	92, 34	40	125	80	80	125	85	96	161.41	
	16	05JUN96	120, 62	40	125	80	80	125	85	92	161.63	
	20	10JUL96	155, 97#	0	116	62	77	108	58	79	159.20	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00245	SC	21MAR96	-7, .	0	100	60	66	96	64	70	131.00	66.0
	BL	28MAR96	1, .	0	98	60	60	90	62	70	127.00	
	1	04APR96	8, .	20	98	62	62	96	60	68	126.50	
329.002.00319	SC	23APR96	-7, -63	0	110	60	100	108	66	94	109.00	61.0
	1	07MAY96	8, -49	20	112	70	78	110	66	84	109.00	
	2	14MAY96	15, -42	20	128	68	70	120	70	64	111.50	
	3	21MAY96	22, -35	20	110	62	64	106	64	80	109.00	
	4	28MAY96	29, -28	30	110	70	66	106	72	68	111.00	
	5	04JUN96	36, -21	30	102	64	80	98	64	76	112.50	
	6	11JUN96	43, -14	30	100	68	64	98	68	72	115.00	
	7	18JUN96	50, -7	30	108	68	80	112	76	64	113.50	
	8	25JUN96	57, 1	30	112	70	72	100	74	80	114.00	
	12	23JUL96	85, 29	30	102	70	66	108	68	68	116.00	
	16	15AUG96	108, 52	30	98	60	80	98	62	88	115.00	
	20	24SEP96	148, 92	30	108	68	66	110	66	68	117.00	
	24	22OCT96	176, 120	30	104	66	64	106	64	68	113.50	
	28	19NOV96	204, 148	30	92	64	80	94	68	80	117.00	
	32	17DEC96	232, 176	30	100	70	76	98	70	72	113.00	
329.003.00075	SC	18JAN95	-7, -63	0	124	66	82	124	70	82	145.75	60.6
	BL	25JAN95	1, -56	0	120	76	88	118	80	85		
	1	01FEB95	8, -49	20	130	78	78	132	88	82	143.55	
	2	08FEB95	15, -42	20	130	88	72	126	86	76	142.22	
	3	15FEB95	22, -35	20	120	66	78	126	64	90	141.34	
	4	21FEB95	28, -29	30	116	88	80	112	90	70	142.44	
	5	01MAR95	36, -21	20	130	76	88	138	80	92	142.22	
	6	08MAR95	43, -14	20	120	82	72	126	80	82	143.10	
	7	15MAR95	50, -7	20	120	82	74	130	84	76	142.22	
	8	22MAR95	57, 1	20	130	76	72	118	84	78	143.33	
	12	19APR95	85, 29	20	112	78	72	128	88	84	141.56	
	16	17MAY95	113, 57	20	114	70	72	118	68	76	142.00	
	20	14JUN95	141, 85	20	124	70	72	110	72	72	141.12	
	24	12JUL95	169, 113	20	130	62	80	120	64	86	142.22	
	28	09AUG95	197, 141	20	120	80	72	110	70	76	140.68	
	32	13SEP95	232, 176	20	120	78	64	130	86	72	140.24	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00077	SC	01MAR95	-5, -64	0	138	70	76	138	72	72	132.30	68.9
	BL	06MAR95	1, -59	0	138	70	76	138	72	72	132.30	
	1	13MAR95	8, -52	20	134	86	76	148	78	90	134.51	
	2	20MAR95	15, -45	20	118	88	76	116	86	88	134.51	
	3	27MAR95	22, -38	20	124	82	82	126	76	88	137.37	
	4	05APR95	31, -29	30	128	84	78	126	88	78	136.27	
	5	12APR95	38, -22	30	128	66	80	134	78	86	138.47	
	6	19APR95	45, -15	30	130	76	80	138	84	84	138.03	
	7	26APR95	52, -8	30	120	82	84	130	80	90	139.58	
	8	03MAY95	59, -1	30	114	78	78	130	86	78	140.68	
	12	07JUN95	94, 35	30	126	76	78	122	80	80	136.71	
329.003.00081	BL	11DEC95	1, .	0	110	70	92	110	80	92	110.00	63.5
	1	18DEC95	8, .	20	92	50	100	110	60	102	111.79	
	2	28DEC95	18, .	20	104	64	86	106	70	96	109.15	
	3	03JAN96	24, .	20	104	58	92	104	66	102	111.35	
	4	10JAN96	31, .	30	104	70	102	106	80	114	110.25	
	5	17JAN96	38, .	30	104	58	104	110	70	108	113.56	
	6	24JAN96	45, .	30	104	60	96	110	62	108	113.34	
	7	31JAN96	52, .	40	100	58	100	94	56	112	110.69	
329.003.00087	SC	23JAN95	-8, .	0	110	70	84	110	70	84	135.00	67.0
	BL	30JAN95	-1, .	0	110	70	84	110	70	84	135.00	
329.003.00089	SC	24FEB95	-11, .	0	110	70	72	.	.	.	115.00	67.5
	BL	07MAR95	1, .	0	96	66	84	96	66	84	115.00	
	1	14MAR95	8, .	20	90	62	92	90	62	92	115.50	
	2	21MAR95	15, .	20	90	60	84	90	60	84	116.00	
	3	28MAR95	22, .	20	90	62	88	90	62	88	117.00	
	4	04APR95	29, .	20	90	60	84	90	60	84	117.00	
	5	11APR95	36, .	20	100	62	96	100	62	96	118.00	
	6	18APR95	43, .	20	100	60	92	100	60	92	116.50	
	7	25APR95	50, .	20	96	60	88	96	60	88	119.00	
329.003.00089	8	02MAY95	57, .	20	100	60	100	100	60	100	120.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00091	SC	14MAR95	-10, -64	0	108	64	72	110	70	72	126.00	67.0
	BL	24MAR95	1, -54	0	90	60	72	90	60	72	131.00	
	1	28MAR95	5, -50	20	90	56	72	90	56	72	131.00	
	2	04APR95	12, -43	20	100	60	84	100	60	84	130.00	
	3	11APR95	19, -36	20	100	60	84	100	60	84	131.50	
	4	18APR95	26, -29	20	90	60	84	90	60	84	132.00	
	5	25APR95	33, -22	30	110	60	80	100	60	80	133.00	
	6	02MAY95	40, -15	40	120	66	80	120	66	80	132.00	
	7	09MAY95	47, -8	40	116	64	84	116	64	84	132.00	
	8	16MAY95	54, -1	40	110	60	80	110	60	80	132.00	
	12	16JUN95	85, 31	40	110	60	76	110	60	76	131.50	
	16	14JUL95	113, 59	40	110	70	84	100	60	84	128.00	
	20	10AUG95	140, 86	40	106	66	72	100	66	72	132.00	
	24	05SEP95	166, 112	40	98	58	72	98	58	72	127.00	
	28	03OCT95	194, 140	40	96	54	80	96	54	80	128.00	
	32	07NOV95	229, 175	40	86	54	84	86	54	84	129.00	
329.003.00248	SC	14FEB96	-16, .	0	100	60	.	.	.	.	121.00	65.5
	BL	22FEB96	-8, .	0	80	50	64	80	50	64	129.00	
	1	05MAR96	5, .	20	88	54	64	80	50	64	125.00	
	2	12MAR96	12, .	20	94	58	68	94	58	68	124.00	
	3	19MAR96	19, .	20	90	60	72	90	60	72	125.00	
	4	26MAR96	26, .	30	96	56	80	90	56	80	126.00	
	5	02APR96	33, .	40	96	62	80	90	60	80	126.00	
	6	11APR96	42, .	40	94	60	80	90	60	80	122.00	
	7	16APR96	47, .	40	94	62	80	90	60	80	124.00	
	8	23APR96	54, .	30	86	62	80	80	60	80	123.00	
329.003.00250	SC	05MAR96	-9, -66	0	110	70	60	100	65	64	180.00	64.0
	BL	14MAR96	1, -57	0	100	60	96	100	60	96	186.00	
	1	19MAR96	6, -52	20	120	66	88	110	60	88	181.00	
	2	26MAR96	13, -45	20	100	60	84	100	60	84	179.00	
	3	02APR96	20, -38	20	110	62	96	100	60	96	180.00	
	4	12APR96	30, -28	30	118	76	96	110	70	96	181.00	
	5	16APR96	34, -24	30	114	72	88	110	70	88	183.00	
	6	23APR96	41, -17	40	112	68	96	110	68	96	181.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00250	7	30APR96	48, -10	30	110	70	88	110	70	88	182.00	
	8	09MAY96	57, -1	30	110	70	96	110	70	96	184.00	
	12	28MAY96	76, 19	30	94	58	88	90	60	88	182.00	
329.003.00292	BL	07AUG96	1, -58	0	126	56	80	130	56	80	143.10	60.6
	1	16AUG96	10, -49	20	138	74	86	142	62	88	141.56	
	2	21AUG96	15, -44	20	112	80	80	118	76	45 L	139.36	
	3	30AUG96	24, -35	20	122	50	80	128	54	82	139.80	
	4	04SEP96	29, -30	20	126	50	92	116	46	106	141.12	
	7	25SEP96	50, -9	20	128	58	95	132	48	98	142.88	
	8	04OCT96	59, 1	20	120	65	100	120	70	96	144.43	
329.003.00313	SC	08MAY96	-9, .	0	116	70	60	118	80	60	175.00	63.0
	BL	17MAY96	1, .	0	90	60	72	82	56	72	191.00	
	1	21MAY96	5, .	20	90	60	72	90	60	72	194.00	
	2	28MAY96	12, .	20	112	74	84	112	74	84	182.00	
329.004.00015	SC	30NOV94	-8, -65	0	100	68	80	110	70	84	109.37	62.6
	BL	07DEC94	-1, -58	0	100	68	60	96	70	80	116.87	
	1	14DEC94	7, -51	20	90	60	96	90	64	104	107.16 L	
	2	21DEC94	14, -44	20	100	60	88	100	64	100	106.06 L	
	3	28DEC94	21, -37	20	100	70	82	100	70	90	104.96 L	
	4	04JAN95	28, -30	20	90	60	74	90	60	80	102.53 L	
	5	11JAN95	35, -23	20	110	70	76	110	78	100	102.97 L	
	6	18JAN95	42, -16	20	98	60	80	90	68	96	105.18 L	
	7	25JAN95	49, -9	20	110	78	94	100	66	100	105.18 L	
	8	03FEB95	58, 1	20	104	68	80	100	66	84	105.84 L	
	12	27FEB95	82, 25	20	102	64	80	98	64	104	99.67 L	
	16	22MAR95	105, 48	20	108	76	72	106	72	72	102.97 L	
	20	19APR95	133, 76	20	90	60	68	90	60	70	103.64 L	
	24	17MAY95	161, 104	20	90	60	64	100	60	64	105.84 L	
	28	14JUN95	189, 132	20	100	60	60	100	64	64	106.94 L	
329.004.00017	SC	15MAR95	-7, -63	0	112	70	56	112	74	60	137.15	63.4
	BL	22MAR95	1, -56	0	90	60	64	100	68	70	135.17	
	1	30MAR95	9, -48	20	80	60	64	90	60	64	135.39	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

CONFIDENTIAL

BRL-029060-329-
individual-data

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.004.00017	2	06APR95	16, -41	20	90	60	68	100	70	70	133.84	
	3	13APR95	23, -34	20	100	60	70	100	60	74	134.95	
	4	20APR95	30, -27	20	100	60	72	110	60	78	137.59	
	5	26APR95	36, -21	30	100	60	64	110	70	68	135.39	
	6	03MAY95	43, -14	30	90	60	60	90	70	72	133.62	
	7	10MAY95	50, -7	30	90	60	64	100	60	68	132.96	
	8	17MAY95	57, 1	30	90	60	68	90	60	70	133.40	
	12	14JUN95	85, 29	30	100	60	70	110	80	70	131.64	
	16	13JUL95	114, 58	30	110	70	72	110	70	80	131.42	
	20	10AUG95	142, 86	30	110	70	60	105	70	68	135.61	
	24	06SEP95	169, 113	30	90	60	60	100	70	64	135.17	
	28	04OCT95	197, 141	30	90	60	64	100	68	68	138.92	
	32	01NOV95	225, 169	20	100	70	78	100	68	68	140.02	
329.004.00019	SC	24MAY95	-7, .	0	90	60	60	100	70	78	120.17	66.1
	BL	31MAY95	1, .	0	100	60	64	110	70	80	117.31	
	1	07JUN95	8, .	20	90	60	80	110	70	84	119.51	
	2	14JUN95	15, .	20	100	60	70	110	80	90	120.61	
329.004.00212	SC	24MAY96	-10, .	0	100	60	60	90	60	72	143.33	65.7
	BL	03JUN96	1, .	0	90	60	72	90	60	78	139.80	
	1	10JUN96	8, .	20	110	60	78	110	78	84	137.81	
	3	21JUN96	19, .	20	116	78	80	108	80	92	139.58	
	4	28JUN96	26, .	20	118	78	90	110	80	98	137.81	
329.004.00214	SC	27SEP96	-7, -67	0	120	90	68	120	90	80	128.99	60.6
	BL	04OCT96	1, -60	0	110	70	78	110	70	80	129.43	
	1	09OCT96	6, -55	20	125	70	84	120	80	84	128.11	
	2	15OCT96	12, -49	20	120	80	84	120	90	88	127.89	
	2	21OCT96	18, -43	20	110	70	78	110	90	98	127.89	
	4	01NOV96	29, -32	30	100	60	60	100	60	120	128.99	
	5	11NOV96	39, -22	30	110	70	98	100	70	120	126.35	
	6	18NOV96	46, -15	20	110	60	100	135	85	120	128.11	
	7	25NOV96	53, -8	20	110	60	78	110	70	84	126.79	
	8	03DEC96	61, 1	20	125	75	84	125	75	95	129.43	
	12	30DEC96	88, 28	20	110	60	88	110	76	96	128.99	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00002	SC	20MAY94	-5, -61	0	80	60	92	80	60	92	115.76	62.0
	BL	25MAY94	1, -56	0	100	70	88	90	70	88	112.90	
	1	01JUN94	8, -49	20	90	60	92	90	64	92	114.88	
	2	08JUN94	15, -42	20	98	60	80	90	60	80	113.78	
	3	15JUN94	22, -35	20	90	60	80	88	60	80	111.79	
	4	23JUN94	30, -27	30	90	60	72	88	60	60	115.54	
	5	30JUN94	37, -20	40	90	60	72	80	60	76	113.12	
	6	07JUL94	44, -13	40	90	60	88	88	60	88	115.10	
	7	14JUL94	51, -6	40	84	60	80	80	60	80	115.10	
	8	20JUL94	57, 1	40	90	60	88	80	60	88	110.47	
	12	17AUG94	85, 29	40	94	68	88	94	70	88	115.10	
	16	15SEP94	114, 58	40	90	70	92	90	60	92	113.56	
	20	18OCT94	147, 91	40	94	70	94	90	70	86	112.20	
329.005.00004	SC	22SEP94	-18, -77	0	130	70	62	124	70	62	143.00	68.0
	BL	10OCT94	1, -59	0	134	74	68	130	70	68	141.50	
	1	20OCT94	11, -49	20	130	70	62	124	70	62	142.00	
	2	27OCT94	18, -42	20	118	74	64	110	70	62	144.80	
	3	03NOV94	25, -35	20	120	70	60	90	70	60	145.40	
	4	10NOV94	32, -28	30	120	70	68	100	60	64	148.00	
	5	17NOV94	39, -21	40	124	80	84	120	80	80	150.50	
	6	23NOV94	45, -15	40	124	80	64	120	80	64	148.00	
	7	01DEC94	53, -7	40	112	70	60	100	60	64	152.90 H	
	8	08DEC94	60, 1	40	110	60	60	118	60	62	149.60	
	12	05JAN95	88, 29	30	118	62	76	110	60	90	153.50 H	
329.005.00008	SC	10NOV94	-6, -61	0	100	70	70	100	68	70	88.50	60.0
	BL	16NOV94	1, -55	0	100	70	80	110	70	80	91.00	
	1	23NOV94	8, -48	20	100	70	72	108	70	72	89.00	
	2	30NOV94	15, -41	20	98	70	76	110	70	80	89.50	
	3	07DEC94	22, -34	20	80	60	84	84	60	88	88.00	
	4	14DEC94	29, -27	30	100	60	80	100	60	88	89.00	
	5	21DEC94	36, -20	40	104	70	76	110	70	76	90.85	
	6	28DEC94	43, -13	40	90	60	84	90	60	88	91.29	
	7	03JAN95	49, -7	40	100	60	80	100	64	84	90.00	
	8	10JAN95	56, 1	30	90	60	72	94	64	80	92.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00008	12	06FEB95	83, 28	30	100	70	80	96	60	80	95.50	
	16	08MAR95	113, 58	30	100	60	80	100	60	88	98.20 H	
	24	10MAY95	176, 121#	0	94	64	88	90	60	88	101.50 H	
329.005.00011	SC	06DEC94	-7, -63	0	112	70	84	100	70	88	122.00	69.0
	BL	13DEC94	1, -56	0	100	70	80	100	70	84	122.00	
	1	20DEC94	8, -49	20	100	70	84	104	70	84	122.00	
	2	27DEC94	15, -42	20	90	60	84	90	60	84	119.00	
	3	03JAN95	22, -35	20	90	60	76	90	60	76	121.50	
	4	09JAN95	28, -29	30	92	60	88	88	60	88	119.50	
	5	17JAN95	36, -21	40	90	60	84	100	70	88	120.50	
	6	23JAN95	42, -15	40	90	60	100	90	60	100	121.00	
	7	31JAN95	50, -7	40	90	60	72	94	60	76	118.10	
	8	07FEB95	57, 1	40	104	70	84	100	60	88	118.50	
	12	09MAR95	87, 31	40	110	70	96	112	64	114	117.50	
	16	06APR95	115, 59	40	110	70	90	100	62	96	118.20	
	20	03MAY95	142, 86	30	100	64	88	98	60	92	119.00	
329.005.00109	SC	22DEC94	-8, -61	0	112	70	60	100	70	60	137.00	67.0
	BL	30DEC94	1, -53	0	98	60	76	90	60	76	137.50	
	1	05JAN95	7, -47	20	110	70	72	120	70	72	138.50	
	2	12JAN95	14, -40	20	100	60	76	108	60	72	137.50	
	3	19JAN95	21, -33	20	112	70	72	112	70	76	136.20	
	4	26JAN95	28, -26	20	120	80	80	110	76	84	136.00	
	5	02FEB95	35, -19	20	100	70	76	98	68	80	132.10	
	6	08FEB95	41, -13	20	90	60	68	100	60	72	135.50	
	7	16FEB95	49, -5	20	128	76	72	128	78	76	135.61	
	8	21FEB95	54, 1	20	118	74	72	110	72	74	134.00	
	12	23MAR95	84, 31	20	90	70	72	104	70	76	134.00	
	16	24APR95	116, 63	20	120	88	60	120	78	68	140.00	
	20	25MAY95	147, 94	20	120	80	68	120	78	72	137.70	
329.005.00112	SC	17JAN95	-9, -64	0	104	70	66	100	70	72	119.00	61.0
	BL	26JAN95	1, -55	0	100	70	68	98	70	68	115.00	
	1	01FEB95	7, -49	20	100	70	80	90	60	84	119.00	
	2	08FEB95	14, -42	20	100	70	76	104	70	76	119.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00112	3	15FEB95	21, -35	20	90	60	84	84	56	88	118.00	
	4	23FEB95	29, -27	20	98	60	84	100	70	84	118.00	
	5	01MAR95	35, -21	20	100	70	80	110	74	80	118.50	
	6	08MAR95	42, -14	20	120	78	100	120	82	110	122.00	
	7	15MAR95	49, -7	20	90	60	92	90	60	96	122.00	
	8	22MAR95	56, 1	20	94	64	76	92	60	80	123.00	
	12	19APR95	84, 29	20	110	74	80	104	70	88	124.00	H
	20	21JUN95	147, 92#	0	100	70	80	104	72	84	124.50	H
329.005.00116	SC	30JAN95	-8, -66	0	118	80	54	110	80	56	206.80	71.0
	BL	07FEB95	1, -58	0	112	80	68	90	72	64	206.50	
	1	13FEB95	7, -52	20	110	80	72	90	60	74	206.70	
	2	20FEB95	14, -45	20	110	70	72	104	60	74	204.10	
	3	27FEB95	21, -38	20	118	62	70	112	70	74	203.30	
	4	09MAR95	31, -28	20	104	78	84	100	74	88	201.00	
	5	16MAR95	38, -21	20	120	78	84	110	80	88	201.00	
	6	23MAR95	45, -14	20	118	70	76	110	70	80	201.50	
	7	30MAR95	52, -7	20	120	84	96	112	80	98	206.00	
	8	06APR95	59, 1	20	120	80	88	112	70	92	208.00	
	12	04MAY95	87, 29	20	100	74	72	98	70	80	211.00	
	16	31MAY95	114, 56	30	104	80	80	98	70	84	214.00	
	20	28JUN95	142, 84	20	90	60	68	88	60	64	212.20	
	24	26JUL95	170, 112#	0	118	80	80	110	74	84	212.00	
329.005.00119	SC	27JUN95	-14, -73	0	118	80	70	110	82	70	150.10	65.0
	BL	11JUL95	1, -59	0	128	80	70	120	80	88	153.20	
	1	18JUL95	8, -52	20	120	80	74	110	72	76	153.50	
	2	26JUL95	16, -44	20	120	82	80	118	88	80	152.60	
	3	02AUG95	23, -37	20	124	74	70	120	80	80	152.00	
	4	08AUG95	29, -31	30	110	64	72	110	64	86	151.00	
	5	15AUG95	36, -24	40	100	60	88	104	60	96	155.20	
	6	23AUG95	44, -16	40	128	80	94	120	80	106	156.80	
	7	29AUG95	50, -10	40	118	78	86	106	74	92	159.00	
	8	08SEP95	60, 1	40	122	80	88	120	72	96	158.00	
	12	03OCT95	85, 26	40	128	80	84	118	86	98	156.00	
	16	30OCT95	112, 53	40	120	80	92	118	68	108	155.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00119	20	28NOV95	141, 82	30	90	60	94	90	50	106	159.00	
329.005.00151	SC	29AUG95	-8, -65	0	110	60	82	108	64	86	112.46	63.0
	BL	06SEP95	1, -57	0	102	64	76	106	66	88	110.91	
	1	14SEP95	9, -49	20	110	60	68	90	60	68	109.00	
	2	20SEP95	15, -43	20	100	60	64	110	70	64	107.50	
	3	28SEP95	23, -35	20	100	60	70	90	62	70	108.00	
	4	03OCT95	28, -30	20	100	60	88	104	60	92	105.20	
	5	11OCT95	36, -22	20	90	50	84	96	56	96	107.00	
	6	19OCT95	44, -14	20	100	64	80	102	66	88	109.59	
	7	26OCT95	51, -7	20	108	70	84	100	60	88	108.50	
	8	02NOV95	58, 1	20	106	66	84	104	64	88	109.81	
	12	28NOV95	84, 27	20	98	50	88	98	48	92	111.00	
	16	02JAN96	119, 62	20	120	80	80	120	70	86	114.00	
	20	31JAN96	148, 91	30	104	70	84	98	68	88	114.00	
	24	27FEB96	175, 118	30	90	50	72	90	60	88	116.70	
	28	27MAR96	204, 147	30	100	60	78	94	60	76	118.41	
	32	01MAY96	239, 182	20	98	68	68	92	64	78	119.75 H	
329.005.00152	SC	12OCT95	-14, .	0	100	70	78	94	70	84	128.00	66.0
	BL	23OCT95	-3, .	0	104	70	76	100	70	84	128.50	
	1	02NOV95	8, .	20	100	60	72	90	60	76	126.00	
329.005.00257	SC	05MAR96	-6, -62	0	110	68	102	100	60	96	112.00	63.0
	BL	11MAR96	1, -56	0	90	60	76	90	60	70	112.50	
	1	18MAR96	8, -49	20	100	50	80	98	48	98	108.00	
	2	25MAR96	15, -42	20	90	60	86	88	58	96	109.00	
	3	01APR96	22, -35	20	100	70	74	102	68	86	111.00	
	4	08APR96	29, -28	20	110	80	70	110	86	80	112.00	
	5	15APR96	36, -21	20	100	60	72	90	52	90	110.00	
	6	22APR96	43, -14	30	110	64	84	110	68	80	112.00	
	7	29APR96	50, -7	30	100	60	80	100	60	80	112.75	
	8	06MAY96	57, 1	30	120	68	86	118	78	94	112.00	
	12	03JUN96	85, 29	30	100	70	74	106	80	90	117.25	
	16	08JUL96	120, 64	30	112	70	86	108	70	86	122.25 H	
	20	07AUG96	150, 94	30	122	72	80	120	80	84	124.50 H	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00257	24	27AUG96	170, 114	30	120	80	84	110	70	86	122.00	H
	28	01OCT96	205, 149	30	118	70	78	118	80	84	123.00	H
	32	21OCT96	225, 169	30	116	72	80	110	70	86	123.00	H
329.005.00258	SC	06FEB96	-35, .	0	102	60	98	100	60	104	169.50	64.0
	BL	20FEB96	-21, .	0	118	70	100	110	70	104	171.70	
	1	19MAR96	8, .	20	100	60	98	98	68	102	171.00	
	2	26MAR96	15, .	20	120	78	80	110	70	98	168.50	
	3	02APR96	22, .	20	120	70	80	110	70	98	171.00	
	4	09APR96	29, .	30	112	76	82	110	80	100	169.00	
	5	18APR96	38, .	40	104	70	80	100	70	84	169.00	
	6	23APR96	43, .	40	126	70	84	122	76	102	171.50	
	7	30APR96	50, .	40	112	70	88	120	80	106	167.50	
	8	07MAY96	57, .	30	120	80	88	120	80	102	168.75	
329.005.00299	SC	28MAY96	-11, -71	0	118	82	72	116	78	78	123.20	63.0
	BL	04JUN96	-4, -64	0	120	80	64	120	80	76	124.00	
	1	18JUN96	11, -50	20	92	64	84	92	60	100	123.00	
	2	25JUN96	18, -43	20	92	64	84	92	60	96	125.75	
	3	02JUL96	25, -36	20	110	70	82	110	80	84	124.00	
	5	10JUL96	33, -28	20	90	68	80	92	56	88	124.00	
	6	22JUL96	45, -16	20	100	48 L	84	90	42 L	100	124.00	
	8	31JUL96	54, -7	20	110	60	80	90	54	84	127.20	
	8	07AUG96	61, 1	20	106	70	80	100	60	84	125.75	
	12	03SEP96	88, 28	20	120	70	72	120	76	86	128.75	
	16	01OCT96	116, 56	20	92	58	84	88 L	54	92	128.00	
	20	29OCT96	144, 84	30	104	60	82	100	60	88	131.25	
329.005.00300	SC	12SEP96	-7, .	0	90	60	60	90	58	62	96.20	62.0
	BL	19SEP96	1, .	0	80	50	60	88	50	62	96.50	
	1	26SEP96	8, .	20	80	50	74	84	60	78	95.50	
	2	03OCT96	15, .	20	88	60	64	84	58	68	94.20	
	3	10OCT96	22, .	20	98	60	80	104	50	86	94.75	
	4	17OCT96	29, .	20	90	60	60	80	60	64	97.50	
	5	24OCT96	36, .	20	70	50	60	90	60	62	95.70	
	6	31OCT96	43, .	20	80	60	60	58 L	54	60	95.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00300	7	07NOV96	50, .	20	80	60	60	78	50	62	95.70	
	8	14NOV96	57, .	20	90	60	60	80	58	64	99.00	
329.005.00333	SC	15JAN97	-8, .	0	122	70	82	124	78	86	123.00	64.0
	BL	23JAN97	1, .	0	126	60	80	128	80	88	123.40	
	1	31JAN97	9, .	20	118	70	74	120	74	76	123.70	
	2	06FEB97	15, .	20	132	74	60	128	70	64	125.20	
	3	13FEB97	22, .	20	124	74	88	118	70	100	124.00	
	4	20FEB97	29, .	20	124	70	80	120	70	80	124.70	
	5	26FEB97	35, .	20	120	80	68	120	80	74	124.00	
329.005.00336	SC	26FEB97	-6, .	0	114	74	64	100	70	68	119.00	65.0
	BL	04MAR97	1, .	0	100	70	64	90	60	68	119.70	
	1	12MAR97	9, .	20	100	70	68	98	60	68	118.70	
	2	19MAR97	16, .	20	104	70	60	90	60	64	116.50	
	3	25MAR97	22, .	20	88	64	68	80	60	72	120.50	
	4	02APR97	30, .	20	82	60	78	80	60	78	121.00	
	5	09APR97	37, .	20	80	60	84	88	60	88	124.00	
	6	16APR97	44, .	20	100	60	68	90	60	72	122.50	
	7	23APR97	51, .	20	110	70	78	90	60	80	123.00	
	8	30APR97	58, .	20	100	70	72	90	60	76	121.70	
329.006.00038	SC	01FEB95	-14, .	0	108	60	64	103	61	72	171.00	67.0
	BL	08FEB95	-7, .	0	90	60	80	90	60	80	171.00	
	1	22FEB95	8, .	20	110	80	68	128	68	72	164.49	
	2	03MAR95	17, .	20	100	70	.	110	80	.	166.92	
	3	08MAR95	22, .	20	90	60	60	100	60	80		
	4	15MAR95	29, .	20	100	60	60	100	70	80	161.00	
	5	22MAR95	36, .	20	90	70	60	100	60	100		
	6	29MAR95	43, .	20	110	70	80	120	70	.	168.68	
	7	05APR95	50, .	20	100	80	60	108	68	80	166.48	
329.006.00039	SC	03FEB95	-5, -66	0	100	60	68	107	66	88	142.22	64.6
	BL	10FEB95	3, -59	20	116	70	71	108	70	66	142.22	
	1	13FEB95	6, -56	20	100	60	60	103	66	60	143.33	
	2	22FEB95	15, -47	20	98	68	70	100	72	80	143.33	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.006.00039	3	01MAR95	22, -40	20	90	60	60	90	60	66	138.92	
	4	08MAR95	29, -33	20	110	70	68	102	70	80		
	5	17MAR95	38, -24	20	100	60	84	110	60	80	135.61	
	6	22MAR95	43, -19	20	88	58	70	85	62	90		
	7	29MAR95	50, -12	30	98	78	80	98	70	90	136.71	
	8	05APR95	57, -5	30	100	60	70	96	60	100	136.71	
	12	01MAY95	83, 22	20	108	78	80	90	60	80	143.33	
329.006.00260	SC	12JUL96	-6, -64	0	115	70	62	113	75	78	140.00	67.0
	BL	18JUL96	1, -58	0	115	80	68	110	70	74	140.00	
	1	26JUL96	9, -50	20	113	80	80	113	78	90	138.00	
	2	01AUG96	15, -44	20	113	75	84	115	80	90	136.50	
	3	07AUG96	21, -38	20	113	78	78	113	80	84	137.00	
	4	14AUG96	28, -31	30	100	70	78	100	80	102	133.00	
	5	21AUG96	35, -24	30	100	80	72	100	75	94	133.50	
	6	28AUG96	42, -17	30	100	70	70	100	80	80	133.50	
	7	04SEP96	49, -10	30	110	70	78	105	70	72	135.00	
	8	18SEP96	63, 5	30	100	70	72	115	70	80	137.00	
	12	09OCT96	84, 26	30	100	80	78	98	70	102	133.00	
	16	06NOV96	112, 54	30	100	75	66	100	75	78	134.00	
	20	05DEC96	141, 83	20	115	80	66	100	70	80	140.00	
329.006.00261	SC	07NOV96	-19, -77	0	100	60	72	98	60	72	172.50	66.0
	BL	22NOV96	-4, -62	0	113	70	70	113	80	74	171.00	
	1	03DEC96	8, -51	20	113	70	60	113	75	80	172.00	
	2	10DEC96	15, -44	20	115	70	72	116	80	66	173.50	
	3	17DEC96	22, -37	20	117	75	72	117	80	72	172.50	
	4	24DEC96	29, -30	30	160	80	70	160	80	72	173.00	
	5	02JAN97	38, -21	30	118	80	66	118	80	78	174.00	
	6	09JAN97	45, -14	30	120	80	72	120	80	78	178.00	
	7	15JAN97	51, -8	30	120	85	66	120	85	72	178.00	
	8	23JAN97	59, 1	30	115	75	66	112	80	72	178.50	
	12	20FEB97	87, 29	30	116	75	66	116	80	70	178.00	
	20	02APR97	128, 70	30	113	80	72	113	80	80	180.00	
329.007.00140	SC	07SEP95	-8, -63	0	104	60	64	102	64	68	74.00	54.0

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.007.00140	BL	14SEP95	-1, -56	0	110	60	72	104	62	76	74.00	
	1	21SEP95	7, -49	20	100	62	60	98	64	68	72.00	
	2	28SEP95	14, -42	20	96	60	60	92	62	68	71.00	
	3	05OCT95	21, -35	20	110	60	64	106	62	68	72.00	
	4	12OCT95	28, -28	20	104	70	68	102	72	72	72.00	
	5	18OCT95	34, -22	20	110	70	64	108	72	68	73.00	
	6	26OCT95	42, -14	20	100	60	64	98	62	68	70.00	
	7	02NOV95	49, -7	20	102	58	64	100	62	68	72.00	
	8	09NOV95	56, 1	20	104	72	64	100	74	73	73.00	
	12	22NOV95	69, 14	20	104	68	78	98	66	72	74.00	
329.007.00142	SC	12OCT95	-6, .	0	124	80	68	120	82	76	212.00	68.0
	BL	18OCT95	1, .	0	124	82	72	120	84	68	213.00	
	1	26OCT95	9, .	20	130	78	68	128	80	72	214.00	
	2	02NOV95	16, .	20	122	84	72	120	88	68	212.00	
	3	09NOV95	23, .	20	124	74	68	118	82	72	211.00	
	4	16NOV95	30, .	30	130	70	80	128	74	72	212.00	
	5	22NOV95	36, .	30	123	78	88	114	79	110	210.00	
	6	30NOV95	44, .	40	140	74	80	132	76	64	214.00	
	8	21DEC95	65, .#	0	128	82	88	132	88	88	214.00	
329.007.00145	SC	04JAN96	-7, -63	0	110	60	68	108	64	72	107.00	62.0
	BL	11JAN96	1, -56	0	110	68	76	108	70	80	106.00	
	1	18JAN96	8, -49	20	118	70	76	116	74	80	106.00	
	2	25JAN96	15, -42	20	118	64	72	116	68	64	106.00	
	3	01FEB96	22, -35	20	118	76	80	112	78	84	108.00	
	4	08FEB96	29, -28	30	112	68	76	110	72	88	107.00	
	5	12FEB96	33, -24	30	118	68	72	114	70	80	108.00	
	6	21FEB96	42, -15	30	114	68	80	112	70	72	107.00	
	7	26FEB96	47, -10	40	112	64	72	110	66	64	106.00	
	8	07MAR96	57, 1	40	120	60	80	118	66	72	107.00	
	12	04APR96	85, 29	40	114	74	64	110	76	72	106.00	
	16	02MAY96	113, 57	30	118	84	68	114	86	74	110.00	
	20	30MAY96	141, 85	20	118	70	68	116	74	76	112.00	
	24	27JUN96	169, 113	20	98	58	88	100	74	88	110.00	
	28	25JUL96	197, 141	20	110	62	58	104	66	58	113.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.007.00145	32	23AUG96	226, 170	20	118	68	72	108	60	68	111.00	
329.007.00265	SC	25JAN96	-7, .	0	110	62	66	118	70	70	140.00	64.0
	BL	01FEB96	1, .	0	112	68	68	110	72	72	140.00	
	2	15FEB96	15, .	20	116	64	64	112	66	72	136.00	
329.007.00268	SC	21MAR96	-11, -70	0	120	70	64	122	76	72	224.00	64.0
	BL	01APR96	1, -59	0	118	68	68	116	72	72	225.00	
	1	11APR96	11, -49	20	118	68	64	114	74	68	224.00	
	2	18APR96	18, -42	20	122	74	72	118	76	76	221.00	
	3	25APR96	25, -35	20	122	70	64	120	70	62	221.00	
	4	02MAY96	32, -28	20	120	74	72	118	82	76	223.00	
	5	09MAY96	39, -21	20	122	80	72	120	84	80	224.00	
	6	16MAY96	46, -14	30	124	78	60	122	80	64	220.00	
	8	30MAY96	60, 1	30	128	74	72	126	80	80	222.00	
	12	27JUN96	88, 29	30	104	72	70	92	58	70	221.00	
	16	01AUG96	123, 64	40	130	76	90	140	84	100	227.00	
	20	30AUG96	152, 93	40	124	92	90	130	80	92	231.00	
	24	30SEP96	183, 124	30	110	78	80	104	74	84	234.00	
	32	07NOV96	221, 162	30	122	76	78	124	76	80	244.00 H	
	32	05DEC96	249, 190	20	106	78	76	112	92	84	243.00 H	
329.007.00294	SC	20FEB97	-8, .	0	101	64	62	90	64	102	154.00	67.0
	BL	27FEB97	-1, .	0	119	64	85	102	69	108	161.00	
	1	10MAR97	11, .	20	106	63	71	114	68	98	161.00	
	2	17MAR97	18, .	20	109	69	78	106	69	92	159.00	
	4	28MAR97	29, .	20	99	63	88	102	63	76	164.00	
	5	03APR97	35, .	30	105	71	74	94	72	84	166.00	
	6	10APR97	42, .	20	106	72	78	114	74	84	165.00	
329.007.00309	SC	02JUL96	-13, -65	0	106	66	80	94	66	96	130.00	67.0
	BL	15JUL96	1, -52	0	106	60	78	100	78	110	130.00	
	1	18JUL96	4, -49	20	108	58	84	92	60	88	131.00	
	1	25JUL96	11, -42	20	120	58	60	104	68	64	128.00	
	2	01AUG96	18, -35	20	114	64	77	110	68	80	131.00	
	3	08AUG96	25, -28	20	128	76	104	140	78	100	124.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.007.00309	4	15AUG96	32, -21	20	118	60	102	120	62	100	130.00	
	6	23AUG96	40, -13	20	120	66	82	118	70	82	127.00	
	7	30AUG96	47, -6	20	110	70	60	112	70	68	126.00	
	7	05SEP96	53, 1	20	109	68	85	114	75	106	128.00	
	12	03OCT96	81, 29	20	112	64	86	118	68	80	130.00	
	16	31OCT96	109, 57	20	106	72	80	108	76	72	131.00	
	20	13DEC96	152, 100	20	104	53	80	103	59	87	128.00	
	24	09JAN97	179, 127	20	111	62	94	100	59	88	129.00	
	28	10FEB97	211, 159	30	115	61	79	115	74	98	130.00	
	32	13MAR97	242, 190	20	100	60	74	100	60	94	129.00	
329.007.00310	SC	19SEP96	-7, -67	0	100	72	80	100	78	76	116.00	60.0
	BL	26SEP96	1, -60	0	104	63	99	109	71	119	116.00	
	1	03OCT96	8, -53	20	110	78	76	108	76	80	114.00	
	2	10OCT96	15, -46	20	112	70	72	110	72	74	115.00	
	3	17OCT96	22, -39	20	102	64	60	100	68	60	115.00	
	5	28OCT96	33, -28	20	104	68	70	100	66	72	116.00	
	5	31OCT96	36, -25	20	100	72	72	98	68	68	114.00	
	6	08NOV96	44, -17	20	96	68	74	100	72	76	114.00	
	8	18NOV96	54, -7	20	101	51	70	96	52	80	116.00	
	8	25NOV96	61, 1	20	96	50	64	94	52	76	115.00	
	12	02JAN97	99, 39	20	98	73	81	100	78	101	109.00	
	20	14FEB97	142, 82	20	102	59	66	98	60	74	111.00	
	24	13MAR97	169, 109	20	103	63	78	98	66	93	113.00	
	28	17APR97	204, 144	20	101	51	78	98	69	89	119.00	
	32	15MAY97	232, 172	20	98	63	71	109	69	69	118.00	
	32	12JUN97	260, 200	20	102	54	86	100	65	97	119.00	
329.007.00318	SC	22NOV96	-10, .	0	116	68	85	112	70	76	120.00	65.0
	BL	02DEC96	1, .	0	111	61	84	101	72	86	123.00	
329.008.00157	SC	16AUG95	-14, -69	0	138	68	72	136	68	72	278.00	72.0
	BL	29AUG95	-1, -56	0	138	78	78	140	78	74	277.00	
	1	05SEP95	7, -49	20	138	78	66	138	76	66	277.00	
	2	12SEP95	14, -42	20	136	78	68	134	74	72		
	3	20SEP95	22, -34	20	136	80	78	138	84	78	277.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.008.00157	4	26SEP95	28, -28	20	136	82	66	134	82	62	278.00	
	5	04OCT95	36, -20	20	136	80	64	133	78	60	278.00	
	6	10OCT95	42, -14	20	122	74	64	120	74	64		
	7	16OCT95	48, -8	20	114	78	66	110	80	70	280.00	
	8	24OCT95	56, 1	20	120	78	72	118	72	72	279.00	
	12	23NOV95	86, 31	20	112	80	58	106	76	60	278.00	
	16	15DEC95	108, 53	20	102	72	72	95	70	78	281.00	
	20	23JAN96	147, 92	20	118	78	78	116	78	90	280.00	
	24	20FEB96	175, 120	20	118	74	90	122	70	96	280.00	
329.008.00160	SC	25OCT95	-7, -73	0	102	65	68	110	85	80	161.00	76.0
	BL	01NOV95	1, -66	0	110	70	84	102	75	92	159.00	
	1	10NOV95	10, -57	20	90	58	76	85	80	80	159.00	
	3	20NOV95	20, -47	20	110	58	84	105	65	88	160.00	
	4	27NOV95	27, -40	20	110	80	80	110	80	92	160.00	
	5	05DEC95	35, -32	20	110	75	80	107	78	92	158.00	
	6	13DEC95	43, -24	30	100	70	80	105	78	96	159.00	
	7	20DEC95	50, -17	30	110	65	76	100	78	84	156.00	
	8	27DEC95	57, -10	30	112	72	72	100	80	88	163.00	
	8	05JAN96	66, -1	30	110	50	84	110	78	100	160.00	
	12	31JAN96	92, 26	30	112	65	92	110	75	96	160.00	
	16	05MAR96	126, 60	30	115	60	84	120	80	84	164.00	
	24	09APR96	161, 95	30	110	80	100	90	60	96	168.00	
	28	16MAY96	198, 132	30	122	78	92	110	80	96	175.00	H
	32	18JUN96	231, 165	30	120	75	108	110	85	100	175.00	H
	32	23JUL96	266, 200	30	120	60	96	90	70	80	175.00	H
329.008.00188	SC	14DEC95	-21, .	0	110	70	80	100	70	100	156.00	63.0
	BL	04JAN96	1, .	0	112	85	88	100	85	132	160.00	
	1	10JAN96	7, .	20	110	85	80	105	75	100	162.00	
	2	17JAN96	14, .	20	112	60	80	100	75	88	162.00	
	3	24JAN96	21, .	20	100	70	88	105	80	112	159.00	
	4	31JAN96	28, .	30	120	80	72	112	82	88	162.00	
	5	07FEB96	35, .	40	110	75	84	110	70	100	164.00	
	6	14FEB96	42, .	40	110	75	88	105	75	120	162.00	
	7	21FEB96	49, .	40	110	65	96	110	80	128	163.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.008.00188	8	27FEB96	55, .	40	110	80	80	108	75	96	165.00	
329.008.00271	SC	25JAN96	-46, -110	0	98	76	68	96	70	72	170.00	63.5
	BL	11MAR96	1, -64	0	98	74	68	96	70	70	172.00	
	1	18MAR96	8, -57	20	132	78	82	116	78	94	175.00	
	2	25MAR96	15, -50	20	115	73	74	126	84	86	174.00	
	3	01APR96	22, -43	20	129	75	76	128	78	67	173.00	
	4	08APR96	29, -36	20	135	73	69	125	66	80	172.00	
	5	15APR96	36, -29	30	124	78	69	127	85	75	168.00	
	6	22APR96	43, -22	40	133	78	76	129	78	73	168.00	
	7	02MAY96	53, -12	40	126	76	67	116	76	75	164.00	
	8	14MAY96	65, 1	40	92	66	73	123	87	87	163.00	
	12	10JUN96	92, 28	40	130	76	76	126	84	78	168.00	
	16	12JUL96	124, 60	40	120	70	76	110	80	92	167.00	
	20	09AUG96	152, 88	40	98	75	80	90	60	112	162.00	
	24	06SEP96	180, 116	40	105	80	80	90	70	100	160.00	
	28	07OCT96	211, 147	40	105	75	72	95	80	92	162.00	
	32	05NOV96	240, 176	30	120	80	80	120	80	84	164.00	
329.008.00275	SC	30APR96	-8, -63	0	100	70	80	110	80	100	166.00	64.0
	BL	07MAY96	-1, -56	0	100	60	100	110	70	76	166.00	
	1	15MAY96	8, -48	20	110	80	80	105	80	100	164.00	
	2	21MAY96	14, -42	20	110	82	100	90	65	76	163.00	
	3	28MAY96	21, -35	20	100	72	88	100	80	96	167.00	
	4	04JUN96	28, -28	30	108	72	66	98	70	90	170.00	
	5	11JUN96	35, -21	30	104	72	66	96	72	88	170.00	
	7	25JUN96	49, -7	40	98	70	72	96	70	88	165.00	
	8	02JUL96	56, 1	30	110	62	72	94	60	90	165.00	
	12	23JUL96	77, 22	30	110	70	78	90	62	108	163.00	
	16	20AUG96	105, 50	30	104	74	74	86	70	96	158.00	
	20	16SEP96	132, 77	30	100	74	72	92	68	96	154.00 L	
	24	21OCT96	167, 112	30	60 L	72	76	88	68	86	154.00 L	
	28	25NOV96	202, 147	30	98	88	78	94	56	90	154.00 L	
	32	16DEC96	223, 168	30	98	64	90	92	60	112	154.00 L	
329.009.00130	SC	12APR95	-6, -62	0	139	58	57	130	70	74	146.30	66.3

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00130	BL	18APR95	1, -56	0	128	56	76	144	71	90	147.60	
	1	25APR95	8, -49	20	135	60	64	137	69	94	145.00	
	2	02MAY95	15, -42	20	128	55	52	131	65	54	145.80	
	3	09MAY95	22, -35	20	130	53	65	137	64	86	145.80	
	4	16MAY95	29, -28	20	133	67	59	122	61	76	145.09	
	5	23MAY95	36, -21	20	130	61	72	131	62	102	145.10	
	6	30MAY95	43, -14	20	130	64	64	122	63	88	147.60	
	7	06JUN95	50, -7	20	129	64	66	130	72	82	148.62	
	8	13JUN95	57, 1	20	130	60	79	138	76	93	151.10	
	16	07AUG95	112, 56	20	.	.	.	138	73	85	162.70	H
	20	19SEP95	155, 99	20	137	60	65	137	66	71	165.30	H
	24	03OCT95	169, 113	20	139	66	59	123	76	67	162.40	H
329.009.00131	SC	26APR95	-6, -62	0	130	64	63	114	56	62	160.90	66.8
	BL	02MAY95	1, -56	0	106	60	64	122	56	72	158.70	
	1	09MAY95	8, -49	20	107	53	63	122	63	84	157.60	
	2	16MAY95	15, -42	20	121	60	69	123	65	85	159.64	
	3	23MAY95	22, -35	20	121	68	66	106	57	71	157.50	
	4	30MAY95	29, -28	20	115	60	73	130	65	100	156.50	
	5	06JUN95	36, -21	20	124	55	64	130	68	80	158.98	
	6	13JUN95	43, -14	20	115	52	67	130	72	86	160.40	
	7	20JUN95	50, -7	20	115	71	70	124	65	67	162.20	
	8	27JUN95	57, 1	20	130	68	69	115	81	102	162.10	
	12	25JUL95	85, 29	20	124	65	70	123	76	84	163.80	
	16	24AUG95	115, 59	20	115	44	63	94	60	72	159.00	
	20	26SEP95	148, 92#	0	106	63	75	107	56	83	155.00	
329.009.00133	SC	07JUN95	-6, .	0	138	72	132	144	59	95	308.26	68.1
	BL	13JUN95	1, .	0	144	98	105	149	85	114	308.80	
	1	20JUN95	8, .	20	152	80	95	155	58	105	308.00	
	2	27JUN95	15, .	20	145	55	88	145	79	97	307.80	
	3	05JUL95	23, .	20	145	79	95	147	72	108	309.50	
	4	11JUL95	29, .	30	138	76	80	138	83	87	308.30	
	5	18JUL95	36, .	40	131	72	109	148	69	111	308.40	
	6	27JUL95	45, .	40	148	72	91	146	62	109	308.90	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00138	SC	02OCT95	-8, .	0	114	64	76	107	71	84	116.50	65.5
	BL	10OCT95	1, .	0	122	61	83	115	65	98	117.70	
	1	17OCT95	8, .	20	104	54	70	107	71	85	117.70	
329.009.00170	SC	26OCT95	-12, -69	0	135	86	112	126	86	115	101.60	65.5
	1	14NOV95	8, -50	20	130	68	112	146	96	133	101.60	
	2	21NOV95	15, -43	20	128	79	114	124	80	126	101.10	
	3	28NOV95	22, -36	20	128	90	109	114	79	109	100.30	
	4	05DEC95	29, -29	30	129	83	115	126	91	119	100.90	
	5	12DEC95	36, -22	40	106	70	97	116	68	108	100.60	
	6	21DEC95	45, -13	40	107	68	84	100	73	90	98.80	
	7	29DEC95	53, -5	30	124	90	108	116	84	105	100.60	
	8	03JAN96	58, 1	30	130	80	125	124	81	125	101.50	
	12	29JAN96	84, 27	30	105	65	105	99	57	100	103.40	
	16	26FEB96	112, 55	30	114	52	106	114	49 L	108	105.90	
	20	01APR96	147, 90	30	93	76	78	115	60	102	106.30	
	24	22APR96	168, 111	30	114	72	93	128	67	98	109.00 H	
	28	23MAY96	199, 142	30	113	96	74	111	74	99	113.40 H	
	32	24JUN96	231, 174	30	128	82	99	131	85	99	114.60 H	
329.009.00173	SC	08NOV95	-12, -75	0	131	68	84	129	68	86	145.80	64.2
	BL	20NOV95	1, -63	0	133	80	85	131	73	96	142.60	
	1	27NOV95	8, -56	20	130	64	80	132	67	84	147.10	
	2	04DEC95	15, -49	20	110	67	66	123	64	74	142.90	
	3	11DEC95	22, -42	20	117	59	80	115	69	83	144.60	
	4	18DEC95	29, -35	30	121	60	75	122	68	80	145.60	
	6	29DEC95	40, -24	30	131	65	87	122	56	88	144.30	
	7	08JAN96	50, -14	20	124	57	98	131	68	96	139.00	
	8	15JAN96	57, -7	20	131	69	88	122	74	94	140.10	
	8	22JAN96	64, 1	20	114	61	80	116	66	87	141.60	
	12	26FEB96	99, 36	20	100	50	80	124	61	85	139.00	
329.009.00193	SC	21NOV95	-7, .	0	121	63	89	127	65	101	131.90	63.8
	BL	28NOV95	1, .	0	111	51	90	130	64	100	134.60	
	1	05DEC95	8, .	20	127	64	80	129	63	79	132.40	
	2	12DEC95	15, .	20	115	57	76	114	57	93	132.90	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00193	3	19DEC95	22, .	20	105	65	91	117	65	119	133.20	
	4	27DEC95	30, .	30	123	57	95	122	60	103	136.10	
	5	05JAN96	39, .	30	109	46	91	99	52	103	134.00	
	6	09JAN96	43, .	30	123	53	94	122	60	108	139.00	
	7	16JAN96	50, .	30	114	52	93	122	62	72	137.50	
	8	24JAN96	58, .	20	114	64	103	134	69	105	139.20	
329.009.00196	SC	11DEC95	-7, .	0	148	85	102	146	76	106	237.00	65.0
	BL	18DEC95	1, .	0	137	75	90	138	71	91	232.40	
	1	27DEC95	10, .	20	146	80	90	138	77	100	231.00	
	2	02JAN96	16, .	20	144	79	75	140	79	86	233.80	
	3	08JAN96	22, .	20	153	87	88	153	87	98	237.90	
	4	15JAN96	29, .	30	146	80	87	146	80	90	237.50	
	5	22JAN96	36, .	30	137	83	74	129	85	85	235.90	
	6	29JAN96	43, .	30	138	77	91	139	66	94	236.00	
	7	05FEB96	50, .	30	137	72	95	150	90	96	239.50	
	8	12FEB96	57, .	20	117	66	100	114	60	102	234.10	
329.009.00201	SC	31JAN96	-6, .	0	106	51	85	122	67	110	151.80	67.0
	BL	06FEB96	1, .	0	127	53	87	130	95	112	150.80	
	1	13FEB96	8, .	20	130	69	85	158	74	102	151.40	
	2	20FEB96	15, .	20	124	57	86	120	61	97	152.40	
	3	28FEB96	23, .	20	118	59	93	121	65	108	153.90	
	4	05MAR96	29, .	20	131	63	101	114	64	105	154.30	
	5	12MAR96	36, .	20	131	80	90	129	65	103	158.90	
	6	19MAR96	43, .	20	125	78	100	131	85	106	157.20	
	7	26MAR96	50, .	30	124	49	90	122	68	97	158.40	
	8	02APR96	57, .	20	136	59	109	121	77	106	163.80 H	
329.009.00204	SC	13MAR96	-6, -62	0	108	59	93	102	64	98	113.20	63.0
	BL	19MAR96	1, -56	0	105	64	87	105	51	89	117.10	
	1	26MAR96	8, -49	20	145	73	89	136	96	100	115.80	
	2	02APR96	15, -42	20	110	56	80	111	63	83	114.40	
	3	09APR96	22, -35	20	106	53	74	97	56	84	115.90	
	4	16APR96	29, -28	20	116	58	88	123	58	102	116.60	
	5	23APR96	36, -21	20	115	50	78	109	62	89	118.10	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00204	6	30APR96	43, -14	20	123	50	86	104	67	86	119.70	
	7	07MAY96	50, -7	20	122	63	93	122	59	98	120.10	
	8	14MAY96	57, 1	20	114	61	80	114	63	80	117.90	
	12	11JUN96	85, 29	20	115	62	93	108	67	102	119.90	
	16	09JUL96	113, 57	20	119	57	91	115	67	105	121.60	
	20	13AUG96	148, 92	20	118	57	86	120	68	101	123.00	
	24	10SEP96	176, 120	20	118	58	90	105	66	106	126.10 H	
	28	14OCT96	210, 154	20	120	57	74	126	55	91	129.00 H	
329.009.00235	SC	10DEC96	-8, -62	0	119	66	82	107	70	109	121.70	65.0
	BL	17DEC96	-1, -55	0	112	66	86	98	65	109	121.60	
	1	23DEC96	6, -49	20	111	67	80	116	66	82	123.60	
	2	30DEC96	13, -42	20	104	59	76	110	63	74	122.20	
	3	06JAN97	20, -35	20	122	63	95	112	54	135	121.50	
	4	15JAN97	29, -26	20	99	57	93	106	61	100	119.40	
	5	20JAN97	34, -21	20	138	91	102	121	55	125	120.20	
	6	27JAN97	41, -14	20	114	60	97	104	66	133	118.00	
	7	03FEB97	48, -7	20	107	57	81	112	58	105	119.80	
	8	10FEB97	55, 1	20	121	60	86	112	70	117	122.20	
	12	17MAR97	90, 36	20	130	65	106	120	77	109	123.30	
	16	14APR97	118, 64	20	145	82	86	135	78	115	121.50	
329.009.00240	SC	03JAN97	-11, .	0	120	84	85	124	82	91	168.00	67.7
	BL	10JAN97	-4, .	0	138	65	80	128	74	93	171.40	
	1	21JAN97	8, .	20	122	56	67	112	66	73	172.50	
	2	28JAN97	15, .	20	108	57	76	114	64	81	168.10	
	3	04FEB97	22, .	20	127	64	71	123	71	88	171.80	
	4	11FEB97	29, .	20	117	46	72	114	68	81	167.40	
	5	18FEB97	36, .	30	123	58	88	115	65	103	173.80	
	6	25FEB97	43, .	30	129	64	89	121	71	106	173.00	
	7	04MAR97	50, .	30	121	63	85	112	66	96	173.20	
329.009.00303	SC	25MAR96	-8, -64	0	116	66	59	123	71	54	166.20	71.0
	BL	02APR96	1, -56	0	108	59	68	122	58	76	166.90	
	1	09APR96	8, -49	20	116	56	62	121	45	65	166.20	
	2	16APR96	15, -42	20	122	57	61	121	60	64	165.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00303	3	23APR96	22, -35	20	123	57	62	120	48	66	165.00	
	4	30APR96	29, -28	20	130	58	61	125	51	59	165.60	
	5	07MAY96	36, -21	20	130	58	62	121	63	60	165.00	
	6	14MAY96	43, -14	20	115	50	62	123	61	64	167.00	
	7	22MAY96	51, -6	20	115	65	72	123	65	72	166.90	
	8	28MAY96	57, 1	20	107	49	49	107	46	56	164.90	
	12	25JUN96	85, 29	20	138	69	75	133	65	72	166.26	
	16	30JUL96	120, 64	20	109	47	62	116	59	68	170.67	
	20	27AUG96	148, 92	20	122	52	64	128	58	70	169.60	
	24	25SEP96	177, 121	20	122	59	68	121	67	68	169.30	
	32	30OCT96	212, 156	20	116	58	67	117	71	72	170.20	
	32	10DEC96	253, 197	20	127	60	67	118	60	76	172.80	
329.009.00304	SC	03APR96	-6, -62	0	122	56	73	131	65	70	201.00	67.0
	BL	09APR96	1, -56	0	118	59	80	121	52	82	200.80	
	1	16APR96	8, -49	20	138	60	72	139	57	73	199.90	
	2	23APR96	15, -42	20	138	59	74	145	63	86	195.90	
	3	30APR96	22, -35	20	140	70	90	145	83	102	198.10	
	4	07MAY96	29, -28	30	132	71	91	139	73	100	197.20	
	5	14MAY96	36, -21	30	137	60	100	139	74	102	195.20	
	6	21MAY96	43, -14	30	138	65	91	68 L	56	109	198.70	
	7	28MAY96	50, -7	30	137	64	69	120	59	79	200.70	
	8	04JUN96	57, 1	30	130	64	99	128	60	102	198.70	
	12	02JUL96	85, 29	30	131	64	70	120	67	75	202.20	
	16	30JUL96	113, 57	30	113	52	78	120	54	98	213.00	
	20	27AUG96	141, 85	30	129	61	88	142	61	96	207.20	
	24	23SEP96	168, 112	30	118	57	88	91	56	89	207.40	
	28	21OCT96	196, 140	30	140	54	70	139	60	73	210.30	
329.009.00324	SC	21OCT96	-7, .	0	126	59	88	116	62	98	127.70	61.0
	BL	28OCT96	1, .	0	130	64	82	131	75	85	126.30	
	1	04NOV96	8, .	20	116	69	78	115	55	86	125.10	
	2	11NOV96	15, .	20	114	66	86	127	66	83	126.50	
	3	18NOV96	22, .	20	114	64	77	106	67	80	123.40	
	4	25NOV96	29, .	20	119	59	89	77 L	55	94	124.80	
	5	02DEC96	36, .	20	115	65	85	107	73	100	127.30	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00324	6	09DEC96	43, .	20	114	72	85	106	57	86	124.90	
	7	16DEC96	50, .	20	122	73	88	108	61	84	123.20	
	8	27DEC96	61, .	20	115	62	86	132	68	89	124.00	
329.009.00328	SC	30SEP96	-7, .	0	123	67	70	112	85	79	85.30	59.5
	BL	07OCT96	1, .	0	111	68	71	112	76	86	86.60	
329.009.00329	SC	01OCT96	-8, .	0	108	62	59	101	67	65	122.30	66.1
	BL	09OCT96	1, .	0	119	56	64	128	62	88	121.60	
	1	16OCT96	8, .	20	123	58	57	122	60	67	120.70	
	2	23OCT96	15, .	20	126	57	66	125	64	71	120.30	
	3	29OCT96	21, .	20	123	57	54	129	71	58	123.50	
	4	05NOV96	28, .	20	124	65	73	114	63	97	119.10	
	5	12NOV96	35, .	20	107	58	50	107	64	62	121.70	
	6	19NOV96	42, .	30	130	64	64	133	63	80	122.20	
	7	26NOV96	49, .	30	114	61	54	115	61	66	120.50	
329.010.00182	8	03DEC96	56, .	30	115	58	62	121	60	66	120.90	
	SC	05DEC95	-14, .	0	.	.	.	.	.	.	137.50	71.0
	BL	19DEC95	1, .	0	110	80	68	112	87	84	140.50	
	3	12JAN96	25, .	20	118	72	72	122	82	84	135.50	
	4	19JAN96	32, .	20	118	75	66	124	70	74	130.00 L	
329.010.00278	SC	12DEC97	725, .#	0	118	70	82	118	75	94		
	SC	02FEB96	-7, -63	0	122	82	64	118	88	88	182.00	65.0
	BL	09FEB96	1, -56	0	127	78	.	118	70	118	184.50	
	1	16FEB96	8, -49	20	120	80	68	118	85	88	180.75	
	2	23FEB96	15, -42	20	124	78	60	118	70	88	181.00	
	3	01MAR96	22, -35	20	135	88	60	115	80	92	179.80	
	4	08MAR96	29, -28	20	118	83	68	120	88	96	179.50	
	5	15MAR96	36, -21	30	120	78	68	118	82	92	177.00	
	6	22MAR96	43, -14	40	110	78	62	104	72	72	179.50	
	7	29MAR96	50, -7	40	118	70	80	114	80	104	178.70	
	8	05APR96	57, 1	40	112	78	60	108	72	96	178.00	
	12	03MAY96	85, 29	40	123	58	72	115	72	85	182.00	
	16	31MAY96	113, 57	40	110	70	60	100	80	96	176.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.010.00278	20	27JUN96	140, 84	40	110	70	72	105	80	92	179.50	
	24	25JUL96	168, 112	40	105	80	72	100	75	88	178.00	
	28	22AUG96	196, 140	40	124	80	68	122	85	92	179.00	
	32	19SEP96	224, 168	40	100	65	76	100	70	96	181.50	
329.010.00280	SC	10MAY96	-7, -62	0	117	60	90	110	70	104	192.00	64.0
	BL	17MAY96	1, -55	0	117	60	90	110	70	104	192.00	
	1	24MAY96	8, -48	20	110	68	72	112	80	85	185.00	
	2	31MAY96	15, -41	20	112	80	76	108	60	98	182.00	
	3	07JUN96	22, -34	20	112	78	92	100	72	96	185.50	
	4	14JUN96	29, -27	20	100	70	80	110	78	98	186.00	
	5	21JUN96	36, -20	30	108	60	80	108	78	110	183.00	
	6	27JUN96	42, -14	40	100	70	80	100	80	84	185.00	
	7	03JUL96	48, -8	40	112	80	72	105	80	104	182.00	
	8	11JUL96	56, 1	40	105	70	80	120	80	88	183.00	
	12	21AUG96	97, 42#	0	.	76	78	110	80	92	193.00	
329.011.00283	SC	30JAN96	-9, -66	0	108	70	64	108	70	68	125.00	67.0
	1	14FEB96	7, -51	20	120	80	80	120	76	80	127.00	
	2	21FEB96	14, -44	20	110	76	60	108	76	62	124.70	
	3	29FEB96	22, -36	20	110	76	76	110	76	84	128.70	
	4	07MAR96	29, -29	20	108	70	76	108	70	76	128.20	
	5	15MAR96	37, -21	20	110	70	60	110	70	70	128.00	
	6	22MAR96	44, -14	20	110	60	76	104	60	70	127.20	
	7	28MAR96	50, -8	20	120	80	60	120	80	72	129.50	
	8	04APR96	57, -1	20	110	70	70	110	70	70	129.50	
329.011.00288	SC	01JUL96	-24, .	0	110	70	84	106	70	88	105.50	65.2
	BL	18JUL96	-7, .	0	110	68	88	110	70	96	105.50	
	1	01AUG96	8, .	20	110	56	70	106	60	76	103.20	
	2	09AUG96	16, .	20	110	60	80	100	60	80	103.00	
	4	19AUG96	26, .	20	104	70	80	100	70	90	104.20	
	5	29AUG96	36, .	20	100	70	80	104	70	80	103.20	
329.012.00025	SC	17OCT95	-7, .	0	114	80	82	118	80	92	114.66	65.0
	BL	24OCT95	1, .	0	110	74	72	114	80	76	114.66	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.012.00025	1	31OCT95	8, .	20	110	70	94	110	74	100	114.88	
	2	07NOV95	15, .	20	108	90	72	110	92	80	115.10	
	3	14NOV95	22, .	20	100	70	76	90	68	76	114.66	
	4	21NOV95	29, .	20	100	76	70	96	64	74	114.88	
	5	28NOV95	36, .	30	90	60	96	100	70	96	113.56	
	6	05DEC95	43, .	40	98	78	92	102	80	100	113.56	
	7	12DEC95	50, .	40	113	69	74	113	60	85	114.44	
	8	19DEC95	57, .	40	100	62	80	110	70	100	113.34	
329.012.00220	SC	04JUN96	-13, -73	0	122	82	76	128	90	80	179.93	66.9
	BL	14JUN96	-3, -63	0	110	80	60	110	70	68	179.49	
	1	22JUN96	6, -55	20	112	76	60	110	80	68	182.13	
	2	28JUN96	12, -49	20	120	80	68	124	84	64	183.24	
	3	05JUL96	19, -42	20	114	80	60	116	78	68	184.34	
	4	12JUL96	26, -35	30	110	74	68	120	70	84	186.32	
	5	19JUL96	33, -28	30	112	70	70	118	72	72	186.54	
	6	29JUL96	43, -18	30	118	78	82	114	74	80	186.54	
	7	06AUG96	51, -10	30	126	90	64	128	88	80	186.32	
	8	16AUG96	61, 1	30	120	80	80	130	90	86	185.22	
	12	13SEP96	89, 29	30	120	70	68	120	80	80	182.79	
	16	11OCT96	117, 57	30	120	82	84	122	84	100	180.37	
	20	08NOV96	145, 85	30	120	80	68	120	72	70	183.02	
	24	06DEC96	173, 113	0	120	80	76	120	70	82	184.12	
329.012.00222	SC	18JUN96	-10, -73	0	100	66	60	100	70	80	119.51	66.1
	BL	28JUN96	1, -63	0	110	70	80	112	76	72	121.05	
	1	05JUL96	8, -56	20	100	68	62	112	70	70	119.95	
	2	12JUL96	15, -49	20	110	70	72	110	62	68	119.07	
	3	19JUL96	22, -42	20	110	62	68	110	70	72	119.29	
	4	29JUL96	32, -32	20	114	70	64	110	68	62	119.51	
	6	06AUG96	40, -24	30	110	70	68	110	74	60	118.63	
	7	13AUG96	47, -17	30	108	76	82	100	80	80	119.51	
	8	20AUG96	54, -10	30	100	70	70	110	70	76	119.95	
	8	30AUG96	64, 1	30	130	78	68	122	74	70	119.51	
	12	27SEP96	92, 29	30	110	80	80	116	76	70	121.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.012.00226	SC	26NOV96	-7, .	0	110	70	100	112	80	110	176.40	73.2
	BL	03DEC96	1, .	0	120	82	76	122	80	84	174.20	
	1	10DEC96	8, .	20	132	80	78	128	76	80	174.20	
	2	20DEC96	18, .	20	112	70	86	118	76	100	175.30	
329.012.00228	SC	04MAR97	-15, .	0	90	66	68	100	70	70	108.05	63.4
	BL	19MAR97	1, .	0	110	70	82	100	70	90	109.15	
	1	27MAR97	9, .	20	100	70	66	100	72	70	109.15	
329.012.00231	SC	26FEB97	-9, -70	0	110	70	68	112	80	72	156.56	63.4
	BL	07MAR97	1, -61	0	120	70	82	128	80	90	155.45	
	1	17MAR97	11, -51	20	110	80	60	120	80	72	157.88	
	2	24MAR97	18, -44	20	118	84	76	108	76	88	158.10	
	4	02APR97	27, -35	20	110	90	80	120	80	90	161.63	
	5	09APR97	34, -28	20	116	80	76	120	82	80	159.64	
	6	17APR97	42, -20	20	122	80	80	126	90	86	161.19	
	7	25APR97	50, -12	30	126	70	67	122	74	68	161.41	
	8	01MAY97	56, -6	30	116	76	74	114	78	78	162.95	
	8	07MAY97	62, 1	30	110	70	64	106	74	62	166.26	
	12	04JUN97	90, 29	30	120	80	72	120	86	72	166.92 H	
	16	30JUN97	116, 55	30	110	70	80	118	84	84	173.31 H	
	20	05AUG97	152, 91	20	128	80	80	120	80	80	176.18 H	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.001.00061	SC	19JUL94	-10, .	0	104	60	76	106	64	76	145.00	61.0
	BL	29JUL94	1, .	0	102	58	72	108	64	72	146.00	
	1	04AUG94	7, .	100	94	62	92	100	70	104	143.00	
	2	11AUG94	14, .	150	104	64	102	96	64	124 H	145.80	
	3	18AUG94	21, .	200	100	62	102	102	64	108	147.80	
	4	25AUG94	28, .	200	108	74	96	102	70	102	147.80	
	5	01SEP94	35, .	200	100	68	100	98	62	112	149.50	
329.001.00066	SC	14NOV94	-8, .	0	104	60	62	110	68	100	142.00	68.0
	BL	21NOV94	-1, .	0	98	60	68	92	70	80	142.00	
	1	28NOV94	7, .	100	114	74	100	100	70	120	135.00	
	2	05DEC94	14, .	100	120	68	96	118	78	124 H	140.50	
329.001.00067	SC	15NOV94	-7, .	0	108	60	78	110	60	96	105.50	64.5
	BL	22NOV94	1, .	0	100	64	64	88	60	88	106.00	
	1	29NOV94	8, .	100	112	76	88	118	84	92	105.00	
	2	06DEC94	15, .	100	96	70	92	92	68	118	105.50	
329.001.00070	SC	14FEB95	-8, .	0	108	70	76	112	74	88	76.00	58.0
	BL	22FEB95	1, .	0	104	70	82	110	70	92	76.00	
	1	28FEB95	7, .	100	100	60	100	98	60	120	76.00	
	2	08MAR95	15, .	150	98	60	100	100	70	108	74.00	
329.001.00122	3	15MAR95	22, .	150	100	60	102	92	62	118	74.00	
	SC	13JUN95	-7, -64	0	120	72	68	112	70	78	166.00	68.5
	BL	20JUN95	1, -57	0	110	60	64	102	70	74	166.00	
	1	27JUN95	8, -50	100	110	78	76	110	60	80	163.50	
	2	05JUL95	16, -42	150	102	70	80	110	70	104	164.00	
	3	11JUL95	22, -36	200	114	80	90	106	84	98	165.00	
	4	18JUL95	29, -29	200	110	74	88	120	80	108	164.00	
	5	25JUL95	36, -22	200	110	74	90	114	80	102	164.00	
	6	01AUG95	43, -15	200	120	80	78	112	86	96	166.00	
	7	08AUG95	50, -8	200	116	80	84	110	82	92	168.20	
	8	16AUG95	58, 1	200	120	76	96	120	80	98	171.00	
	12	12SEP95	85, 28	200	118	70	96	116	80	104	171.00	
	16	10OCT95	113, 56	200	110	80	82	108	76	84	171.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.001.00122	20	07NOV95	141, 84	200	120	70	88	112	80	112	179.00	H
	24	05DEC95	169, 112	200	120	80	94	114	80	106	180.50	H
329.002.00050	SC	10MAR95	-13, .	0	140	74	70	149	82	76	152.15	67.5
	BL	22MAR95	-1, .	0	135	75	88	135	75	96	154.00	
	1	29MAR95	7, .	50	115	70	92	115	70	104	154.00	
	2	05APR95	14, .	100	139	69	94	123	73	111	154.00	
	3	12APR95	21, .	150	120	80	104	120	85	112	153.00	
	5	28APR95	37, .	150	139	68	95	122	76	102	155.67	
329.002.00056	SC	24JUN94	-25, .	0	90	52	84	80	50	108	111.00	59.4
	BL	19JUL94	1, .	0	82	40	100	84	44	102	113.00	
	1	26JUL94	8, .	100	84	58	100	84	56	120	110.00	
	2	02AUG94	15, .	150	90	50	108	72	40	112	109.00	
	3	09AUG94	22, .	200	92	60	132 H	90	60	104	110.00	
	4	16AUG94	29, .	200	84	52	120	78	42	140 H	112.50	
329.002.00057	SC	11AUG94	-28, -85	0	98	62	72	88	60	88	162.50	66.5
	BL	08SEP94	1, -57	0	99	62	73	92	61	89	163.00	
	1	15SEP94	8, -50	100	90	60	88	84	60	84	160.50	
	2	22SEP94	15, -43	150	102	70	102	94	60	140 H	158.00	
	3	29SEP94	22, -36	200	90	60	100	94	60	100	158.00	
	4	06OCT94	29, -29	250	112	68	96	110	66	100	157.00	
	5	13OCT94	36, -22	300	104	60	100	88	50	102	159.50	
	6	20OCT94	43, -15	300	100	62	100	98	60	104	159.00	
	7	27OCT94	50, -8	300	102	64	100	94	62	102	160.00	
	8	03NOV94	57, -1	300	90	60	120	80	58	140 H	160.00	
	12	01DEC94	85, 28	300	110	60	100	90	60	128 H	163.00	
	16	29DEC94	113, 56	300	104	64	100	102	60	120	157.00	
329.002.00098	SC	20DEC94	-14, .	0	98	58	88	96	58	92	127.50	61.0
	BL	03JAN95	1, .	0	98	58	88	96	58	92	127.50	
	1	10JAN95	8, .	100	100	58	84	95	60	104	127.00	
	2	18JAN95	16, .	150	118	68	84	110	68	88	126.00	
	3	24JAN95	22, .	200	108	66	84	100	64	86	126.00	
	4	31JAN95	29, .	250	110	72	100	106	72	104	127.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00098	5	07FEB95	36, .	300	116	78	74	106	74	80	128.00	
	6	14FEB95	43, .	250	118	78	108	116	78	112	127.00	
	7	21FEB95	50, .	250	118	70	70	120	72	76	127.00	
	8	02MAR95	59, .	250	102	64	100	102	68	100	127.00	
329.002.00100	BL	07MAR95	1, -58	0	130	70	96	132	70	98	144.00	
	1	14MAR95	8, -51	100	116	70	78	112	70	90	145.00	
	2	21MAR95	15, -44	150	120	80	90	118	80	96	148.00	
	3	28MAR95	22, -37	200	120	80	80	114	80	80	146.25	
	4	04APR95	29, -30	200	116	78	110	120	78	112	147.25	
	5	11APR95	36, -23	250	110	80	84	114	80	86	145.25	
	6	18APR95	43, -16	250	118	80	100	112	80	114	147.75	
	7	25APR95	50, -9	250	110	62	98	108	62	100	147.50	
	8	04MAY95	59, 1	250	108	78	90	100	76	98	148.75	
	12	30MAY95	85, 27	250	126	80	100	108	80	112	146.50	
	16	27JUN95	113, 55#	0	112	80	100	118	80	116	145.25	
329.002.00103	SC	11APR95	-9, -65	0	110	64	65	110	64	66	116.50	60.0
	BL	20APR95	1, -56	0	94	62	68	90	62	68	115.00	
	1	27APR95	8, -49	100	92	62	70	90	60	68	114.00	
	2	02MAY95	13, -44	150	100	70	70	100	70	72	117.25	
	3	09MAY95	20, -37	200	102	70	100	102	70	92	114.25	
	4	16MAY95	27, -30	200	112	80	80	112	76	80	116.50	
	5	25MAY95	36, -21	200	98	68	60	90	64	74	115.00	
	6	30MAY95	41, -16	250	102	70	80	98	70	100	115.00	
	7	06JUN95	48, -9	250	100	66	88	96	60	84	111.25	
	8	15JUN95	57, 1	250	94	68	72	80	64	70	110.50	
	12	13JUL95	85, 29	250	102	70	88	96	68	80	112.00	
	16	10AUG95	113, 57	250	100	68	90	100	64	84	114.00	
329.002.00104	SC	28APR95	-6, -62	0	100	60	94	98	58	90	128.50	67.0
	1	11MAY95	8, -49	100	120	68	80	118	66	84	127.70	
	2	18MAY95	15, -42	150	106	74	76	100	70	80	130.50	
	3	25MAY95	22, -35	200	110	76	81	100	70	74	130.00	
	4	01JUN95	29, -28	250	122	80	92	120	72	100	126.00	
	5	09JUN95	37, -20	300	90	60	88	102	64	80	128.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00104	6	16JUN95	44, -13	300	90	66	80	82	64	74	129.00	
	7	22JUN95	50, -7	300	88	60	90	80	60	100	128.20	
	8	29JUN95	57, 1	300	122	76	100	100	70	68	130.00	
	12	25JUL95	83, 27	300	110	70	109	90	64	94	130.00	
	16	29AUG95	118, 62	300	102	76	90	96	60	130 H	128.00	
	20	03OCT95	153, 97	300	94	68	84	80	68	78	131.00	
	28	06NOV95	187, 131	300	108	70	106	112	72	80	129.50	
	32	06DEC95	217, 161	300	120	72	100	110	74	84	130.50	
	32	02JAN96	244, 188	250	110	60	100	108	60	92	127.50	
329.002.00243	SC	27FEB96	-16, .	0	94	64	68	92	60	64	112.50	62.0
	1	21MAR96	8, .	100	98	66	66	98	64	68	111.00	
	2	28MAR96	15, .	150	90	60	78	88	60	64	111.00	
	3	04APR96	22, .	150	90	62	74	88	64	76	113.00	
329.002.00244	SC	14MAR96	-7, -64	0	122	72	84	120	70	80	141.00	63.0
	BL	21MAR96	1, -57	0	110	66	80	112	70	98	143.00	
	1	28MAR96	8, -50	100	120	78	78	118	70	70	142.00	
	2	04APR96	15, -43	150	122	74	89	120	76	82	143.00	
	3	11APR96	22, -36	200	112	70	99	110	72	110	143.00	
	4	18APR96	29, -29	250	106	74	106	100	72	100	144.00	
	5	25APR96	36, -22	200	110	64	75	108	68	80	145.00	
	6	02MAY96	43, -15	250	120	70	84	116	70	86	144.00	
	7	09MAY96	50, -8	300	110	70	94	112	70	88	144.50	
	8	16MAY96	57, -1	300	104	68	106	92	70	104	144.20	
329.002.00321	BL	23MAY96	1, .	0	96	64	64	100	70	66	112.00	65.0
	1	30MAY96	8, .	50	88	64	66	88	64	80	114.00	
329.002.00322	SC	06JAN97	-3, .	0	120	84	80	120	80	86	136.00	68.5
	1	16JAN97	8, .	100	120	68	108	114	68	130 H	136.00	
	2	23JAN97	15, .	150	120	76	80	110	70	84	135.00	
	3	30JAN97	22, .	200	90	70	86	88 L	70	82	132.00	
	4	04FEB97	27, .	200	112	68	80	108	70	74	134.00	
	5	13FEB97	36, .	200	125	70	110	100	90	132 H	132.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00073	SC	11JAN95	-8, .	0	110	72	86	112	72	88	138.92	63.8
	BL	18JAN95	-1, .	0	100	70	82	90	68	87	140.00	
	1	25JAN95	7, .	100	110	68	100	100	70	120	136.70	
	2	03FEB95	16, .	150	114	74	92	96	70	120	135.61	
	3	07FEB95	20, .	200	114	72	120	96	78	132 H	136.27	
	4	14FEB95	27, .	200	112	78	92	102	66	120	134.73	
	5	22FEB95	35, .	250	116	82	116	114	90	130 H	135.61	
	6	01MAR95	42, .	250	128	72	114	116	68	128 H	134.73	
	7	08MAR95	49, .	250	100	76	120	104	80	140 H	128.11 L	
329.003.00076	SC	24JAN95	-7, -62	0	126	66	80	132	66	86	200.66	65.4
	BL	31JAN95	1, -55	0	114	76	76	110	72	80	197.70	
	1	07FEB95	8, -48	100	118	82	100	120	78	118	201.76	
	2	14FEB95	15, -41	150	126	80	88	130	78	112	198.01	
	3	21FEB95	22, -34	200	110	78	117	104	70	112	200.66	
	4	27FEB95	28, -28	200	128	68	112	120	80	118	201.76	
	5	06MAR95	35, -21	200	128	76	102	124	80	112	202.20	
	6	13MAR95	42, -14	200	130	66	96	132	82	108	203.52	
	7	20MAR95	49, -7	200	112	84	96	110	80	112	206.17	
	8	27MAR95	56, 1	200	124	80	112	130	82	120	206.17	
	12	03MAY95	93, 38	200	116	60	86	114	66	100	205.07	
	16	31MAY95	121, 66	200	114	60	92	104	68	112	205.07	
	20	28JUN95	149, 94	200	102	60	110	104	68	122 H	209.92	
	28	02AUG95	184, 129	200	124	70	100	120	76	104	206.39	
	32	06SEP95	219, 164	200	122	68	120	120	74	120	209.25	
	32	11OCT95	254, 199	0	120	52	100	130	64	108	218.30 H	
329.003.00079	BL	03MAY95	1, .	0	112	78	64	100	70	84	152.15	68.1
	1	10MAY95	8, .	100	110	74	78	100	80	86	150.38	
	2	19MAY95	17, .	150	124	74	90	112	80	112	149.28	
329.003.00082	SC	11DEC95	1, .	0	108	66	56	110	67	93	120.00	63.5
	2	28DEC95	18, .	100	100	65	70	110	70	90	118.50	
	3	03JAN96	24, .	150	116	60	88	104	58	118	119.07	
	4	11JAN96	32, .	200	132	63	93	121	55	89	120.25	
	5	17JAN96	38, .	250	124	80	92	114	74	116	121.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00088	SC	06FEB95	-22, .	0	.	.	.	110	62	84	109.00	52.3
	BL	28FEB95	1, .	0	90	60	80	90	60	80	113.00	
	1	09MAR95	10, .	100	90	60	96	90	60	96	111.00	
	2	14MAR95	15, .	100	96	56	100	96	56	100	111.00	
	3	21MAR95	22, .	200	90	60	96	90	60	96	112.00	
	4	30MAR95	31, .	200	80	50	96	80	50	96	111.00	
	5	04APR95	36, .	200	82	50	96	82	50	96	110.00	
329.003.00090	6	11APR95	43, .	200	84	58	96	84	58	96	109.00	64.0
	SC	08MAR95	-6, .	0	100	60	70	100	60	72	137.00	
	BL	14MAR95	1, .	0	70	44	80	70	44	80	140.00	
	2	28MAR95	15, .	100	96	60	84	96	60	84	139.00	
	3	04APR95	22, .	150	100	60	80	100	60	80	138.00	
	4	11APR95	29, .	200	96	60	84	90	60	84	140.00	
	5	18APR95	36, .	200	96	60	84	80	60	84	137.50	
	6	25APR95	43, .	200	90	60	84	90	60	84	139.50	
	7	02MAY95	50, .	200	100	60	88	100	60	88	138.00	
	8	09MAY95	57, .	200	96	56	84	96	56	84	139.00	
329.003.00092	8	16MAY95	64, .	150	92	58	96	92	58	96	140.00	60.5
	SC	13APR95	-20, -78	0	104	60	68	104	62	72	99.00	
	BL	02MAY95	-1, -59	0	94	56	72	94	56	72	102.00	
	1	11MAY95	9, -50	50	88	56	76	88	56	76	101.00	
	2	16MAY95	14, -45	100	90	60	96	90	60	96	101.50	
	3	26MAY95	24, -35	200	90	60	88	90	60	88	99.50	
	4	02JUN95	31, -28	200	90	64	96	90	64	96	99.50	
	5	06JUN95	35, -24	200	100	60	88	.	.	.	100.00	
	6	13JUN95	42, -17	200	106	66	88	106	66	88	98.50	
	7	20JUN95	49, -10	200	100	60	84	100	60	84	99.00	
	8	30JUN95	59, 1	200	100	60	84	100	60	84	99.50	
	12	08AUG95	98, 40	200	96	62	84	90	62	84	97.00	
	16	05SEP95	126, 68	200	92	66	84	90	66	84	98.00	
	20	26SEP95	147, 89	200	96	62	96	90	60	96	101.00	
	28	07NOV95	189, 131	200	90	58	88	90	58	88	98.00	
	32	05DEC95	217, 159	200	90	60	84	90	60	84	103.00	
	32	02JAN96	245, 187	200	100	60	84	100	60	84	102.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00093	SC	08JUN95	-13, -76	0	106	70	64	110	70	70	127.00	61.5
	BL	20JUN95	-1, -64	0	90	60	84	90	60	84	125.00	
	1	27JUN95	7, -57	100	90	60	84	90	60	84	122.50	
	2	06JUL95	16, -48	100	90	60	84	90	60	84	125.00	
	4	21JUL95	31, -33	150	96	60	84	80	60	84	125.00	
	5	25JUL95	35, -29	200	92	56	88	90	56	88	125.00	
	6	01AUG95	42, -22	250	84	54	100	86	54	100	126.00	
	7	10AUG95	51, -13	300	86	54	96	80	54	96	126.00	
	8	22AUG95	63, -1	300	90	60	88	86	60	88	126.00	
	16	03OCT95	105, 42#	0	90	60	80	90	60	80	128.00	
329.003.00247	SC	05JAN96	-27, -81	0	90	62	.	.	.	.	132.00	70.5
	BL	30JAN96	-2, -56	0	100	60	72	100	60	72	130.00	
	1	06FEB96	6, -49	50	100	60	72	100	60	72	130.00	
	2	13FEB96	13, -42	150	96	60	84	80	56	84	131.00	
	3	20FEB96	20, -35	150	98	56	88	100	56	88	131.00	
	4	27FEB96	27, -28	200	96	68	112	90	64	112	130.00	
	5	07MAR96	36, -19	200	102	60	96	102	60	96	135.00	
	6	12MAR96	41, -14	200	96	62	96	96	60	96	132.00	
	7	21MAR96	50, -5	200	94	60	96	94	60	96	132.00	
	8	26MAR96	55, 1	200	90	60	84	90	60	84	131.00	
	12	30APR96	90, 36	200	100	60	84	96	60	88	135.00	
	16	21MAY96	111, 57	200	90	60	96	90	60	96	131.00	
329.003.00249	SC	01MAR96	-6, .	0	90	60	78	90	58	76	176.00	63.3
	BL	07MAR96	1, .	0	86	60	88	86	60	88	176.00	
	1	12MAR96	6, .	100	90	60	84	90	60	84	176.00	
	2	19MAR96	13, .	150	100	70	96	100	70	96	177.00	
	3	26MAR96	20, .	200	92	56	84	90	56	84	175.00	
	4	02APR96	27, .	250	100	60	84	90	60	88	176.00	
	5	09APR96	34, .	300	106	70	84	100	66	84	178.00	
	6	16APR96	41, .	300	106	72	96	100	66	96	180.00	
	7	23APR96	48, .	300	98	78	88	90	74	88	176.00	
	8	30APR96	55, .	250	100	70	96	96	70	96	177.00	
329.003.00289	SC	12FEB96	-16, -72	0	110	56	76	104	62	76	118.63	63.0

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00289	1	06MAR96	8, -49	100	114	82	84	102	72	84	119.07	
	2	13MAR96	15, -42	150	94	70	108	88	68	120	118.41	
	3	20MAR96	22, -35	200	102	70	96	98	70	112	117.53	
	4	27MAR96	29, -28	200	104	70	94	94	76	112	114.66	
	5	03APR96	36, -21	200	94	64	96	84	66	112	113.12	
	6	10APR96	43, -14	200	98	70	82	86	66	96	114.66	
	7	17APR96	50, -7	200	100	66	98	92	62	112	116.87	
	8	24APR96	57, 1	200	106	74	84	98	68	82	118.41	
	12	22MAY96	85, 29	200	104	74	102	90	70	108	113.78	
	16	20JUN96	114, 58	200	90	62	92	84	64	100	115.10	
	20	19JUL96	143, 87	200	99	65	86	93	66	90	105.80 L	
	24	16AUG96	171, 115	200	80 L	60	100	84	60	104	102.09 L	
	28	13SEP96	199, 143	200	92	58	80	82	64	90	106.06 L	
	32	11OCT96	227, 171	150	88	60	68	86	64	70	108.93 L	
329.003.00290	SC	06MAR96	-5, .	0	122	70	90	128	72	112	176.18	66.1
	1	20MAR96	10, .	100	150	76	112	160	86	124	175.08	
	2	22MAR96	12, .	100	136	70	104	160	88	118		
329.003.00314	SC	15OCT96	-7, .	0	100	60	70	.	.	.	145.00	65.5
	BL	22OCT96	1, .	0	106	64	84	106	64	84	148.00	
	1	29OCT96	8, .	100	90	60	96	90	60	96	147.00	
	2	05NOV96	15, .	150	100	60	96	100	60	96	147.00	
	3	14NOV96	24, .	200	104	64	84	104	64	84	151.00	
	5	26NOV96	36, .	200	110	70	84	110	70	84	150.00	
	6	03DEC96	43, .	200	106	70	96	100	70	96	152.00	
	7	10DEC96	50, .	200	112	74	84	112	74	84	152.00	
	8	17DEC96	57, .	200	110	76	84	110	76	84	153.00	
	8	23DEC96	63, .	250	110	60	80	105	60	80	150.00	
329.003.00317	SC	12DEC96	-7, .	0	110	70	80	108	64	88	120.00	62.3
	BL	17DEC96	-2, .	0	110	70	96	110	70	96	122.00	
	1	23DEC96	5, .	50	90	60	96	90	60	110	119.00	
	3	07JAN97	20, .	150	115	80	88	115	70	96	118.50	
	4	14JAN97	27, .	200	110	80	96	100	80	96	118.00	
	5	21JAN97	34, .	200	110	80	88	100	80	88	118.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00317	6	28JAN97	41, .	250	110	80	92	100	80	92	118.00	
	7	04FEB97	48, .	300	110	74	84	110	74	84	118.00	
	8	11FEB97	55, .	250	120	70	84	120	70	84	116.00	
329.004.00013	SC	05JUL94	-14, -73	0	90	60	78	100	60	84	132.30	68.5
	BL	19JUL94	1, -59	0	108	70	60	104	70	64	131.86	
	1	26JUL94	8, -52	100	104	56	84	104	58	88	133.62	
	2	02AUG94	15, -45	150	104	78	74	96	76	88	132.30	
	3	09AUG94	22, -38	200	110	84	80	108	80	96	134.06	
	4	15AUG94	28, -32	200	115	80	78	100	75	100	136.71	
	5	23AUG94	36, -24	200	112	82	88	112	80	116	136.93	
	6	31AUG94	44, -16	200	120	82	92	100	72	104	136.71	
	7	08SEP94	52, -8	200	100	80	100	98	80	100	136.27	
	8	16SEP94	60, 1	200	102	82	92	104	82	108	138.92	
	12	11OCT94	85, 26	200	114	82	84	112	80	96	141.12 H	
	16	08NOV94	113, 54	250	110	80	90	120	90	100	144.43 H	
	20	06DEC94	141, 82	250	110	80	80	110	80	88	148.84 H	
	24	10JAN95	176, 117	250	110	70	80	110	70	100	151.04 H	
	28	07FEB95	204, 145	250	112	84	88	110	82	96	153.25 H	
	32	10MAR95	235, 176	200	112	84	92	116	86	92	153.03 H	
329.004.00014	SC	22NOV94	-7, .	0	100	68	70	110	80	80	145.31	72.8
	BL	29NOV94	1, .	0	100	60	78	100	60	80	147.51	
	1	05DEC94	7, .	100	130	70	84	120	70	88	142.44	
	2	13DEC94	15, .	100	100	60	80	100	70	88	138.03	
329.004.00211	SC	24JAN96	-9, .	0	80	60	60	90	60	68	102.53	63.0
	BL	01FEB96	-1, .	0	100	60	64	100	60	72	102.53	
	1	08FEB96	7, .	50	100	60	60	100	60	70	100.33	
	2	16FEB96	15, .	150	100	70	78	90	70	80	102.53	
	3	23FEB96	22, .	200	100	70	70	100	70	74	101.87	
	4	29FEB96	28, .	200	100	72	80	100	70	80	103.64	
	5	07MAR96	35, .	200	100	60	78	110	80	88	104.96	
	6	14MAR96	42, .	200	90	60	70	100	60	90	104.08	
	7	25MAR96	53, .	200	90	60	80	90	60	84	98.12	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.004.00215	SC	12MAR97	-8, .	0	98	64	60	98	70	64	103.19	58.3
	BL	20MAR97	1, .	0	98	50	76	98	45	76	102.31	
	1	27MAR97	8, .	100	105	60	84	100	60	88	99.23	
	2	03APR97	15, .	150	100	65	92	95	50	100	99.23	
	3	10APR97	22, .	200	100	60	100	95	50	108	98.78	
	4	15APR97	27, .	200	110	70	104	98	65	112	98.12	
	5	24APR97	36, .	200	108	70	104	100	68	108	99.89	
329.005.00003	6	29APR97	41, .	200	108	65	96	104	70	104	97.68	60.0
	SC	12SEP94	-8, .	0	106	70	80	108	70	84	116.50	
	BL	20SEP94	1, .	0	110	78	82	110	80	90	116.70	
	1	27SEP94	8, .	100	112	72	106	102	80	116	114.60	
329.005.00006	2	04OCT94	15, .	100	106	70	106	102	70	110	112.20	68.0
	SC	27OCT94	-8, -68	0	110	70	72	108	68	72	145.00	
	BL	03NOV94	-1, -61	0	100	70	60	90	70	62	141.90	
	1	14NOV94	11, -50	100	110	70	76	100	68	78	141.00	
	2	21NOV94	18, -43	150	110	70	64	100	70	64	141.00	
	3	28NOV94	25, -36	200	118	74	76	110	70	76	140.24	
	4	05DEC94	32, -29	250	100	60	70	90	60	72	142.00	
	5	12DEC94	39, -22	300	110	60	64	110	70	68	141.50	
	6	19DEC94	46, -15	300	100	64	80	90	60	94	139.00	
	8	27DEC94	54, -7	300	106	68	92	94	70	104	138.92	
	8	03JAN95	61, 1	300	104	70	90	90	60	94	139.14	
	12	02FEB95	91, 31	300	108	70	88	110	60	92	140.00	
	16	27FEB95	116, 56	300	104	70	84	100	70	88	145.31	
	20	05APR95	153, 93	300	120	70	92	104	70	96	147.00	
329.005.00007	SC	02NOV94	-7, -70	0	110	70	64	104	68	74	135.00	64.0
	BL	09NOV94	1, -63	0	110	70	74	100	70	72	132.30	
	2	23NOV94	15, -49	100	110	70	72	100	68	72	132.95	
	3	30NOV94	22, -42	150	100	70	74	94	68	74	132.52	
	4	07DEC94	29, -35	200	100	68	90	90	60	92	129.00	
	5	14DEC94	36, -28	250	110	80	80	94	70	80	127.80	
	6	21DEC94	43, -21	300	114	70	100	88	64	100	128.20	
	7	28DEC94	50, -14	250	110	80	100	100	70	104	129.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00007	8	04JAN95	57, -7	250	100	70	104	104	68	108	128.00	
	8	11JAN95	64, 1	250	104	74	86	90	70	92	128.10	
	12	15FEB95	99, 36	250	120	80	104	110	80	108	126.00	
	20	22MAR95	134, 71	250	120	70	80	98	60	88		
	24	19APR95	162, 99	250	104	70	100	100	60	104	127.00	
	28	17MAY95	190, 127	250	104	70	100	90	60	104	129.00	
	32	09AUG95	274, 211#	0	104	74	92	100	70	98	129.50	
329.005.00009	SC	07DEC94	-5, .	0	110	70	76	104	70	80	146.00	63.0
	BL	12DEC94	1, .	0	100	70	80	100	60	88	145.00	
	1	19DEC94	8, .	100	110	70	84	116	70	96	143.00	
	2	27DEC94	16, .	150	110	70	100	100	70	100	143.00	
	3	03JAN95	23, .	200	110	70	92	104	74	92	143.00	
	4	11JAN95	31, .	250	110	70	90	94	60	94	145.00	
	5	18JAN95	38, .	300	108	62	80	100	62	100	144.65	
	6	25JAN95	45, .	250	100	70	84	94	70	88	144.43	
	7	31JAN95	51, .	250	110	80	80	100	80	80	144.21	
329.005.00110	8	07FEB95	58, .	250	100	88	96	94	70	104	145.00	
	SC	04JAN95	-7, .	0	98	54	80	106	66	88	124.36	67.0
	BL	11JAN95	1, .	0	100	70	72	100	60	80	123.00	
	1	18JAN95	8, .	100	110	72	70	98	64	90	120.00	
	2	25JAN95	15, .	100	110	70	74	100	70	78	122.00	
329.005.00113	SC	20JAN95	-10, .	0	110	70	68	100	70	72	145.00	67.0
	BL	30JAN95	1, .	0	90	60	80	100	70	84	143.33	
	1	08FEB95	10, .	100	110	70	72	100	60	74	145.20	
	2	16FEB95	18, .	150	104	70	88	104	68	100	141.34	
	3	23FEB95	25, .	200	110	70	72	100	70	80	140.00	
	4	02MAR95	32, .	200	100	70	80	84	60	80	140.00	
329.005.00117	SC	06MAR95	-12, .	0	120	84	82	116	80	86	245.64	52.0
	BL	16MAR95	-2, .	0	124	84	84	100	80	88	246.96	
	1	27MAR95	10, .	100	108	80	98	122	90	98	245.86	
	2	03APR95	17, .	150	114	68	98	118	70	108	249.20	
	3	10APR95	24, .	200	120	70	102	110	70	110	248.40	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00117	4	17APR95	31, .	200	110	70	100	114	70	108	246.50	
	5	24APR95	38, .	200	100	58	96	98	50	104	246.20	
	6	01MAY95	45, .	200	114	68	98	120	76	108	243.87	
	7	08MAY95	52, .	200	100	72	92	90	60	106	239.46	
	8	15MAY95	59, .	200	98	68	90	90	60	96	237.26	
329.005.00118	SC	09MAY95	-8, .	0	116	70	64	112	72	70	151.00	65.0
	BL	17MAY95	1, .	0	110	68	60	108	70	66	151.90	
	1	24MAY95	8, .	100	100	70	80	98	64	84	152.20	
	2	30MAY95	14, .	150	116	70	86	108	70	96	152.59	
	3	06JUN95	21, .	200	108	74	98	98	60	98	151.92	
	4	14JUN95	29, .	250	114	78	84	116	80	94	153.47	
	5	20JUN95	35, .	300	110	70	94	98	64	110	154.00	
329.005.00153	6	27JUN95	42, .	250	112	76	98	104	70	108	153.00	
	BL	25JAN96	1, -56	0	110	62	72	102	64	80	174.20	
	1	01FEB96	8, -49	100	102	64	96	96	60	104	171.99	
	2	08FEB96	15, -42	150	98	70	104	90	68	108	172.65	
	3	15FEB96	22, -35	200	102	70	108	96	72	112	174.64	
	4	22FEB96	29, -28	250	98	74	112	92	74	116	176.40	
	5	29FEB96	36, -21	250	110	72	104	100	68	112	179.71	
	6	06MAR96	42, -15	250	120	82	96	122	80	116	179.93	
	7	14MAR96	50, -7	250	116	70	104	114	70	112	179.93	
	8	21MAR96	57, 1	250	108	72	84	100	72	104	180.59	
	12	17APR96	84, 28	300	106	66	100	100	68	108	184.12	
	16	15MAY96	112, 56	300	116	76	96	108	72	104	188.50 H	
	20	12JUN96	140, 84	300	120	80	100	116	74	108	187.20 H	
	24	10JUL96	168, 112	300	102	72	108	96	70	112	193.00 H	
	28	05AUG96	194, 138	300	106	78	100	96	78	104	191.20 H	
	32	04SEP96	224, 168	250	114	72	108	114	70	112		
329.005.00255	SC	26FEB96	-7, .	0	120	80	60	120	78	76	150.20	69.0
	BL	04MAR96	1, .	0	100	60	86	90	50	82	149.30	
	1	11MAR96	8, .	100	110	78	86	100	70	96	151.00	
	2	18MAR96	15, .	150	104	80	76	100	70	76	149.00	
	3	25MAR96	22, .	200	102	66	96	100	60	108	149.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00255	4	01APR96	29, .	250	112	80	86	100	70	104	148.50	
	5	08APR96	36, .	300	112	70	106	118	80	110	153.50	
	6	15APR96	43, .	250	110	80	90	110	76	100	145.00	
	7	23APR96	51, .	250	110	80	90	120	84	102	150.50	
	8	29APR96	57, .	200	90	60	96	90	60	100	147.25	
329.005.00256	SC	20FEB96	-14, -70	0	96	58	86	90	56	94	111.00	64.0
	BL	05MAR96	1, -56	0	98	66	88	92	60	98	110.50	
	1	12MAR96	8, -49	100	98	70	88	90	60	104	110.50	
	2	21MAR96	17, -40	150	90	60	88	90	58	90	111.00	
	3	26MAR96	22, -35	200	88	50	82	80	48	104	111.00	
	4	02APR96	29, -28	250	100	60	94	94	58	108	111.00	
	5	11APR96	38, -19	250	100	60	98	90	58	108	111.50	
	6	16APR96	43, -14	250	110	60	96	100	56	108	111.50	
	7	23APR96	50, -7	300	110	70	102	100	60	108	111.50	
	8	30APR96	57, 1	300	100	60	98	100	60	104	113.00	
	12	28MAY96	85, 29	300	80	40 L	96	80	40 L	96	114.50	
	16	02JUL96	120, 64	250	90	60	92	80	52	90	113.00	
329.005.00295	SC	21MAR96	-7, .	0	110	70	80	100	70	84	120.50	61.0
	BL	28MAR96	1, .	0	110	72	76	104	70	80	120.50	
	1	04APR96	8, .	100	120	78	88	110	68	94	119.20	
	2	11APR96	15, .	150	100	70	84	90	60	88	119.50	
	3	18APR96	22, .	200	100	68	88	94	60	88	119.00	
	4	24APR96	28, .	200	118	80	94	110	70	100	120.00	
	6	06MAY96	40, .	200	116	70	86	110	68	86	121.75	
	6	09MAY96	43, .	250	120	70	96	110	70	100	122.50	
	7	16MAY96	50, .	250	110	70	92	100	70	96	125.00	
329.005.00297	8	22MAY96	56, .	250	110	70	104	104	70	110	124.00	
	SC	28MAR96	-22, .	0	124	80	80	114	78	80	184.50	69.0
	BL	19APR96	1, .	0	118	72	80	120	70	80	180.00	
	1	26APR96	8, .	100	114	74	88	112	78	92	180.50	
	2	02MAY96	14, .	150	120	80	88	110	80	90	181.50	
	4	14MAY96	26, .	200	130	70	90	120	70	98	181.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00332	SC	05DEC96	-7, .	0	104	70	58	100	68	64	119.00	67.0
	BL	12DEC96	1, .	0	100	70	60	110	70	60	118.70	
	1	19DEC96	8, .	100	120	82	60	112	80	64	120.00	
	2	26DEC96	15, .	150	104	70	68	100	64	72	123.00	
	3	02JAN97	22, .	200	108	68	78	100	60	80	120.70	
	4	09JAN97	29, .	250	100	70	76	100	68	78	121.00	
	5	16JAN97	36, .	300	110	80	76	100	70	76	122.70	
	6	23JAN97	43, .	300	120	80	68	112	80	72	123.70	
	7	30JAN97	50, .	300	112	80	80	110	70	88	123.50	
	8	06FEB97	57, .	250	118	84	80	112	80	84	122.50	
329.005.00335	SC	20FEB97	-8, .	0	100	70	60	100	70	64	111.50	65.0
	BL	28FEB97	1, .	0	100	70	64	100	68	68	111.50	
	1	07MAR97	8, .	100	104	78	76	104	70	76	110.50	
	2	14MAR97	15, .	150	108	70	92	90	60	84	113.50	
	3	21MAR97	22, .	200	110	72	72	94	60	74	109.50	
	4	27MAR97	28, .	250	98	70	96	80	60	96	110.70	
	5	03APR97	35, .	200	110	80	104	100	70	88	113.20	
	6	10APR97	42, .	200	112	76	76	90	60	76	112.70	
	7	17APR97	49, .	200	110	80	100	100	70	88	113.00	
	8	24APR97	56, .	200	114	70	80	90	60	80	113.70	
329.006.00040	SC	10FEB95	-6, .	0	113	72	72	110	70	72	102.75	63.4
	BL	15FEB95	-1, .	0	118	70	72	110	70	84	102.75	
	1	22FEB95	7, .	50	110	80	88	106	76	90	102.97	
	2	01MAR95	14, .	50	90	60	132 H	90	60	140 H	103.00	
329.006.00041	SC	22MAR95	-14, -78	0	100	75	65	100	78	68	151.48	71.3
	BL	05APR95	1, -64	0	98	68	60	98	68	66	151.50	
	1	10APR95	6, -59	100	98	55	60	100	58	80	151.50	
	2	19APR95	15, -50	150	110	65	70	100	80	90	156.50	
	3	24APR95	20, -45	200	120	70	88	116	70	100	152.00	
	4	01MAY95	27, -38	200	110	65	80	100	80	100	154.00	
	5	08MAY95	34, -31	200	110	75	78	90	75	90	154.00	
	6	15MAY95	41, -24	200	108	70	78	90	75	95	154.50	
	7	24MAY95	50, -15	250	110	80	90	100	70	102	154.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.006.00041	8	31MAY95	57, -8	250	108	85	85	100	80	109	160.50	
	12	05JUL95	92, 28	300	102	78	78	92	78	120	162.00	
	16	31JUL95	118, 54	300	110	70	80	108	80	72	166.00	H
	20	24AUG95	142, 78	300	110	70	100	92	78	100	167.00	H
	24	21SEP95	170, 106	300	114	80	72	90	78	114	167.00	H
	28	24OCT95	203, 139	300	118	80	85	100	80	90	170.00	H
	32	21NOV95	231, 167	250	115	90	90	112	90	96	172.00	H
329.007.00139	SC	04MAY95	-4, .	0	96	60	72	94	64	76	78.00	56.5
	BL	05MAY95	-3, .	0	96	60	77	94	64	76	78.00	
	1	18MAY95	11, .	100	102	68	72	98	70	76	75.00	
	2	25MAY95	18, .	100	102	68	80	98	70	84	76.00	
	6	19JUN95	43, .#	0	102	62	64	100	64	76	78.00	
329.007.00143	SC	26OCT95	-14, .	0	120	72	72	118	76	74	212.00	63.0
	BL	09NOV95	1, .	0	120	72	72	116	74	68	215.00	
	1	16NOV95	8, .	100	120	70	76	118	74	80	212.00	
	2	22NOV95	14, .	100	125	78	84	112	72	120	211.00	
329.007.00146	SC	18JAN96	-7, -60	0	130	80	88	128	86	96	228.00	63.0
	BL	25JAN96	1, -53	0	130	80	88	128	84	80	226.00	
	1	01FEB96	8, -46	100	138	84	88	136	88	96	227.00	
	2	05FEB96	12, -42	150	138	86	72	132	88	88	234.00	
	3	12FEB96	19, -35	200	130	84	76	128	88	68	231.00	
	4	19FEB96	26, -28	250	126	84	72	126	88	80	231.00	
	5	26FEB96	33, -21	250	128	82	76	130	86	84	232.00	
	6	04MAR96	40, -14	250	124	82	88	122	86	96	232.00	
	7	11MAR96	47, -7	200	128	86	84	126	90	96	234.00	
	8	18MAR96	54, 1	200	128	86	88	126	88	96	231.00	
	12	15APR96	82, 29	250	120	82	72	124	86	88	235.00	
	16	13MAY96	110, 57	200	128	88	88	124	92	96	234.00	
	20	06JUN96	134, 81	200	130	86	98	132	90	100	232.00	
	24	08JUL96	166, 113	200	116	84	104	124	92	96	234.00	
	28	05AUG96	194, 141	200	140	92	100	138	88	92	237.00	
	32	09SEP96	229, 176	200	126	98	106	128	99	126 H	235.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.007.00269	SC	04APR96	-7, .	0	138	80	64	132	86	72	239.00	68.0
	BL	11APR96	1, .	0	120	74	80	126	80	88	241.00	
	1	18APR96	8, .	100	132	82	96	130	84	92	237.00	
	2	25APR96	15, .	100	138	76	96	130	80	92	239.00	
	3	02MAY96	22, .	100	130	76	76	.	.	.	238.00	
329.007.00270	SC	02MAY96	-7, .	0	116	70	64	112	72	72	135.00	68.0
	BL	09MAY96	1, .	0	108	74	64	106	76	68	137.00	
	1	16MAY96	8, .	100	108	64	68	106	72	72	135.00	
	2	23MAY96	15, .	150	114	68	68	110	70	76	135.00	
	3	30MAY96	22, .	200	114	70	72	112	72	68	133.00	
	4	06JUN96	29, .	200	110	70	72	108	74	76	135.00	
	5	13JUN96	36, .	200	118	72	64	114	76	68	132.00	
	6	20JUN96	43, .	200	110	72	68	108	80	72	129.00	
329.007.00307	SC	09MAY96	-7, .	0	120	72	76	118	76	84	146.00	61.0
	BL	16MAY96	1, .	0	122	72	84	118	74	88	148.00	
	1	23MAY96	8, .	100	120	80	80	118	84	78	145.00	
	2	30MAY96	15, .	150	132	84	82	128	88	88	149.00	
	3	06JUN96	22, .	200	120	76	92	118	80	98	148.00	
	4	13JUN96	29, .	200	124	82	88	120	84	94	154.00	
	5	20JUN96	36, .	200	140	88	92	136	90	98	154.00	
	8	25JUL96	71, .#	0	124	74	98	130	88	108	151.00	
329.007.00308	SC	27JUN96	-5, .	0	102	68	74	102	70	74	142.00	71.0
	BL	02JUL96	1, .	0	100	64	72	102	60	72	142.00	
329.008.00159	SC	06SEP95	-7, -69	0	100	70	92	100	73	96	104.00	62.0
	BL	13SEP95	1, -62	0	103	70	68	100	65	80		
	1	19SEP95	7, -56	100	96	62	.	96	62	.	101.00	
	2	27SEP95	15, -48	150	96	62	.	94	64	.	101.00	
	3	03OCT95	21, -42	200	94	60	72	92	60	72	101.00	
	4	10OCT95	28, -35	250	100	78	84	92	62	88	101.00	
	5	16OCT95	34, -29	250	110	72	108	96	70	104	101.00	
	6	24OCT95	42, -21	250	102	78	118	100	76	118	101.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.008.00159	7	31OCT95	49, -14	200	116	78	100	100	76	122 H	101.00	
	8	14NOV95	63, 1	200	110	65	88	110	56	120	102.00	
	16	26DEC95	105, 43	200	102	74	80	96	70	90	100.00	
	20	23JAN96	133, 71	200	104	76	72	98	68	84	104.00	
329.008.00161	SC	31OCT95	-16, -71	0	110	72	60	.	.	.	261.00	73.0
	BL	16NOV95	1, -55	0	118	78	78	118	72	80	263.00	
	1	22NOV95	7, -49	100	104	78	74	100	76	78	263.00	
	2	29NOV95	14, -42	150	106	78	72	96	72	78	266.00	
	3	07DEC95	22, -34	200	118	74	72	110	78	86	259.00	
	4	15DEC95	30, -26	200	114	78	78	100	72	72	265.00	
	6	27DEC95	42, -14	200	120	80	72	118	78	90	268.00	
	7	03JAN96	49, -7	200	122	78	66	118	74	84		
	8	10JAN96	56, 1	200	118	74	72	110	70	82	272.00	
329.008.00187	SC	15NOV95	-14, .	0	100	70	84	100	70	93	108.00	63.0
	BL	29NOV95	1, .	0	100	70	84	100	70	93		
	1	07DEC95	9, .	100	120	78	88	115	82	92	111.00	
	2	14DEC95	16, .	100	116	84	100	90	70	104	111.00	
	3	21DEC95	23, .	200	118	78	104	104	78	116	113.00	
	4	28DEC95	30, .	200	110	70	108	100	70	120	109.00	
	5	04JAN96	37, .	200	124	98	100	118	90	100	115.00	
	6	11JAN96	44, .	250	110	82	108	104	80	116	112.00	
	7	18JAN96	51, .	200	110	78	100	110	82	100	112.00	
329.008.00192	SC	14FEB96	-20, .	0	114	66	84	104	60	96	126.00	65.0
	BL	05MAR96	1, .	0	110	72	72	98	64	90	126.00	
	1	11MAR96	7, .	50	100	70	78	94	62	90	133.00	
	2	18MAR96	14, .	100	102	70	78	94	70	90	133.00	
	3	25MAR96	21, .	200	102	60	90	92	60	120	131.00	
	4	03APR96	30, .	200	102	70	90	94	68	98	133.00	
329.008.00272	SC	19MAR96	-15, -71	0	106	62	60	100	68	66	120.00	61.0
	BL	03APR96	1, -56	0	102	70	72	94	68	82	122.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.008.00272	1	10APR96	8, -49	50	102	72	78	96	64	96	120.00	
	2	17APR96	15, -42	100	102	70	78	96	66	84	120.00	
	3	26APR96	24, -33	150	102	70	84	98	68	108	122.00	
	4	01MAY96	29, -28	200	98	64	90	102	64	102	123.00	
	5	07MAY96	35, -22	200	116	72	90	98	66	96	125.00	
	7	22MAY96	50, -7	200	110	78	108	100	80	116	127.00	
	8	29MAY96	57, 1	200	110	75	100	110	80	108	128.00	
	12	26JUN96	85, 29	200	112	78	90	106	78	102	131.00	H
	16	24JUL96	113, 57	200	118	96	96	100	58	110	135.00	H
	20	21AUG96	141, 85	200	112	76	108	114	80	138	141.00	H
	24	18SEP96	169, 113	200	168	72	72	116	60	96	145.00	H
329.008.00273	SC	19APR96	-28, -91	0	120	85	80	120	85	92	152.00	72.0
	BL	17MAY96	1, -63	0	120	80	96	105	83	102	153.00	
	1	24MAY96	8, -56	100	110	85	112	105	82	136	150.00	
	2	31MAY96	15, -49	150	112	84	92	108	85	100	150.00	
	3	10JUN96	25, -39	200	100	80	96	100	80	112	147.00	
	4	17JUN96	32, -32	200	110	85	96	100	85	108	145.00	
	5	24JUN96	39, -25	250	110	80	100	110	80	108	145.00	
	6	01JUL96	46, -18	300	124	79	104	131	81	104	140.00	L
	8	11JUL96	56, -8	300	112	82	106	110	80	120	138.00	L
	8	19JUL96	64, 1	300	105	85	96	100	80	100	140.00	L
	16	04SEP96	111, 48	300	110	85	104	110	80	112	140.00	L
329.009.00127	SC	03APR95	-7, .	0	104	66	62	105	55	68	79.90	58.0
	BL	10APR95	1, .	0	114	54	75	.	.	.	79.70	
	1	17APR95	8, .	100	112	61	78	119	53	91	80.90	
	2	24APR95	15, .	150	111	62	74	111	63	83	78.20	
	3	01MAY95	22, .	200	115	54	74	118	78	72	79.60	
	4	08MAY95	29, .	200	127	52	79	111	82	89	77.60	
	5	15MAY95	36, .	200	118	57	91	111	68	103	78.30	
329.009.00132	SC	17MAY95	-6, -63	0	114	77	54	112	70	79	111.35	62.0
	BL	23MAY95	1, -57	0	117	58	85	123	72	94	112.90	
	1	30MAY95	8, -50	100	131	68	79	108	64	108	110.50	
	2	06JUN95	15, -43	150	114	63	95	113	67	106	111.79	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00132	3	13JUN95	22, -36	200	115	69	103	123	80	106	114.00	
	4	20JUN95	29, -29	200	121	69	89	114	68	112	109.30	
	5	27JUN95	36, -22	200	122	71	91	122	72	105	110.30	
	6	05JUL95	44, -14	200	122	68	95	123	72	112	111.30	
	7	11JUL95	50, -8	200	114	64	93	116	72	105	109.50	
	8	19JUL95	58, 1	200	131	84	108	140	81	97	111.30	
	12	24AUG95	94, 37	200	116	72	96	115	72	96	112.50	
	16	15SEP95	116, 59	200	116	62	95	114	67	99	113.30	
	20	24OCT95	155, 98	200	114	67	95	116	62	99	112.50	
329.009.00134	SC	28JUN95	-8, .	0	114	60	76	115	76	93	122.50	66.0
	BL	06JUL95	1, .	0	122	68	93	128	73	119	122.50	
	1	14JUL95	9, .	100	114	56	95	106	72	111	122.70	
	2	19JUL95	14, .	150	122	72	101	122	75	105	124.70	
	3	26JUL95	21, .	200	114	76	93	121	84	112	122.20	
	4	03AUG95	29, .	200	115	76	98	122	72	114	123.90	
	5	08AUG95	34, .	200	122	76	115	115	80	117	123.50	
	6	15AUG95	41, .	200	122	90	108	131	84	108	124.00	
	7	24AUG95	50, .	200	136	81	88	129	82	101	124.20	
329.009.00137	8	29AUG95	55, .	150	115	69	94	104	88	115	122.80	
	SC	03OCT95	-7, .	0	101	53	100	111	64	115	87.30	62.0
	BL	10OCT95	1, .	0	99	54	85	98	57	101	88.30	
	1	17OCT95	8, .	100	114	60	98	106	60	101	86.50	
	2	24OCT95	15, .	150	120	72	105	109	64	114	85.70	
	3	31OCT95	22, .	200	111	60	88	102	63	.	84.80	
	4	07NOV95	29, .	200	93	50	108	84	52	117	85.10	
	5	14NOV95	36, .	200	106	56	101	91	56	126	85.60	
	6	21NOV95	43, .	200	118	69	102	98	54	114	86.00	
329.009.00171	7	28NOV95	50, .	200	99	60	112	98	52	111	84.90	
	8	05DEC95	57, .	150	130	59	111	103	56	119	85.90	
	SC	31OCT95	-7, .	0	131	69	79	135	74	109	200.60	62.0
	BL	07NOV95	1, .	0	116	60	98	116	59	97	201.90	
	1	14NOV95	8, .	50	122	71	93	115	74	105	199.30	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00172	SC	06NOV95	-7, -64	0	125	71	100	147	76	115	126.50	64.0
	BL	13NOV95	1, -57	0	129	63	84	124	73	109	126.50	
	1	20NOV95	8, -50	100	122	70	129 H	115	57	137	123.60	
	2	27NOV95	15, -43	150	98	66	101	104	58	92	123.00	
	3	04DEC95	22, -36	200	126	81	92	121	69	96	125.00	
	4	11DEC95	29, -29	200	102	53	88	129	67	100	122.50	
	5	21DEC95	39, -19	200	117	67	108	108	56	.	121.40	
	6	27DEC95	45, -13	200	131	81	104	112	47 L	108	121.90	
	7	03JAN96	52, -6	200	115	61	102	102	56	110	121.70	
	8	09JAN96	58, 1	200	101	76	102	85 L	33 L	108	121.50	
	12	07FEB96	87, 30	200	99	49	104	91	37 L	108	122.80	
	16	04MAR96	113, 56	200	107	53	109	118	57	114	121.20	
	20	01APR96	141, 84	200	123	65	120	108	41 L	120	125.10	
	24	29APR96	169, 112	200	123	74	92	114	79	104	123.30	
	28	10JUN96	211, 154	200	123	77	112	106	68	115	122.40	
	32	08JUL96	239, 182	200	114	64	114	91	41 L	90	121.90	
329.009.00194	SC	28NOV95	-7, -63	0	109	58	66	98	69	68	90.40	56.8
	BL	05DEC95	1, -56	0	116	55	77	95	62	88	91.40	
	1	12DEC95	8, -49	100	105	53	88	104	54	83	90.20	
	2	19DEC95	15, -42	150	112	69	95	118	62	89	90.20	
	3	27DEC95	23, -34	200	114	65	98	108	62	111	91.30	
	4	02JAN96	29, -28	200	116	80	117	138	73	119	90.00	
	5	09JAN96	36, -21	200	109	57	105	106	62	109	91.00	
	6	16JAN96	43, -14	200	114	68	106	116	66	102	90.80	
	7	23JAN96	50, -7	200	107	62	106	100	56	108	91.10	
	8	30JAN96	57, 1	200	106	57	98	113	62	102	89.90	
	12	27FEB96	85, 29	200	93	48	97	114	48	87	89.90	
	16	02APR96	120, 64	200	95	60	88	97	65	87	87.00	
	20	30APR96	148, 92	200	106	53	81	111	52	83	86.70	
	24	04JUN96	183, 127	200	104	56	99	117	53	100	87.40	
329.009.00195	SC	06DEC95	-9, .	0	115	65	72	122	71	86	112.40	64.0
	BL	15DEC95	1, .	0	123	58	63	107	63	77	112.30	
	1	19DEC95	5, .	100	116	47	65	107	60	86	112.80	
	2	27DEC95	13, .	150	106	65	79	115	54	79	110.70	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00195	3	02JAN96	19, .	200	115	57	98	106	62	129 H	111.20	
	3	08JAN96	25, .	150	140	85	96	139	73	125 H		
329.009.00199	SC	10JAN96	-6, .	0	130	65	73	136	81	96	160.30	66.0
	BL	16JAN96	1, .	0	114	61	69	106	56	88	158.90	
	1	23JAN96	8, .	100	138	59	95	107	69	108	160.50	
	2	29JAN96	14, .	150	111	61	88	103	53	100	158.90	
	3	07FEB96	23, .	200	123	49	109	91	54	114	159.80	
	4	14FEB96	30, .	200	114	50	101	98	41	105	158.10	
	5	21FEB96	37, .	250	114	61	95	105	58	98	156.10	
	6	28FEB96	44, .	250	137	76	96	112	64	105	157.70	
	7	06MAR96	51, .	250	100	62	86	98	48	94	158.20	
	8	13MAR96	58, .	200	122	72	96	90	55	105	155.50	
329.009.00203	SC	28FEB96	-5, .	0	95	65	103	103	49	109	85.80	57.5
	BL	04MAR96	1, .	0	115	68	77	107	71	103	85.00	
	1	11MAR96	8, .	100	108	61	100	110	65	105	84.00	
	2	19MAR96	16, .	150	113	58	105	99	58	106	84.70	
	3	26MAR96	23, .	150	110	55	104	109	54	109	84.67	
329.009.00236	SC	17DEC96	-13, .	0	136	72	87	124	56	94	146.90	63.1
	BL	30DEC96	1, .	0	113	44	75	103	57	86	147.30	
	1	06JAN97	8, .	100	115	57	98	100	52	121 H	144.30	
	2	15JAN97	17, .	150	115	66	90	121	71	106	141.50	
	3	20JAN97	22, .	200	131	74	109	108	58	133 H	143.30	
	4	27JAN97	29, .	200	130	69	84	114	63	103	137.00	
329.009.00239	SC	11NOV96	-8, -65	0	122	60	54	113	62	53	148.90	65.5
	BL	18NOV96	-1, -58	0	114	60	53	123	57	74	149.40	
	1	25NOV96	7, -51	100	115	61	88	106	63	96	147.70	
	2	02DEC96	14, -44	150	115	69	85	112	60	109	146.80	
	3	09DEC96	21, -37	200	124	74	94	107	68	117	147.70	
	4	16DEC96	28, -30	200	121	66	86	113	58	115	149.10	
	5	23DEC96	35, -23	200	126	77	106	121	77	121 H	149.50	
	6	30DEC96	42, -16	200	113	75	100	115	73	102	143.40	
	7	06JAN97	49, -9	200	121	59	108	119	81	131 H	146.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00239	8	15JAN97	58, 1	200	120	74	68	131	82	91	143.40	
	12	18FEB97	92, 35	200	115	55	80	106	64	97	144.90	
	16	17MAR97	119, 62	200	114	52	65	105	54	80	149.80	
	20	14APR97	147, 90	200	126	62	64	122	66	65	144.40	
	24	12MAY97	175, 118#	0	114	65	59	115	65	71	153.60	
329.009.00262	SC	07FEB97	-10, .	0	122	69	54	134	75	68	145.40	62.3
	BL	17FEB97	1, .	0	126	83	74	131	79	84	145.90	
	1	24FEB97	8, .	100	129	63	77	120	70	112	141.20	
	2	03MAR97	15, .	150	130	85	91	120	72	119	143.60	
	3	07MAR97	19, .	200	131	75	90	113	63	119	141.90	
	4	17MAR97	29, .	200	127	85	103	119	65	129 H	139.20	
	5	24MAR97	36, .	200	147	91	106	147	84	112	136.70	
	6	31MAR97	43, .	200	143	83	96	122	74	117	136.90	
	7	07APR97	50, .	200	139	81	108	116	76	121 H	134.50 L	
329.009.00264	SC	25OCT96	-7, .	0	138	73	71	129	82	83	171.00	62.5
	BL	01NOV96	1, .	0	109	72	102	122	66	82	171.00	
	1	08NOV96	8, .	100	121	79	108	.	.	.	170.30	
	1	11NOV96	11, .	150	145	80	105	126	87	140 H		
	2	18NOV96	18, .	200	130	88	104	130	68	133 H	168.00	
	3	25NOV96	25, .	200	145	88	117	120	73	145 H	168.00	
	4	02DEC96	32, .	200	137	76	115	104	57	137 H	169.40	
	6	11DEC96	41, .	200	135	86	126	123	61	150 H	165.80	
	6	16DEC96	46, .	200	144	91	137 H	125	72	140 H	169.60	
329.009.00301	SC	06MAR96	-13, -69	0	91	45	79	108	59	101	127.00	80.0
	BL	19MAR96	1, -56	0	93	45	75	95	57	75	129.00	
	1	26MAR96	8, -49	100	91	44	84	114	49	72	129.50	
	2	05APR96	18, -39	150	105	59	77	107	65	89	125.20	
	3	12APR96	25, -32	200	106	52	90	99	61	108	126.50	
	4	16APR96	29, -28	200	116	63	74	108	58	90	125.70	
	5	23APR96	36, -21	200	124	70	114	107	59	126 H	124.80	
	6	30APR96	43, -14	200	97	46	83	93	62	95	127.40	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00301	7	07MAY96	50, -7	200	101	53	86	115	62	92	128.60	
	8	14MAY96	57, 1	200	99	52	66	105	57	88	127.10	
	12	11JUN96	85, 29	200	107	56	66	107	75	78	129.70	
329.009.00305	SC	01MAY96	-6, -63	0	114	53	80	111	66	105	136.50	72.3
	BL	07MAY96	1, -57	0	108	54	86	107	53	89	135.90	
	1	14MAY96	8, -50	100	107	65	92	108	69	98	135.10	
	2	21MAY96	15, -43	150	96	54	94	99	37	98	133.80	
	3	28MAY96	22, -36	200	123	62	96	106	64	96	133.70	
	4	04JUN96	29, -29	200	126	76	100	93	47	132 H	135.60	
	5	11JUN96	36, -22	200	123	72	96	98	38	.	135.60	
	6	19JUN96	44, -14	200	115	65	96	103	53	120	133.90	
	7	25JUN96	50, -8	200	120	74	100	114	60	135 H	134.06	
	8	03JUL96	58, 1	200	105	60	115	95	53	140 H	134.50	
	12	06AUG96	92, 35	200	113	61	96	99	46	120	136.30	
	16	27AUG96	113, 56	200	114	56	89	105	55	123 H	134.30	
	20	24SEP96	141, 84	200	103	57	91	90	53	117	132.80	
	24	29OCT96	176, 119	200	115	65	88	100	50	126 H	137.00	
	28	03DEC96	211, 154	200	115	62	100	105	71	121 H	138.60	
	32	10JAN97	249, 192	200	122	65	98	106	68	125 H	137.40	
329.009.00325	SC	21AUG96	-6, -61	0	103	53	72	106	45	90	118.63	67.0
	BL	27AUG96	1, -55	0	108	53	65	96	55	97	116.00	
	1	03SEP96	8, -48	100	107	73	88	94	57	108	114.80	
	2	09SEP96	14, -42	150	113	67	109	100	65	114	114.44	
	3	16SEP96	21, -35	200	102	53	93	90	.	115	120.39	
	4	23SEP96	28, -28	200	112	56	103	99	51	131 H	115.32	
	5	30SEP96	35, -21	200	123	61	74	101	61	114	116.30	
	6	10OCT96	45, -11	200	121	63	93	107	59	119	117.40	
	7	14OCT96	49, -7	200	149	70	94	118	60	123	117.80	
	8	21OCT96	56, 1	200	130	68	93	128	58	119	117.20	
329.009.00326	12	18NOV96	84, 29	200	131	67	89	113	74	125	118.90	
	16	16DEC96	112, 57	200	113	60	87	92	47	131 H	118.20	
329.009.00326	SC	26AUG96	-10, -63	0	139	64	93	143	74	98	227.10	68.0
	BL	05SEP96	1, -53	0	152	81	91	158	87	108	227.70	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00326	1	09SEP96	5, -49	100	139	58	88	124	69	98	226.50	
	2	16SEP96	12, -42	150	136	63	88	95	70	98	223.60	
	3	23SEP96	19, -35	200	139	78	98	138	76	105	223.50	
	4	30SEP96	26, -28	200	125	65	111	105	57	126	222.00	
	5	07OCT96	33, -21	200	139	72	108	129	86	121	221.50	
	6	17OCT96	43, -11	200	141	67	98	124	51	112	215.30	
	7	24OCT96	50, -4	200	152	76	96	134	55	125	218.90	
	8	28OCT96	54, 1	200	139	70	106	123	86	105	215.50	
	12	25NOV96	82, 29	200	146	74	112	85 L	74	126	213.00	
	16	16DEC96	103, 50	200	.	.	.	.	.	.	211.10 L	
329.010.00279	SC	08MAR96	-14, -70	0	115	82	88	110	75	96	127.80	66.0
	BL	22MAR96	1, -56	0	170	70	75	106	85	92	129.00	
	1	29MAR96	8, -49	100	98	60	80	100	70	110	128.00	
	2	05APR96	15, -42	150	110	70	92	108	78	108	128.00	
	3	12APR96	22, -35	200	128	78	92	118	88	108	129.25	
	4	19APR96	29, -28	250	110	60	70	110	70	72	129.00	
	5	25APR96	35, -22	300	118	77	78	117	61	87		
	6	03MAY96	43, -14	300	118	70	65	115	80	74	129.20	
	7	10MAY96	50, -7	300	112	88	85	110	80	96	129.00	
	8	17MAY96	57, 1	300	120	80	85	114	85	90	128.50	
	12	14JUN96	85, 29	300	120	80	85	108	70	95	127.00	
	16	11JUL96	112, 56	300	115	70	84	110	70	88	125.50	
	20	08AUG96	140, 84	300	115	65	84	110	70	92	129.50	
	24	05SEP96	168, 112	300	115	70	72	118	75	88	128.00	
	28	02OCT96	195, 139	300	116	68	78	120	78	92	129.50	
	32	06NOV96	230, 174	250	114	68	82	110	68	96	129.50	
329.010.00281	SC	19JUL96	-7, -68	0	118	78	68	115	78	70	138.20	67.0
	BL	26JUL96	1, -61	0	110	80	62	108	76	80	138.20	
	1	02AUG96	8, -54	100	118	70	80	115	68	92	138.50	
	2	09AUG96	15, -47	150	122	74	68	120	72	74	138.50	
	3	19AUG96	25, -37	200	122	68	76	118	65	88	135.00	
	4	26AUG96	32, -30	250	118	80	64	118	78	72	133.00	
	6	04SEP96	41, -21	300	120	76	86	114	70	92	138.00	
	6	09SEP96	46, -16	300	120	78	80	118	74	88	136.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.010.00281	8	18SEP96	55, -7	300	116	78	92	112	72	98	138.50	
	8	25SEP96	62, 1	300	118	80	80	110	76	88	138.00	
	12	25OCT96	92, 31	300	122	72	84	118	66	92	141.00	
	16	20NOV96	118, 57	300	118	76	88	114	80	96	140.20	
	20	20DEC96	148, 87	300	116	72	88	112	76	96	137.50	
	24	03JAN97	162, 101	300	128	80	88	120	70	96	139.50	
329.011.00163	SC	18NOV95	-7, .	0	108	60	90	104	60	90	136.00	58.0
	BL	24NOV95	-1, .	0	110	60	76	110	68	80	134.00	
	1	01DEC95	7, .	50	90	50	90	90	52	92	134.20	
	2	11DEC95	17, .	100	90	50	90	92	50	90	134.70	
	3	18DEC95	24, .	150	110	76	94	110	76	96	130.00	
	5	27DEC95	33, .	200	110	70	80	110	70	80	130.70	
329.011.00208	SC	22AUG96	-15, -74	0	110	60	84	110	60	88	84.50	57.5
	BL	05SEP96	-1, -60	0	110	60	80	110	62	84	84.50	
	1	11SEP96	6, -54	50	108	62	80	110	60	84	82.00	
	2	17SEP96	12, -48	100	118	70	84	116	74	88	83.20	
	3	26SEP96	21, -39	150	110	80	90	110	84	86	83.20	
	4	03OCT96	28, -32	200	110	70	90	110	76	90	82.70	
	5	10OCT96	35, -25	250	108	70	80	110	70	84	83.00	
	6	17OCT96	42, -18	300	102	60	80	100	60	86	85.50	
	7	24OCT96	49, -11	300	110	70	96	110	76	100	84.70	
329.011.00209	SC	23AUG96	-19, -81	0	120	90	80	120	90	80	122.00	64.0
	BL	10SEP96	-1, -63	0	118	88	86	120	90	88	122.00	
	1	19SEP96	9, -54	50	110	80	84	112	84	84	117.70	
	2	26SEP96	16, -47	100	120	90	90	114	88	96	115.00	
	3	03OCT96	23, -40	150	120	80	100	118	78	100	117.00	
	4	11OCT96	31, -32	200	118	72	96	116	74	100	117.00	
	5	17OCT96	37, -26	200	118	80	80	110	78	84	116.20	
	6	24OCT96	44, -19	200	118	78	80	110	76	88	116.70	
	7	01NOV96	52, -11	200	120	80	86	112	84	88	116.50	
	8	11NOV96	62, -1	250	120	76	84	120	80	92	115.50	
	12	18DEC96	99, 37	250	108	68	80	100	64	84	110.50 L	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.011.00284	SC	13MAR96	-9, -65	0	122	78	80	122	70	80	154.70	72.0
	BL	21MAR96	-1, -57	0	122	78	80	122	70	80	154.70	
	1	28MAR96	7, -50	50	120	78	76	120	80	80	151.70	
	2	05APR96	15, -42	100	108	70	80	110	70	88	151.70	
	3	11APR96	21, -36	150	110	80	90	110	86	96	152.00	
	4	19APR96	29, -28	200	110	80	80	118	80	90	152.20	
	5	25APR96	35, -22	200	110	70	80	110	76	80	153.00	
	6	02MAY96	42, -15	250	120	80	80	120	80	80	152.00	
	7	09MAY96	49, -8	250	120	78	80	120	84	86	152.00	
	8	16MAY96	56, -1	250	120	80	80	120	80	80	150.00	
	12	10JUN96	81, 25	250	110	72	80	116	70	88	147.00	
	16	08JUL96	109, 53	250	126	78	80	120	70	96	147.00	
	20	05AUG96	137, 81	250	122	88	76	120	84	80	147.50	
329.011.00286	SC	15MAY96	-22, -90	0	118	80	80	110	80	80	166.20	61.5
	BL	05JUN96	-1, -69	0	112	80	72	110	70	76	166.20	
	1	14JUN96	9, -60	50	110	80	65	100	70	65	164.00	
	2	21JUN96	16, -53	100	100	80	96	114	82	96	165.50	
	3	28JUN96	23, -46	150	106	82	92	110	80	90	164.00	
	5	08JUL96	33, -36	200	120	78	90	120	80	96	167.00	
	6	17JUL96	42, -27	250	118	80	88	120	80	92	164.20	
	7	24JUL96	49, -20	250	120	80	86	120	76	84	163.20	
	8	02AUG96	58, -11	300	116	80	84	120	80	88	160.00	
	8	09AUG96	65, -4	300	110	70	80	112	74	84	160.00	
	16	17SEP96	104, 36	300	110	70	88	110	72	84	160.50	
	20	24OCT96	141, 73	300	104	70	84	106	72	88	156.70	
	24	25NOV96	173, 105	300	110	70	86	110	74	90	153.70 L	
	28	30DEC96	208, 140	300	110	80	80	110	80	84	151.20 L	
329.012.00026	SC	09NOV95	-19, .	0	110	70	68	100	72	80	159.20	63.8
	BL	28NOV95	1, .	0	110	78	56	90	62	80	161.63	
	1	05DEC95	8, .	100	100	66	80	104	80	84	163.17	
329.012.00219	SC	24MAY96	-7, -67	0	100	70	64	110	70	72	167.36	78.7
	BL	31MAY96	1, -60	0	110	80	72	120	90	64	166.92	
	1	07JUN96	8, -53	100	110	70	80	100	80	100	165.38	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.012.00219	2	14JUN96	15, -46	150	120	80	68	110	80	60	163.39	
	3	24JUN96	25, -36	200	110	70	74	112	76	80	165.38	
	5	02JUL96	33, -28	200	104	70	60	102	80	68	167.36	
	6	09JUL96	40, -21	200	112	70	60	120	78	68	168.46	
	7	16JUL96	47, -14	200	120	80	84	110	80	74	169.12	
	8	23JUL96	54, -7	200	110	80	110	100	86	90	168.24	
	8	30JUL96	61, 1	200	112	76	74	120	70	84	168.02	
	12	30AUG96	92, 32	200	130	78	80	132	80	82	165.82	
	16	26SEP96	119, 59	200	118	76	100	120	80	90	170.23	
	20	25OCT96	148, 88	200	118	80	86	110	86	80	169.34	
	24	22NOV96	176, 116	200	122	80	80	120	70	74	168.24	
	28	20DEC96	204, 144	200	110	72	82	112	80	76	168.24	
	32	24JAN97	239, 179	200	126	82	64	120	80	72	170.89	
329.012.00221	SC	18JUN96	-7, -70	0	110	70	80	120	80	80	148.18	69.3
	BL	25JUN96	1, -63	0	114	80	64	110	80	80	147.96	
	1	02JUL96	8, -56	100	110	70	84	110	80	100	147.29	
	2	09JUL96	15, -49	150	110	78	72	118	76	80	144.87	
	3	16JUL96	22, -42	200	110	80	104	120	80	100	148.62	
	4	23JUL96	29, -35	250	124	80	88	118	90	92	148.18	
	5	30JUL96	36, -28	250	110	72	90	120	80	96	148.40	
	6	09AUG96	46, -18	200	110	80	96	100	70	100	150.16	
	8	19AUG96	56, -8	200	124	78	92	118	78	90	147.74	
	8	27AUG96	64, 1	200	120	74	84	118	74	90	147.96	
	12	23SEP96	91, 28	200	120	86	88	110	80	80	151.26	
	16	21OCT96	119, 56	200	110	80	88	100	80	100	154.35	
	20	04NOV96	133, 70	200	120	70	90	124	68	90	157.66	
329.012.00223	SC	23AUG96	-7, .	0	104	70	72	110	70	80	194.04	61.8
	BL	30AUG96	1, .	0	132	86	88	136	88	90	196.25	
	1	06SEP96	8, .	100	136	100	100	130	90	92	196.47	
	2	16SEP96	18, .	150	130	90	108	128	90	100	195.36	
	3	23SEP96	25, .	200	132	84	96	138	86	92	195.14	
	5	01OCT96	33, .	150	140	98	90	140	104	100	195.14	
329.012.00227	SC	12DEC96	-6, -75	0	130	70	60	130	76	70	153.25	70.1

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.012.00227	BL	18DEC96	1, -69	0	128	82	80	122	76	84	150.38	
	1	27DEC96	10, -60	100	128	80	80	126	78	90	150.38	
	3	06JAN97	20, -50	150	120	90	100	120	80	95	150.38	
	4	15JAN97	29, -41	200	124	80	92	120	78	94	150.38	
	5	24JAN97	38, -32	200	130	90	100	124	82	102	150.38	
	7	04FEB97	49, -21	200	126	90	90	122	80	92	151.04	
	8	14FEB97	59, -11	250	122	82	80	120	78	82	151.04	
	8	20FEB97	65, -5	250	130	80	82	120	86	88	152.15	
	8	25FEB97	70, 1	300	128	90	78	120	90	90	151.48	
	16	27MAR97	100, 31	300	136	90	90	134	90	100	156.56	
	20	25APR97	129, 60	300	152	80	96	152	80	105	159.42	
	24	26MAY97	160, 91	300	144	90	94	134	80	120	159.86	
	28	25JUN97	190, 121	300	130	90	100	120	90	110	157.44	
	32	21JUL97	216, 147	300	120	80	88	136	90	100	156.56	
	32	19AUG97	245, 176	250	120	70	90	128	70	96	157.66	
329.012.00230	SC	20FEB97	-8, -77	0	120	80	76	120	78	72	121.50	65.4
	BL	28FEB97	1, -69	0	120	76	80	120	78	82	121.28	
	1	07MAR97	8, -62	100	110	80	84	120	80	96	121.50	
	2	14MAR97	15, -55	150	124	70	60	110	70	100	122.38	
	3	24MAR97	25, -45	200	120	80	90	114	76	80	122.60	
	5	03APR97	35, -35	200	114	76	82	108	80	82	121.72	
	6	11APR97	43, -27	200	118	78	90	120	80	96	122.82	
	8	23APR97	55, -15	200	106	74	109	90	70	120	119.07	
	8	02MAY97	64, -6	250	106	74	100	104	70	116	123.04	
	8	08MAY97	70, 1	250	106	68	110	104	60	120	122.16	
	12	16MAY97	78, 9	100	106	58	102	100	68	120	122.38	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.001.00062	SC	06OCT94	-14, .	0	88	50	80	84	60	88	98.00	60.5
	BL	20OCT94	1, .	0	90	60	68	100	56	84	98.00	
	1	27OCT94	8, .	0	98	60	80	90	68	100	99.75	
	2	03NOV94	15, .	0	92	56	80	86	60	96	99.75	
	3	10NOV94	22, .	0	92	58	80	100	60	96	101.00	
329.001.00064	SC	04NOV94	-6, -60	0	120	60	80	130	70	84	165.00	71.5
	BL	10NOV94	1, -54	0	110	60	72	106	70	88	165.00	
	1	16NOV94	7, -48	0	104	68	68	122	70	80	165.00	
	2	22NOV94	13, -42	0	114	72	68	104	60	88	166.00	
	3	29NOV94	20, -35	0	110	70	68	128	70	80	166.00	
	4	06DEC94	27, -28	0	100	70	64	120	78	74	165.00	
	5	13DEC94	34, -21	0	108	70	70	106	66	84	165.00	
	6	20DEC94	41, -14	0	104	68	60	110	70	88	165.50	
	7	27DEC94	48, -7	0	114	70	66	120	72	72	167.00	
	8	03JAN95	55, 1	0	112	60	76	118	64	92	167.00	
	12	31JAN95	83, 29	0	116	80	68	110	74	84	169.80	
	16	28FEB95	111, 57	0	116	70	66	110	80	84	169.00	
	20	28MAR95	139, 85	0	100	70	64	112	78	82	169.20	
329.001.00069	SC	07FEB95	-9, .	0	110	60	64	104	60	80	125.00	70.5
	BL	16FEB95	1, .	0	112	72	60	106	68	72	127.00	
	1	23FEB95	8, .	0	100	70	80	104	70	100	125.00	
	2	02MAR95	15, .	0	112	70	68	118	78	80	127.00	
	3	09MAR95	22, .	0	110	74	66	110	80	100	123.00	
	4	16MAR95	29, .	0	110	70	66	116	80	84	127.00	
	5	23MAR95	36, .	0	106	66	64	98	60	88	123.00	
	6	30MAR95	43, .	0	110	72	72	108	80	100	126.50	
	7	06APR95	50, .	0	122	84	72	128	88	76	127.00	
	8	13APR95	57, .	0	110	70	72	116	80	88	132.00	
329.001.00071	SC	02FEB95	-21, .	0	100	60	80	104	66	100	97.00	61.8
	BL	23FEB95	1, .	0	90	58	72	100	60	92	99.00	
	1	02MAR95	8, .	0	110	60	84	106	60	100	95.00	
	2	09MAR95	15, .	0	100	54	82	102	60	88	96.50	
	3	16MAR95	22, .	0	104	60	76	110	70	84	95.70	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.001.00071	4	23MAR95	29, .	0	106	64	74	100	60	88	96.50	
	5	30MAR95	36, .	0	110	70	76	100	60	78	96.00	
	6	06APR95	43, .	0	104	64	96	100	80	100	98.00	
	7	13APR95	50, .	0	100	60	82	100	70	96	97.50	
	8	20APR95	57, .	0	100	60	72	106	68	76	97.50	
329.001.00123	SC	14DEC95	-21, .	0	122	68	64	120	70	84	183.00	69.3
	BL	04JAN96	1, .	0	108	72	64	110	70	78	185.00	
	1	12JAN96	9, .	0	112	70	80	110	70	100	185.50	
	2	18JAN96	15, .	0	104	64	82	108	70	68	184.00	
	3	25JAN96	22, .	0	100	60	78	102	70	80	182.75	
	4	01FEB96	29, .	0	120	70	66	116	70	80	186.50	
	5	08FEB96	36, .	0	106	62	68	114	72	70	187.00	
	6	15FEB96	43, .	0	120	70	62	110	68	92	187.50	
	7	22FEB96	50, .	0	102	68	66	90	60	96	184.00	
329.001.00207	SC	19FEB96	-9, .	0	120	76	76	116	72	80	217.00	70.5
	BL	28FEB96	1, .	0	118	70	72	120	78	80	215.00	
	1	06MAR96	8, .	0	120	78	84	120	76	98	220.00	
	2	13MAR96	15, .	0	116	70	92	124	80	100	220.00	
	3	20MAR96	22, .	0	122	76	84	118	82	92	217.50	
	4	26MAR96	28, .	0	112	62	80	116	70	90	217.50	
	5	03APR96	36, .	0	122	74	88	118	78	96	214.00	
	6	10APR96	43, .	0	122	80	88	116	82	96	217.50	
	7	17APR96	50, .	0	116	70	88	114	80	94	220.00	
329.002.00049	SC	03MAR95	-6, .	0	110	65	64	110	80	96	210.00	75.0
	BL	08MAR95	-1, .	0	110	60	80	110	75	104	211.00	
	1	15MAR95	7, .	0	130	65	88	125	70	100	211.50	
	2	22MAR95	14, .	0	115	60	84	115	70	96	211.00	
	3	29MAR95	21, .	0	100	65	68	100	70	92	210.00	
	4	05APR95	28, .	0	100	70	72	100	70	84	211.00	
	5	12APR95	35, .	0	110	65	76	100	75	96	210.50	
	6	19APR95	42, .	0	100	68	82	112	68	105	212.56	
	7	27APR95	50, .	0	110	60	80	100	70	104	208.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00049	8	05MAY95	58, .	0	115	61	81	115	65	106	210.36	
329.002.00059	SC	03NOV94	-7, .	0	90	60	72	100	70	88	124.00	71.0
	BL	10NOV94	1, .	0	102	64	80	94	60	88	123.50	
	1	17NOV94	8, .	0	100	72	88	98	68	112	125.00	
	2	23NOV94	14, .	0	102	60	72	90	60	96	126.00	
	3	01DEC94	22, .	0	90	60	80	110	60	100	126.00	
	4	08DEC94	29, .	0	92	52	80	98	60	96	124.00	
	5	15DEC94	36, .	0	100	68	86	98	60	92	125.00	
	6	22DEC94	43, .	0	106	66	88	108	70	80	126.00	
	7	29DEC94	50, .	0	90	60	84	102	78	92	125.00	
	8	05JAN95	57, .	0	104	60	88	100	60	92	124.00	
329.002.00060	BL	31JAN95	1, -56	0	108	74	88	112	76	88	117.00	64.0
	1	07FEB95	8, -49	0	92	50	88	92	54	84	120.00	
	2	14FEB95	15, -42	0	90	60	80	90	62	80	119.00	
	3	21FEB95	22, -35	0	90	68	80	90	68	80	117.50	
	4	28FEB95	29, -28	0	96	64	84	92	64	84	118.00	
	5	07MAR95	36, -21	0	88	56	80	70 L	58	84	117.70	
	6	14MAR95	43, -14	0	110	64	84	106	64	82	120.00	
	7	21MAR95	50, -7	0	110	70	100	102	70	100	120.50	
	8	28MAR95	57, 1	0	104	64	74	94	60	74	120.20	
	12	25APR95	85, 29	0	100	62	90	100	60	90	117.30	
	SC	20DEC94	-14, -72	0	104	64	83	100	64	89	122.00	
	1	10JAN95	8, -51	0	110	65	80	108	55	88	123.00	
329.002.00097	2	18JAN95	16, -43	0	100	64	100	106	68	106	123.00	60.0
	3	24JAN95	22, -37	0	102	62	84	106	64	86	121.30	
	4	31JAN95	29, -30	0	104	60	84	100	60	90	122.75	
	5	07FEB95	36, -23	0	118	72	64	116	70	66	124.50	
	6	14FEB95	43, -16	0	118	80	72	115	78	84	123.50	
	7	21FEB95	50, -9	0	118	80	72	114	77	83	122.00	
	8	02MAR95	59, 1	0	104	70	70	100	70	70	124.00	
	12	30MAR95	87, 29	0	114	72	80	112	70	72	124.75	
	16	27APR95	115, 57	0	104	66	67	106	66	76	126.50	
	20	23MAY95	141, 83	0	114	70	78	114	70	98	126.25	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00097	24	29JUN95	178, 120	0	110	68	76	106	64	78	128.00	
	28	01AUG95	211, 153	0	110	70	90	108	66	96	133.00	H
	32	05SEP95	246, 188	0	100	68	74	92	66	70	131.00	H
329.002.00101	BL	20MAR95	-8, -66	0	.	.	.	.	.	.		68.0
	BL	28MAR95	1, -58	0	116	78	84	114	78	80	147.00	
	1	04APR95	8, -51	0	124	76	100	122	72	88	149.00	
	2	13APR95	17, -42	0	122	78	84	124	80	96	147.00	
	3	20APR95	24, -35	0	122	70	68	120	72	66	150.20	
	4	27APR95	31, -28	0	110	80	64	102	80	68	150.50	
	5	04MAY95	38, -21	0	122	70	86	110	70	100	152.70	
	6	11MAY95	45, -14	0	122	68	60	118	66	88	149.00	
	7	18MAY95	52, -7	0	102	64	60	100	60	68	150.00	
	8	25MAY95	59, 1	0	98	72	64	90	68	61	150.00	
	12	22JUN95	87, 29	0	108	60	88	102	60	88	145.20	
	12	27JUN95	92, 34	0	108	66	88	102	60	88	145.20	
329.002.00107	SC	18JAN96	-7, -63	0	112	74	70	110	72	68	167.00	65.0
	1	01FEB96	8, -49	0	108	78	66	106	76	60	172.00	
	2	08FEB96	15, -42	0	110	76	64	106	72	62	174.00	
	3	13FEB96	20, -37	0	108	74	64	110	76	80	173.00	
	4	20FEB96	27, -30	0	110	68	68	104	70	62	174.50	
	5	27FEB96	34, -23	0	106	70	66	100	66	62	174.00	
	6	05MAR96	41, -16	0	114	74	70	110	72	68	179.00	H
	7	15MAR96	51, -6	0	106	72	64	104	70	64	179.50	H
	8	21MAR96	57, 1	0	94	72	70	92	68	92	178.00	
	12	23APR96	90, 34	0	104	68	60	110	76	64	178.00	
	16	21MAY96	118, 62	0	106	64	64	100	68	78	177.00	
	20	20JUN96	148, 92	0	110	62	48	104	64	70	167.00	
	24	18JUL96	176, 120	0	110	62	60	100	60	62	162.00	
	32	29AUG96	218, 162	0	108	64	62	104	64	70	157.00	
	32	26SEP96	246, 190	0	100	62	60	94	60	78	156.00	
329.002.00241	SC	25JAN96	-12, -68	0	110	70	66	106	70	80	202.00	69.0
	BL	06FEB96	1, -56	0	110	72	64	110	70	80	202.00	
	1	13FEB96	8, -49	0	108	60	60	110	70	70	205.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00241	2	22FEB96	17, -40	0	110	60	62	108	60	66	205.00	
	3	27FEB96	22, -35	0	112	78	64	106	74	72	202.00	
	4	05MAR96	29, -28	0	110	70	62	104	68	60	205.00	
	5	12MAR96	36, -21	0	120	68	60	114	70	58	205.00	
	6	19MAR96	43, -14	0	120	64	64	112	60	68	205.00	
	7	26MAR96	50, -7	0	122	70	70	120	72	62	204.00	
	8	02APR96	57, 1	0	110	64	64	108	68	72	199.00	
	12	30APR96	85, 29	0	106	60	60	100	62	61	207.00	
329.002.00246	SC	01APR96	-17, .	0	126	74	62	120	70	66	190.00	61.0
	1	25APR96	8, .	0	122	68	72	120	64	66	191.00	
	2	02MAY96	15, .	0	122	66	72	120	68	80	187.00	
	3	09MAY96	22, .	0	104	64	76	100	60	72	189.00	
	4	16MAY96	29, .	0	108	85	88	115	88	95	189.50	
	5	23MAY96	36, .	0	110	80	70	118	78	88	189.00	
	6	30MAY96	43, .	0	108	62	88	110	66	88	194.00	
	7	04JUN96	48, .	0	102	64	88	98	62	90	191.00	
329.002.00320	8	18JUN96	62, .	0	130	70	74	124	72	86	194.00	
	BL	16MAY96	1, -61	0	94	62	96	78	60	115	154.00	
	1	23MAY96	8, -54	0	96	60	84	90	58	92	154.50	
	2	30MAY96	15, -47	0	106	62	68	90	60	72	155.50	
	3	04JUN96	20, -42	0	98	64	64	100	68	70	154.50	
	5	18JUN96	34, -28	0	122	70	68	120	74	64	155.00	
	6	25JUN96	41, -21	0	98	62	100	96	64	116	156.25	
	7	02JUL96	48, -14	0	120	64	80	116	66	102	158.00	
	8	09JUL96	55, -7	0	108	70	75	106	72	86	160.00	
	8	16JUL96	62, 1	0	108	70	84	110	74	100	160.00	
	12	13AUG96	90, 29	0	110	70	66	108	68	88	160.00	
	16	17SEP96	125, 64	0	92	70	80	90	68	86	159.40	
329.002.00323	SC	04NOV96	-8, -66	0	92	68	84	90	64	90	118.00	63.0
	BL	12NOV96	1, -58	0	92	68	84	90	64	90	118.00	
	1	19NOV96	8, -51	0	94	66	88	98	64	80	117.00	
	2	26NOV96	15, -44	0	102	78	84	100	78	78	109.00 L	
	3	05DEC96	24, -35	0	96	70	80	94	66	82	112.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.002.00323	4	10DEC96	29, -30	0	100	68	66	96	66	64	112.00	
	5	17DEC96	36, -23	0	98	60	90	94	62	84	114.00	
	6	26DEC96	45, -14	0	88	66	74	88	64	76	112.00	
	7	02JAN97	52, -7	0	102	72	80	104	60	84	112.00	
	8	09JAN97	59, 1	0	100	68	74	100	66	80	114.50	
	12	04FEB97	85, 27	0	102	64	74	102	60	84	116.00	
	16	04MAR97	113, 55	0	108	68	84	104	66	88	118.00	
	20	03APR97	143, 85	0	108	62	100	112	70	106	120.00	
	24	30APR97	170, 112	0	116	58	82	116	58	92	119.00	
	28	27MAY97	197, 139	0	110	70	72	110	80	100	118.50	
	32	12JUN97	213, 155	0	110	80	76	105	75	76	114.00	
329.003.00074	SC	18JAN95	-7, -63	0	110	66	76	106	58	76	91.07	61.4
	BL	25JAN95	1, -56	0	104	86	75	98	78	90	94.20	
	1	01FEB95	8, -49	0	110	76	72	108	80	82	95.48	
	2	08FEB95	15, -42	0	110	84	84	110	70	96	94.82	
	3	15FEB95	22, -35	0	100	70	76	100	78	88	95.70	
	4	21FEB95	28, -29	0	102	78	88	102	80	117	95.48	
	5	01MAR95	36, -21	0	100	72	76	110	66	84	96.36	
	7	15MAR95	50, -7	0	110	86	76	104	88	98	97.02	
	8	22MAR95	57, 1	0	104	74	68	100	78	92	96.80	
	12	19APR95	85, 29	0	106	76	72	92	70	104	98.34	
	16	17MAY95	113, 57	0	94	66	80	98	72	78	98.34	
	20	19JUN95	146, 90	0	100	72	60	94	76	80	97.46	
	24	24JUL95	181, 125	0	104	74	85	100	76	104	101.65 H	
	32	30AUG95	218, 162	0	108	74	68	96	70	88	103.19 H	
	32	11OCT95	260, 204	0	90	70	96	100	76	100	102.53 H	
329.003.00078	SC	11APR95	-15, .	0	110	65	72	110	65	72	195.00	68.5
	BL	26APR95	1, .	0	120	75	80	.	.	.	198.00	
	1	02MAY95	7, .	0	110	78	80	105	75	90	198.00	
	2	10MAY95	15, .	0	110	70	80	120	80	84	200.00	
	3	17MAY95	22, .	0	118	70	80	110	80	88	195.50	
	4	24MAY95	29, .	0	122	76	80	114	80	88	194.00	
	5	30MAY95	35, .	0	120	80	82	110	78	88	196.00	
	6	07JUN95	43, .	0	118	68	82	110	76	84	192.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00078	7	15JUN95	51, .	0	110	80	90	112	80	78	192.00	
	8	21JUN95	57, .	0	112	80	80	110	84	84	196.00	
329.003.00080	SC	22NOV95	-5, .	0	110	70	68	124	62	84	177.94	62.6
	1	04DEC95	8, .	0	122	72	80	110	80	96	178.61	
	1	07DEC95	11, .	0	124	64	94	120	62	100	179.27	
	3	18DEC95	22, .	0	114	58	88	110	66	100	177.50	
	5	29DEC95	33, .	0	134	48 L	98	112	60	106	181.03	
	5	04JAN96	39, .	0	128	58	86	126	74	90	179.05	
	6	10JAN96	45, .	0	122	58	82	110	48	88	179.71	
	7	17JAN96	52, .	0	122	68	82	120	74	100	181.47	
	8	24JAN96	59, .	0	120	64	102	110	60	112	179.27	
329.003.00085	SC	26OCT94	-13, .	0	110	70	110	100	80	120	199.00	63.8
	BL	07NOV94	-1, .	0	90	60	96	90	60	96	207.50	
	1	14NOV94	7, .	0	98	58	104	.	.	104	204.50	
	2	21NOV94	14, .	0	110	70	100	110	70	100	203.00	
	3	28NOV94	21, .	0	110	80	100	106	80	100	206.00	
	4	05DEC94	28, .	0	110	70	104	110	70	104	208.00	
	5	12DEC94	35, .	0	108	74	96	108	74	96	209.00	
	6	19DEC94	42, .	0	110	70	96	110	72	96	203.00	
	7	27DEC94	50, .	0	110	76	92	112	76	92	205.00	
329.003.00086	8	03JAN95	57, .	0	130	86	100	120	86	100	207.50	58.0
	SC	09NOV94	-19, -76	0	127	70	71	123	76	78	93.70	
	BL	21NOV94	-7, -64	0	78	54	64	78	54	64	100.00	
	1	05DEC94	8, -50	0	92	60	72	90	60	72	96.00	
	2	12DEC94	15, -43	0	88	62	72	88	62	76	96.00	
	3	19DEC94	22, -36	0	84	56	80	84	56	84	97.50	
	4	27DEC94	30, -28	0	76	48	72	76	48	72	97.00	
	5	03JAN95	37, -21	0	86	50	88	86	50	84	97.00	
	6	09JAN95	43, -15	0	86	56	70	86	56	70	96.50	
	7	17JAN95	51, -7	0	90	58	84	90	58	84	98.50	
	8	23JAN95	57, -1	0	84	56	72	84	56	76	98.00	
	12	13FEB95	78, 21	0	84	56	80	84	56	80	98.00	
	16	28MAR95	121, 64	0	86	54	72	86	54	72	100.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00086	20	25APR95	149, 92	0	84	54	80	84	54	80	100.00	
	28	30MAY95	184, 127	0	80	50	84	80	50	84	100.50	
	32	11JUL95	226, 169	0	82	52	84	80	50	84	100.00	
	32	17AUG95	263, 206	0	84	52	84	80	52	84	95.00	
329.003.00094	SC	20OCT95	-4, .	0	108	62	.	100	70	70	112.00	64.5
	BL	24OCT95	1, .	0	110	20	84	110	70	84	118.00	
	1	31OCT95	8, .	0	116	74	108	116	74	108	113.00	
	2	07NOV95	15, .	0	110	70	88	110	70	84	111.00	
	3	14NOV95	22, .	0	114	78	84	114	78	84	111.50	
	4	21NOV95	29, .	0	110	70	84	110	70	84	112.00	
	5	28NOV95	36, .	0	112	74	104	112	74	104	113.00	
	6	05DEC95	43, .	0	114	74	84	114	74	84	111.00	
	7	12DEC95	50, .	0	100	64	96	100	64	96	110.50	
	8	19DEC95	57, .	0	100	66	96	100	66	96	111.00	
329.003.00251	SC	19MAR96	-9, .	0	120	80	60	120	90	61	124.50	61.0
	1	04APR96	8, .	0	110	70	96	100	66	96	130.00	
	2	09APR96	13, .	0	112	64	96	106	56	96	131.00	
329.003.00252	SC	19MAR96	-22, .	0	100	68	68	100	64	66	106.00	66.5
	BL	09APR96	-1, .	0	100	60	88	100	60	88	109.00	
	1	16APR96	7, .	0	102	58	96	100	58	96	113.00	
	2	23APR96	14, .	0	90	56	.	100	56	104	113.00	
	3	30APR96	21, .	0	102	54	100	100	54	100	113.00	
	4	09MAY96	30, .	0	98	54	96	96	54	96	114.00	
	5	14MAY96	35, .	0	100	56	96	100	56	96	114.00	
	6	21MAY96	42, .	0	102	56	84	102	56	84	113.00	
	7	28MAY96	49, .	0	100	60	84	100	60	84	113.00	
	8	04JUN96	56, .	0	100	60	96	100	60	96	112.00	
329.003.00291	SC	01JUL96	-2, -67	0	100	58	84	102	60	84	101.65	62.2
	BL	03JUL96	1, -65	0	97	75	66	97	64	70		
	2	15JUL96	13, -53	0	109	68	84	105	64	96	102.53	
	3	24JUL96	22, -44	0	110	62	80	102	64	88	101.43	
	4	31JUL96	29, -37	0	108	56	92	104	58	92	103.19	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.003.00291	5	07AUG96	36, -30	0	112	64	78	108	66	86	102.75	
	6	14AUG96	43, -23	0	108	60	86	100	62	104	102.09	
	7	21AUG96	50, -16	0	110	70	78	110	65	92	102.53	
	8	28AUG96	57, -9	0	102	62	84	108	58	90	102.75	
	8	04SEP96	64, -2	0	104	58	92	104	62	98	103.19	
	12	02OCT96	92, 27	0	104	60	92	108	62	98	100.99	
	16	30OCT96	120, 55	0	106	60	90	108	70	90	102.31	
329.003.00315	BL	05NOV96	-7, .	0	110	70	84	110	70	84	177.00	65.0
	SC	12NOV96	1, .	0	112	62	80	110	68	84	173.00	
	1	21NOV96	10, .	0	120	80	96	120	80	96	178.00	
	2	26NOV96	15, .	0	116	80	96	116	80	96	178.00	
	3	03DEC96	22, .	0	130	84	84	130	84	84	181.00	
	4	12DEC96	31, .	0	120	84	84	120	84	84	182.00	
	5	17DEC96	36, .	0	120	76	84	120	76	84	182.00	
	6	23DEC96	42, .	0	126	80	80	120	80	80	185.00	
	8	07JAN97	57, .	0	120	80	78	100	80	78	187.00	
329.003.00316	SC	05DEC96	-12, .	0	110	70	.	.	.	.	135.00	65.8
	BL	17DEC96	1, .	0	96	62	96	96	62	96	135.00	
	1	23DEC96	7, .	0	110	70	80	110	70	90	138.00	
	3	07JAN97	22, .	0	100	70	80	100	70	88	136.50	
	4	14JAN97	29, .	0	104	64	96	104	64	96	138.00	
	5	21JAN97	36, .	0	100	66	96	100	66	96	140.00	
	6	28JAN97	43, .	0	96	66	84	96	66	84	140.00	
	7	04FEB97	50, .	0	106	70	84	106	70	84	138.00	
	8	11FEB97	57, .	0	110	70	84	100	70	84	140.00	
329.004.00016	SC	01MAR95	-12, .	0	104	60	64	98	74	68	155.45	68.5
	BL	13MAR95	1, .	0	104	80	72	108	84	80	155.45	
	1	20MAR95	8, .	0	108	72	72	108	76	72	157.66	
	2	29MAR95	17, .	0	110	60	78	120	70	84	158.76	
	3	05APR95	24, .	0	112	72	80	114	84	80	157.66	
	4	12APR95	31, .	0	100	60	70	110	78	78	158.98	
	5	19APR95	38, .	0	110	68	84	110	70	84	159.20	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.004.00018	SC	19APR95	-14, .	0	125	75	88	125	75	88	126.79	64.2
	BL	03MAY95	1, .	0	120	70	70	120	70	72	126.79	
	1	11MAY95	9, .	0	100	60	70	100	60	84	127.89	
	2	18MAY95	16, .	0	100	60	80	100	60	84	127.89	
	3	25MAY95	23, .	0	110	70	90	110	70	98	127.23	
	4	01JUN95	30, .	0	120	70	104	118	70	108	126.35	
	5	08JUN95	37, .	0	100	60	72	110	70	84	126.79	
	7	19JUN95	48, .	0	118	70	68	120	70	78	126.13	
	7	22JUN95	51, .	0	100	70	84	120	70	96	124.14	
	8	29JUN95	58, .	0	140	84	90	145	90	100	127.01	
329.004.00020	SC	02NOV95	-7, .	0	90	60	72	100	60	80	110.47	62.6
	BL	09NOV95	1, .	0	90	60	70	90	60	74	110.25	
	1	16NOV95	8, .	0	90	64	78	98	70	80	109.15	
	2	24NOV95	16, .	0	90	60	60	90	60	78	109.15	
329.004.00213	SC	18JUL96	-15, -69	0	98	78	90	110	98	100	191.17	63.8
	BL	01AUG96	-1, -55	0	100	70	74	110	78	80	190.73	
	1	08AUG96	7, -48	0	100	70	88	110	78	90	192.94	
	2	15AUG96	14, -41	0	100	60	84	110	78	90	194.04	
	3	21AUG96	20, -35	0	110	70	64	110	80	88	193.60	
	4	29AUG96	28, -27	0	124	64	92	110	68	100	196.25	
	5	03SEP96	33, -22	0	110	80	90	120	88	104	197.79	
	6	10SEP96	40, -15	0	120	88	80	110	70	90	195.36	
	7	17SEP96	47, -8	0	110	70	104	120	80	120	195.80	
	8	24SEP96	54, -1	0	120	70	84	120	80	100	196.25	
	12	22OCT96	82, 28	0	110	70	120	100	60	120	191.84	
	16	19NOV96	110, 56	0	120	70	80	110	70	84	196.25	
	20	20DEC96	141, 87	0	130	70	84	120	70	90	193.82	
	24	21JAN97	173, 119	0	120	66	84	116	70	88	198.01	
	28	18FEB97	201, 147	0	120	58	84	110	60	80	196.69	
	32	19MAR97	230, 176	0	115	60	68	114	58	76	195.58	
329.005.00001	SC	11APR94	-9, .	0	110	70	105	108	72	108	125.00	67.0
	BL	20APR94	1, .	0	114	80	92	110	78	96	125.91	
	1	27APR94	8, .	0	100	60	96	92	60	106	122.82	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00001	2	04MAY94	15, .	0	108	60	90	108	80	94	123.92	
	3	11MAY94	22, .	0	126	78	92	124	88	96	123.92	
	4	18MAY94	29, .	0	120	80	96	118	80	90	124.80	
	5	25MAY94	36, .	0	124	78	84	124	78	96	124.80	
	6	01JUN94	43, .	0	122	62	98	118	70	92	124.80	
	7	08JUN94	50, .	0	118	68	80	110	68	92	126.35	
	8	15JUN94	57, .	0	102	60	92	118	78	98	125.02	
329.005.00005	SC	24OCT94	-8, .	0	100	64	80	100	60	88	111.57	60.5
	BL	01NOV94	1, .	0	98	58	88	104	68	88	114.66	
	1	08NOV94	8, .	0	104	66	98	108	62	136 H	114.00	
329.005.00010	SC	07DEC94	-6, -63	0	100	72	68	94	60	72	121.00	69.0
	BL	13DEC94	1, -57	0	100	60	68	110	68	70	121.00	
	1	20DEC94	8, -50	0	100	70	78	100	70	78	120.00	
	2	27DEC94	15, -43	0	100	68	88	110	70	88	119.00	
	3	04JAN95	23, -35	0	100	60	76	90	60	78	122.16	
	4	11JAN95	30, -28	0	104	70	76	100	60	80	123.04	
	5	18JAN95	37, -21	0	102	70	72	110	70	72	123.70	
	6	25JAN95	44, -14	0	90	60	70	100	70	74	120.39	
	7	02FEB95	52, -6	0	104	60	74	90	60	76	121.00	
	8	08FEB95	58, 1	0	100	70	76	90	60	76	121.50	
	12	10MAR95	88, 31	0	90	60	76	94	60	78	123.00	
	16	13APR95	122, 65	0	100	70	80	90	64	84	120.70	
	20	10MAY95	149, 92	0	90	60	72	88	58	74	123.00	
	24	06JUN95	176, 119	0	100	60	70	100	58	76	120.39	
	32	12JUL95	212, 155	0	100	60	70	90	60	76	118.63	
	32	09AUG95	240, 183	0	80	60	72	80 L	60	78	120.50	
329.005.00012	SC	12DEC94	-7, -66	0	110	74	80	110	70	84	145.50	69.0
	BL	19DEC94	1, -59	0	100	70	84	110	70	88	145.00	
	1	27DEC94	9, -51	0	110	70	88	112	72	92	144.00	
	2	05JAN95	18, -42	0	120	80	92	118	70	94	143.50	
	3	12JAN95	25, -35	0	94	68	68	100	70	72	143.50	
	4	18JAN95	31, -29	0	118	74	72	100	70	74	144.00	
	5	25JAN95	38, -22	0	110	70	60	108	72	64	142.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00012	6	31JAN95	44, -16	0	112	70	60	120	82	64	140.10	
	7	08FEB95	52, -8	0	112	70	68	112	80	72	140.00	
	8	16FEB95	60, 1	0	110	60	78	100	60	80	145.00	
	12	27MAR95	99, 40	0	120	80	80	110	78	84	146.00	
	20	04MAY95	137, 78	0	110	64	64	100	70	68	149.30	
	24	31MAY95	164, 105	0	110	80	60	100	82	64	147.74	
329.005.00111	SC	05JAN95	-6, -62	0	94	64	84	100	70	88	132.50	65.0
	BL	11JAN95	1, -56	0	90	60	88	94	60	92	132.00	
	1	18JAN95	8, -49	0	100	68	92	120	70	98	132.00	
	2	25JAN95	15, -42	0	98	60	76	110	80	80	134.70	
	3	01FEB95	22, -35	0	90	60	72	98	70	74	132.20	
	4	08FEB95	29, -28	0	108	70	88	90	68	88	130.50	
	5	15FEB95	36, -21	0	90	60	72	84	60	72	133.50	
	6	22FEB95	43, -14	0	100	70	76	94	70	76	132.00	
	7	01MAR95	50, -7	0	110	70	70	90	60	90	132.50	
	8	08MAR95	57, 1	0	110	70	80	100	70	84	129.00	
	12	05APR95	85, 29	0	90	60	80	104	64	76	129.87	
	12	19APR95	99, 43	0	94	68	80	90	60	80	128.00	
	16	03MAY95	113, 57	0	90	68	80	90	60	84	128.50	
329.005.00114	SC	23JAN95	-8, -65	0	112	70	68	108	72	72	145.20	70.0
	BL	31JAN95	1, -57	0	80	60	72	70	50	72	145.00	
	1	07FEB95	8, -50	0	108	62	80	102	62	88	153.50	
	2	14FEB95	15, -43	0	110	80	60	90	70	64	154.50	
	3	21FEB95	22, -36	0	100	70	58	104	70	60	155.89 H	
	4	28FEB95	29, -29	0	110	70	70	90	60	72	157.00 H	
	5	09MAR95	38, -20	0	100	70	80	90	64	80	157.00 H	
	6	15MAR95	44, -14	0	104	80	80	100	70	84	155.00	
	7	22MAR95	51, -7	0	104	70	60	90	70	64	154.50	
	8	29MAR95	58, 1	0	100	70	68	92	70	72	153.00	
	12	26APR95	86, 29	0	90	60	70	98	68	74	155.10	
	16	17MAY95	107, 50	0	104	70	72	100	70	74	155.50 H	
329.005.00115	SC	27JAN95	-10, -81	0	118	76	78	110	74	82	144.00	64.0
	BL	06FEB95	1, -71	0	120	70	84	118	60	88	143.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00115	1	13FEB95	8, -64	0	104	70	80	110	70	84	143.70	
	2	20FEB95	15, -57	0	120	70	88	110	68	92	142.22	
	3	02MAR95	25, -47	0	124	80	88	118	70	88	146.00	
	5	10MAR95	33, -39	0	120	76	80	112	70	84	144.00	
	6	17MAR95	40, -32	0	112	70	76	110	64	80	144.70	
	7	28MAR95	51, -21	0	106	70	84	118	80	94	145.00	
	8	10APR95	64, -8	0	116	78	60	120	70	60	152.00	
	8	18APR95	72, 1	0	110	54	76	110	60	82	140.00	
	12	27APR95	81, 10	0	114	70	68	110	68	74	141.00	
329.005.00120	SC	22AUG95	-8, .	0	124	60	96	120	60	98	152.00	61.5
	BL	30AUG95	1, .	0	110	72	72	106	66	80	152.15	
	1	07SEP95	9, .	0	104	62	68	108	66	84	155.23	
	2	14SEP95	16, .	0	112	66	80	108	66	84	159.20	
	3	21SEP95	23, .	0	116	72	84	114	70	88	160.52	
	4	28SEP95	30, .	0	116	68	84	110	66	88	159.86	
	5	05OCT95	37, .	0	108	72	68	104	68	68	162.51	
	6	12OCT95	44, .	0	116	66	68	114	68	72	162.51	
	7	19OCT95	51, .	0	122	68	72	116	66	76	164.71	H
	8	26OCT95	58, .	0	120	64	88	116	68	80	166.04	H
329.005.00253	SC	31JAN96	-8, .	0	106	62	72	102	60	80	133.40	63.0
	BL	08FEB96	1, .	0	96	68	72	94	66	78	133.62	
	1	14FEB96	7, .	0	122	72	76	118	70	88	133.18	
	2	21FEB96	14, .	0	118	64	96	108	62	108	133.84	
	3	28FEB96	21, .	0	120	76	80	110	76	104	132.30	
	4	06MAR96	28, .	0	108	72	72	106	72	80	132.74	
	5	14MAR96	36, .	0	118	72	84	116	70	96	134.51	
	6	20MAR96	42, .	0	104	66	88	102	62	92	133.84	
	7	28MAR96	50, .	0	104	68	80	100	60	100	133.84	
	8	03APR96	56, .	0	112	66	76	106	62	88	129.00	
329.005.00254	SC	08FEB96	-7, -62	0	94	72	76	90	68	84	130.00	67.0
	BL	14FEB96	-1, -56	0	82	60	80	80	60	80	126.00	
	1	21FEB96	7, -49	0	104	68	80	90	60	76	130.00	
	2	28FEB96	14, -42	0	90	60	80	100	70	84	128.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00254	3	06MAR96	21, -35	0	80	60	76	78	58	80	130.00	
	4	13MAR96	28, -28	0	88	60	76	80	64	76	127.00	
	5	20MAR96	35, -21	0	90	60	76	90	60	80	129.50	
	6	27MAR96	42, -14	0	90	60	76	94	60	80	129.50	
	7	03APR96	49, -7	0	98	70	80	98	68	80	128.00	
	8	10APR96	56, 1	0	90	60	80	88	60	80	128.00	
	12	22MAY96	98, 43	0	104	70	80	98	60	84	125.00	
	16	12JUN96	119, 64	0	102	70	80	90	70	80	122.20	
	20	10JUL96	147, 92	0	112	70	76	110	70	80	122.50	
	28	12SEP96	211, 156	0	94	70	74	90	60	80	129.00	
	32	16OCT96	245, 190	0	90	60	80	90	64	84	128.50	
329.005.00293	SC	06MAR97	-6, .	0	108	70	70	106	70	74	175.00	63.0
	BL	12MAR97	1, .	0	122	78	80	108	70	96	171.75	
	1	19MAR97	8, .	0	110	80	68	110	80	78	174.00	
	2	25MAR97	14, .	0	120	74	90	116	68	106	173.25	
	3	02APR97	22, .	0	120	80	92	110	70	100	173.25	
	4	09APR97	29, .	0	124	80	90	118	80	98	175.00	
	5	16APR97	36, .	0	120	84	80	110	80	90	174.00	
	6	23APR97	43, .	0	128	74	90	118	78	104	172.00	
	7	30APR97	50, .	0	120	82	94	126	76	102	174.50	
329.005.00298	8	07MAY97	57, .	0	120	70	90	120	82	100	172.50	
	SC	15MAY96	-7, -63	0	110	80	68	112	80	68	149.50	64.0
	BL	22MAY96	1, -56	0	118	80	74	112	80	76	147.70	
	1	30MAY96	9, -48	0	90	60	60	90	56	64	147.50	
	2	06JUN96	16, -41	0	118	80	60	114	80	60	146.20	
	3	12JUN96	22, -35	0	110	60	58	104	68	60	148.00	
	4	19JUN96	29, -28	0	98	60	60	94	60	60	147.70	
	5	26JUN96	36, -21	0	118	70	54	110	60	58	148.20	
	6	03JUL96	43, -14	0	116	74	56	112	72	60	148.70	
	7	10JUL96	50, -7	0	100	60	64	110	70	72	146.50	
	8	17JUL96	57, 1	0	104	64	60	90	60	62	147.70	
	16	19SEP96	121, 65	0	104	60	54	112	60	64	147.50	
	20	17OCT96	149, 93	0	90	64	60	90	60	60	148.00	
	24	14NOV96	177, 121	0	92	60	60	90	50	62	148.70	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.005.00298	28	12DEC96	205, 149	0	104	78	64	110	76	64	150.00	
	32	13JAN97	237, 181	0	100	60	60	100	60	64	149.00	
329.005.00331	SC	14NOV96	-7, .	0	100	70	84	90	70	88	163.00	66.0
	BL	21NOV96	1, .	0	90	60	84	90	60	88	162.50	
	1	27NOV96	7, .	0	120	70	88	112	70	100	164.70	
	2	04DEC96	14, .	0	110	70	84	104	70	88	164.00	
	3	12DEC96	22, .	0	100	70	88	110	74	84	164.00	
	4	19DEC96	29, .	0	104	70	92	112	70	96	163.00	
	6	02JAN97	43, .	0	124	80	80	120	70	84	166.70	
	7	10JAN97	51, .	0	100	64	80	90	60	84	162.00	
	8	16JAN97	57, .	0	100	70	74	90	60	80	162.50	
329.005.00334	SC	24JAN97	-7, .	0	112	70	72	100	70	76	174.00	63.0
	BL	29JAN97	-2, .	0	112	78	84	110	70	88	173.00	
	1	06FEB97	7, .	0	120	80	88	118	80	96	172.50	
	2	13FEB97	14, .	0	112	70	80	114	80	84	173.00	
	3	21FEB97	22, .	0	118	70	78	112	70	80	175.50	
	4	26FEB97	27, .	0	112	70	64	100	60	68	170.00	
	5	06MAR97	35, .	0	118	80	80	104	80	80	171.00	
	6	13MAR97	42, .	0	98	60	80	98	60	80	173.00	
	7	21MAR97	50, .	0	114	70	76	90	60	80	167.50	
329.006.00037	SC	20JAN95	-8, .	0	135	68	82	.	.	.	144.43	65.0
	BL	27JAN95	-1, .	0	128	70	88	132	70	92	144.43	
	1	03FEB95	7, .	0	125	78	85	.	.	.	144.43	
	2	13FEB95	17, .	0	120	76	84	120	70	72	142.22	
	4	22FEB95	26, .	0	110	80	72	130	70	78	142.22	
329.006.00042	SC	01DEC95	-6, -63	0	120	90	84	120	90	96	226.01	65.4
	BL	06DEC95	-1, -58	0	123	90	90	125	95	90		
	1	13DEC95	7, -51	0	120	80	96	120	85	120	233.00	
	2	20DEC95	14, -44	0	125	90	90	125	85	120	234.00	
	3	27DEC95	21, -37	0	125	85	80	120	80	110	235.00	
	4	03JAN96	28, -30	0	120	90	70	120	95	90	233.30	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.006.00042	5	10JAN96	35, -23	0	120	90	78	120	90	78	237.40	
	6	17JAN96	42, -16	0	120	90	68	118	80	76	235.50	
	7	23JAN96	48, -10	0	120	90	65	120	94	80	235.00	
	8	02FEB96	58, 1	0	120	94	80	120	94	78	236.00	
	12	29FEB96	85, 28	0	120	90	78	118	90	90	236.50	
	16	26MAR96	111, 54	0	125	95	74	125	95	82	240.00	
	20	23APR96	139, 82	0	120	90	80	120	90	80	238.00	
	24	21MAY96	167, 110	0	120	85	62	120	85	60	242.00 H	
	28	18JUN96	195, 138	0	120	90	70	120	90	80	250.00 H	
	32	16JUL96	223, 166	0	125	85	74	120	80	90	248.00 H	
329.006.00259	SC	22APR96	-32, .	0	125	75	66	120	75	66	136.00	67.0
	BL	22MAY96	-2, .	0	120	70	78	110	70	110	132.00	
	1	30MAY96	7, .	0	110	70	66	118	84	78	131.00	
	2	06JUN96	14, .	0	125	70	78	120	75	68	132.00	
	3	13JUN96	21, .	0	120	70	60	113	70	94	130.00	
	4	20JUN96	28, .	0	110	70	72	110	75	80	128.50	
	5	27JUN96	35, .	0	115	75	60	115	70	76	128.50	
	6	03JUL96	41, .	0	120	80	66	115	80	70	128.00	
	7	10JUL96	48, .	0	120	70	68	115	70	90	128.50	
329.007.00141	8	17JUL96	55, .	0	115	70	60	118	70	60	130.00	
	SC	14SEP95	-7, .	0	128	78	76	124	80	80	181.00	66.0
	BL	21SEP95	1, .	0	128	78	81	126	80	87	183.00	
	1	28SEP95	8, .	0	128	70	80	122	76	84	184.00	
	2	05OCT95	15, .	0	128	78	72	126	80	68	184.00	
329.007.00144	3	12OCT95	22, .	0	126	82	80	122	84	76	185.00	
	SC	30NOV95	-7, -63	0	132	52	76	122	70	56	155.00	60.0
	BL	07DEC95	1, -56	0	120	70	72	110	70	80	158.00	
	1	14DEC95	8, -49	0	110	70	68	92	72	88	160.00	
	2	21DEC95	15, -42	0	136	64	76	112	56	88	162.00	
	3	28DEC95	22, -35	0	124	72	76	104	74	88	159.00	
	4	04JAN96	29, -28	0	128	70	80	124	76	76	160.00	
	5	11JAN96	36, -21	0	120	74	80	118	78	78	165.00	
	6	18JAN96	43, -14	0	126	70	68	120	74	72	168.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.007.00144	7	25JAN96	50, -7	0	128	82	72	126	84	80	165.00	
	8	01FEB96	57, 1	0	118	80	76	120	82	72	166.00	
329.007.00266	SC	29FEB96	-7, .	0	118	76	72	116	78	68	98.00	61.0
	BL	07MAR96	1, .	0	108	58	60	106	62	68	99.00	
	1	14MAR96	8, .	0	108	70	72	104	74	76	98.00	
	3	25MAR96	19, .	0	112	64	72	110	66	80	100.00	
	3	28MAR96	22, .	0	114	64	72	110	68	76	103.00	
	4	04APR96	29, .	0	110	74	76	108	76	80	103.00	
	5	11APR96	36, .	0	118	76	72	114	78	74	105.00	
	6	18APR96	43, .	0	112	64	68	110	70	72	103.00	
	8	29APR96	54, .	0	110	62	56	106	70	64	102.00	
	8	02MAY96	57, .	0	108	72	60	104	74	68	102.00	
329.007.00267	SC	29FEB96	-7, .	0	120	80	64	118	82	64	258.00	73.0
	BL	07MAR96	1, .	0	120	76	72	118	78	76	258.00	
	1	14MAR96	8, .	0	128	70	84	126	78	88	263.00	
	2	21MAR96	15, .	0	130	76	72	128	82	76	262.00	
	3	28MAR96	22, .	0	120	82	76	118	86	80	260.00	
	4	04APR96	29, .	0	132	86	80	130	88	88	257.00	
	5	11APR96	36, .	0	130	74	68	124	80	78	257.00	
	6	18APR96	43, .	0	120	78	68	118	82	72	257.00	
	7	25APR96	50, .	0	120	74	80	118	80	76	257.00	
	8	02MAY96	57, .	0	120	72	64	118	76	72	257.00	
329.007.00311	SC	26SEP96	-7, -67	0	102	75	69	123	72	68	118.00	65.0
	BL	03OCT96	1, -60	0	120	78	72	118	76	74	122.00	
	1	10OCT96	8, -53	0	120	78	74	118	74	78	120.00	
	2	17OCT96	15, -46	0	114	66	83	104	66	100	119.00	
	4	28OCT96	26, -35	0	120	74	72	122	76	68	121.00	
	4	31OCT96	29, -32	0	118	66	84	120	70	88	119.00	
	5	07NOV96	36, -25	0	116	72	72	118	78	76	123.00	
	6	14NOV96	43, -18	0	118	74	72	120	68	76	123.00	
	7	22NOV96	51, -10	0	110	74	60	118	76	64	123.00	
	8	02DEC96	61, 1	0	110	65	85	118	81	68	122.00	
	12	02JAN97	92, 32	0	123	57	73	114	62	81	127.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.007.00311	16	30JAN97	120, 60	0	118	59	66	122	66	73	127.00	
	24	13MAR97	162, 102	0	110	80	83	110	76	86	130.00	
	28	11APR97	191, 131	0	108	70	68	106	68	72	126.00	
329.008.00158	SC	06SEP95	-7, -69	0	110	92	76	110	92	96	156.00	62.0
	BL	13SEP95	1, -62	0	112	75	100	110	82	108		
	1	19SEP95	7, -56	0	118	82	96	105	90	100	158.30	
	2	27SEP95	15, -48	0	108	85	92	110	90	100	156.00	
	3	03OCT95	21, -42	0	112	75	76	110	82	92	158.00	
	4	10OCT95	28, -35	0	110	70	68	110	85	76	155.00	
	5	16OCT95	34, -29	0	112	80	84	120	85	104	156.00	
	6	24OCT95	42, -21	0	110	78	72	100	80	88	154.00	
	7	31OCT95	49, -14	0	110	84	72	104	90	96	154.00	
	8	14NOV95	63, 1	0	105	70	80	100	70	100	153.00	
	16	26DEC95	105, 43	0	110	80	72	110	85	100	156.00	
	20	23JAN96	133, 71#	0	108	78	68	110	80	80	155.00	
329.008.00162	SC	26OCT95	-6, -71	0	102	70	66	.	.	.	132.00	74.0
	1	10NOV95	10, -56	0	100	68	88	96	70	100		
	3	20NOV95	20, -46	0	100	70	76	110	75	84	134.00	
	4	29NOV95	29, -37	0	100	60	80	100	68	88	133.00	
	5	07DEC95	37, -29	0	100	58	76	100	60	88	132.00	
	6	14DEC95	44, -22	0	103	75	96	100	70	100	130.00	
	7	20DEC95	50, -16	0	90	58	56	95	70	76	133.00	
	8	27DEC95	57, -9	0	105	65	72	105	70	88	131.00	
	8	05JAN96	66, 1	0	100	55	68	90	60	88	137.00	
	16	09FEB96	101, 36	0	100	70	80	80	50	100	133.00	
	20	08MAR96	129, 64	0	90	62	68	90	65	84	136.00	
	24	01MAY96	183, 118	0	90	60	84	88	60	80	132.00	
	32	05JUN96	218, 153	0	110	55	76	90	60	88	132.00	
	32	02JUL96	245, 180	0	128	70	68	138	79	78	133.00	
329.008.00191	SC	12JAN96	-20, -81	0	104	74	67	.	.	.	119.00	60.0
	BL	01FEB96	1, -61	0	108	68	72	96	64	78	117.00	
	2	12FEB96	12, -50	0	108	72	78	96	66	86	119.00	
	3	20FEB96	20, -42	0	102	68	84	92	58	104	121.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.008.00191	4	27FEB96	27, -35	0	98	64	82	88	58	90	119.00	
	5	05MAR96	34, -28	0	102	68	72	98	58	78	119.00	
	6	12MAR96	41, -21	0	102	64	72	99	56	90	119.00	
	7	18MAR96	47, -15	0	102	70	90	94	64	94	119.00	
	8	26MAR96	55, -7	0	102	70	78	98	68	90	120.00	
	8	02APR96	62, 1	0	102	62	78	94	64	90	119.00	
	12	01MAY96	91, 30	0	94	60	84	90	60	90	121.00	
	16	05JUN96	126, 65	0	96	64	72	89	60	84	120.00	
329.009.00128	SC	05APR95	-6, .	0	121	65	91	84	74	101	114.88	62.2
	BL	11APR95	1, .	0	115	61	98	122	54	114	111.60	
	1	18APR95	8, .	0	123	66	98	107	68	96	111.50	
	2	25APR95	15, .	0	115	53	85	114	68	90	112.50	
329.009.00129	SC	22MAR95	-20, .	0	115	42	68	108	50	79	187.80	69.3
	BL	11APR95	1, .	0	131	53	64	130	49	68	189.50	
	1	18APR95	8, .	0	131	53	58	137	89	64	188.70	
	2	25APR95	15, .	0	115	54	64	123	57	64	186.70	
	3	02MAY95	22, .	0	114	57	67	123	60	69	189.40	
	4	09MAY95	29, .	0	106	40	59	108	56	75	187.50	
	5	16MAY95	36, .	0	123	49	57	115	49	65	190.07	
329.009.00135	SC	25SEP95	-7, .	0	113	74	89	122	60	100	133.60	71.0
	BL	02OCT95	1, .	0	113	63	78	.	.	.	131.60	
	1	09OCT95	8, .	0	118	56	83	124	59	91	132.70	
	2	16OCT95	15, .	0	119	60	80	121	70	88	131.70	
	3	23OCT95	22, .	0	123	56	86	122	56	88	133.90	
	4	30OCT95	29, .	0	122	64	74	122	56	80	132.40	
	5	06NOV95	36, .	0	107	82	86	123	68	105	133.50	
329.009.00136	SC	26SEP95	-7, .	0	131	56	109	105	72	115	287.60	66.5
	BL	03OCT95	1, .	0	119	76	102	124	66	115	299.60	
	1	10OCT95	8, .	0	132	57	81	84 L	63	114	296.40	
	2	17OCT95	15, .	0	124	48 L	90	102	73	117	288.90	
	3	24OCT95	22, .	0	101	50	86	114	56	115	292.80	
	4	03NOV95	32, .	0	109	54	54	117	67	86		

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00136	5	07NOV95	36, .	0	133	80	66	131	50	103	294.00	
	6	14NOV95	43, .	0	124	60	84	109	55	111	287.40	
	7	21NOV95	50, .	0	116	62	74	110	82	100	293.80	
	8	28NOV95	57, .	0	125	57	86	105	49	96	296.00	
329.009.00169	SC	25OCT95	-6, -71	0	110	57	70	110	69	67	80.90	56.0
	BL	31OCT95	1, -65	0	108	52	94	111	57	98	80.20	
	1	07NOV95	8, -58	0	92	42	74	99	45	90	80.40	
	2	14NOV95	15, -51	0	113	63	86	110	56	106	81.90	
	3	21NOV95	22, -44	0	110	53	80	106	53	79	83.40	
	4	28NOV95	29, -37	0	106	56	102	107	57	106	83.00	
	5	05DEC95	36, -30	0	119	54	74	112	61	75	83.30	
	6	12DEC95	43, -23	0	99	45	86	98	46	97	83.10	
	7	19DEC95	50, -16	0	108	57	84	99	57	95	84.10	
	8	27DEC95	58, -8	0	95	53	76	98	52	93	82.50	
	12	23JAN96	85, 20	0	122	68	108	107	44	111	86.20 H	
329.009.00174	SC	14NOV95	-7, -64	0	115	60	64	123	85	98	219.20	65.5
	BL	21NOV95	1, -57	0	132	74	91	124	66	105	219.60	
	1	28NOV95	8, -50	0	125	77	101	135	72	111	222.40	
	2	05DEC95	15, -43	0	145	89	84	158	84	105	218.90	
	3	12DEC95	22, -36	0	135	66	81	136	71	100	223.00	
	4	19DEC95	29, -29	0	129	79	106	137	67	114	222.40	
	5	27DEC95	37, -21	0	145	88	105	138	72	126	224.00	
	6	02JAN96	43, -15	0	123	68	80	147	78	86	224.10	
	7	09JAN96	50, -8	0	136	83	104	150	85	109	222.40	
	8	17JAN96	58, 1	0	138	83	108	149	76	104	220.40	
	12	31JAN96	72, 15	0	114	68	95	122	70	105	221.70	
329.009.00197	SC	20DEC95	-9, -63	0	118	54	88	110	59	115	99.40	58.0
	BL	29DEC95	1, -54	0	106	49	86	124	60	95	97.80	
	1	02JAN96	5, -50	0	92	40	72	101	55	86	98.60	
	1	08JAN96	11, -44	0	102	50	79	107	50	96	100.00	
	3	16JAN96	19, -36	0	100	38	71	97	49	81	99.60	
	4	23JAN96	26, -29	0	94	43	81	100	46	83	101.60	
	5	30JAN96	33, -22	0	115	68	81	116	49	105	100.30	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00197	6	06FEB96	40, -15	0	82	47	96	86 L	53	100	99.70	
	7	13FEB96	47, -8	0	89	40	75	90	52	84	98.80	
	8	20FEB96	54, -1	0	90	47	91	98	52	120	99.10	
	12	19MAR96	82, 28	0	100	49	83	107	42	95	100.00	
	16	23APR96	117, 63	0	99	53	71	99	57	94	99.60	
	20	21MAY96	145, 91	0	97	63	76	83 L	61	90	102.30	
	24	25JUN96	180, 126	0	114	61	98	112	63	112	106.94 H	
	28	16JUL96	201, 147	0	106	53	93	105	52	100	107.40 H	
	32	20AUG96	236, 182	0	103	44	89	98	62	84	109.20 H	
329.009.00198	SC	19DEC95	-14, .	0	116	66	86	123	68	94	103.00	61.5
	BL	02JAN96	1, .	0	112	63	91	115	66	95	103.90	
	1	08JAN96	7, .	0	113	67	91	108	65	93	102.80	
	2	16JAN96	15, .	0	107	57	81	105	59	88	105.60	
	3	23JAN96	22, .	0	108	65	80	115	64	81	105.90	
	4	30JAN96	29, .	0	131	65	94	124	64	115	104.50	
	5	06FEB96	36, .	0	97	50	86	106	48	105	104.60	
	6	13FEB96	43, .	0	132	70	91	126	75	90	105.10	
	7	20FEB96	50, .	0	99	52	76	99	53	97	105.00	
	8	27FEB96	57, .	0	106	59	86	106	57	88	105.70	
329.009.00200	SC	17JAN96	-6, .	0	115	76	70	121	79	74	118.20	62.0
	BL	23JAN96	1, .	0	122	72	81	.	.	.	121.40	
	1	02FEB96	11, .	0	110	60	79	114	59	78	119.30	
	2	06FEB96	15, .	0	110	80	91	123	69	106	123.00	
	3	13FEB96	22, .	0	100	62	105	122	60	101	120.20	
	4	20FEB96	29, .	0	122	83	84	107	69	105	119.90	
	5	28FEB96	37, .	0	107	56	86	112	77	95	120.20	
329.009.00202	SC	14FEB96	-6, .	0	101	65	83	107	71	93	103.80	62.0
	BL	20FEB96	1, .	0	114	75	88	102	59	98	105.30	
	1	27FEB96	8, .	0	100	50	86	106	60	90	103.70	
	2	08MAR96	18, .	0	107	56	86	113	66	102	104.80	
	4	19MAR96	29, .	0	110	71	79	122	75	84	105.50	
	5	26MAR96	36, .	0	130	78	108	135	67	100	103.50	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00237	SC	04NOV96	-7, .	0	124	58	66	114	64	75	149.50	68.0
	BL	11NOV96	1, .	0	113	63	96	111	51	103	146.60	
	1	18NOV96	8, .	0	115	57	84	107	64	98	148.80	
329.009.00238	SC	28OCT96	-15, .	0	115	60	83	106	55	100	112.20	66.5
	BL	12NOV96	1, .	0	107	53	88	106	52	97	113.60	
	1	19NOV96	8, .	0	106	48	74	112	62	95	114.80	
	2	26NOV96	15, .	0	108	47	74	99	57	86	115.00	
	3	03DEC96	22, .	0	99	42	78	105	47	88	115.80	
	4	10DEC96	29, .	0	107	49	72	105	54	78	114.50	
	5	17DEC96	36, .	0	112	51	82	115	59	100	112.80	
	6	23DEC96	42, .	0	97	45	76	108	47	88	114.40	
	7	31DEC96	50, .	0	111	54	77	109	58	86	115.00	
329.009.00276	SC	07JAN97	57, .	0	104	56	72	110	52	87	112.50	66.6
	BL	17JAN97	-4, .	0	123	39	77	116	64	101	127.40	
	1	21JAN97	1, .	0	115	59	85	.	.	.	128.60	
	2	28JAN97	8, .	0	116	58	78	109	54	90	125.10	
	3	04FEB97	15, .	0	115	56	85	114	64	93	127.00	
	4	11FEB97	22, .	0	112	43	73	119	49	100	126.50	
	5	18FEB97	29, .	0	122	64	91	115	59	97	129.00	
	6	25FEB97	36, .	0	123	61	80	121	49	95	128.10	
	7	04MAR97	43, .	0	121	62	91	107	70	111	128.10	
329.009.00302	SC	13MAR97	52, .	0	125	67	82	112	68	101	123.70	68.0
	BL	18MAR97	57, .	0	105	49	76	107	57	98	121.50	
	1	20MAR96	-7, .	0	145	51	56	147	50	77	157.10	
	2	27MAR96	1, .	0	138	59	85	130	44	85	158.20	
329.009.00306	SC	03APR96	8, .	0	122	50	64	123	43	84	157.10	64.0
	BL	10APR96	15, .	0	123	50	66	115	50	60	158.60	
	1	03JUN96	-8, .	0	106	60	57	99	53	89	115.40	
	2	11JUN96	1, .	0	115	49	70	117	70	98	120.30	
	3	18JUN96	8, .	0	94	53	99	98	58	96	118.50	
	SC	25JUN96	15, .	0	140	90	90	131	76	87	116.20	
	BL	02JUL96	22, .	0	117	59	79	118	72	93	118.40	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.009.00306	4	09JUL96	29, .	0	114	66	78	92	60	100	117.60	
	5	16JUL96	36, .	0	104	55	85	114	58	94	117.20	
	6	23JUL96	43, .	0	110	55	79	107	67	98	118.60	
	7	30JUL96	50, .	0	98	45	76	93	58	95	119.40	
	8	06AUG96	57, .	0	105	40	91	94	44 L	96	118.70	
329.009.00312	SC	30OCT96	-5, .	0	129	66	89	119	83	102	152.40	58.0
	BL	04NOV96	1, .	0	103	54	.	109	56	.	151.70	
	2	15NOV96	12, .	0	106	67	81	122	68	87	154.60	
	2	18NOV96	15, .	0	106	78	100	112	50	106	153.30	
	4	02DEC96	29, .	0	129	61	94	127	61	97	157.30	
	5	09DEC96	36, .	0	121	57	96	120	62	103	156.70	
	6	16DEC96	43, .	0	126	65	83	117	70	97	156.80	
	8	27DEC96	54, .	0	111	61	82	114	68	68	160.00	
	8	30DEC96	57, .	0	126	66	91	121	73	97	154.60	
	8	06JAN97	64, .	0	122	64	88	128	46	102	159.40	
329.009.00327	SC	09SEP96	-7, .	0	111	56	93	109	49	101	90.80	60.1
	BL	16SEP96	1, .	0	88	50	87	94	47	93	94.40	
	1	23SEP96	8, .	0	88	45	93	96	53	106	89.90	
	2	30SEP96	15, .	0	98	43	93	109	68	106	90.70	
	3	07OCT96	22, .	0	96	46	91	92	66	112	90.40	
	4	14OCT96	29, .	0	118	53	84	118	57	94	92.10	
	5	21OCT96	36, .	0	99	50	79	104	55	89	91.00	
329.009.00330	SC	15OCT96	-6, .	0	117	79	68	106	88	70	93.50	59.0
	BL	21OCT96	1, .	0	106	68	65	120	71	80	94.00	
	1	28OCT96	8, .	0	115	72	68	106	71	73	96.80	
	2	04NOV96	15, .	0	112	66	62	106	72	72	96.70	
329.010.00183	SC	21NOV95	-12, .	0	112	78	68	105	80	80	150.20	71.0
	BL	28NOV95	-5, .	0	100	60	65	100	50	72	155.50	
	1	05DEC95	3, .	0	125	75	68	110	70	82	154.00	
	1	12DEC95	10, .	0	115	70	72	98	65	92	153.50	
	2	19DEC95	17, .	0	122	78	68	108	68	92	158.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.010.00263	SC	24JUL96	-16, .	0	125	85	80	125	85	96	224.00	72.0
	BL	09AUG96	1, .	0	130	82	68	125	78	74	230.00	
	1	14AUG96	6, .	0	130	76	70	125	80	76	235.00	
	2	21AUG96	13, .	0	126	80	80	118	74	88	232.20	
	3	28AUG96	20, .	0	124	76	84	118	70	90	230.50	
	4	04SEP96	27, .	0	126	84	78	116	76	90	233.20	
	5	11SEP96	34, .	0	122	78	78	116	74	92	235.00	
	6	18SEP96	41, .	0	130	86	92	118	78	96	236.50	
	7	25SEP96	48, .	0	118	80	88	112	74	92	233.50	
	8	09OCT96	62, .	0	118	76	100	108	70	108	237.50	
329.010.00277	SC	23FEB96	-7, -63	0	130	90	88	115	70	92	203.00	64.0
	BL	01MAR96	1, -56	0	130	80	96	110	70	108	205.80	
	1	08MAR96	8, -49	0	130	90	96	125	75	110	206.50	
	3	22MAR96	22, -35	0	115	60	72	110	68	80	204.50	
	4	29MAR96	29, -28	0	122	88	80	112	80	82	201.50	
	6	15APR96	46, -11	0	105	90	87	134	78	87		
	7	19APR96	50, -7	0	130	70	80	130	85	90	198.00	
	8	26APR96	57, 1	0	129	78	77	136	78	92	198.00	
	12	24MAY96	85, 29	0	130	90	72	118	80	90	204.00	
	16	21JUN96	113, 57	0	132	90	90	135	96	95	208.50	
	24	07AUG96	160, 104#	0	125	75	84	118	70	96	219.00	
329.010.00282	SC	19JUL96	-7, .	0	115	68	70	110	65	74	158.00	66.0
	BL	26JUL96	1, .	0	118	78	78	100	72	92	157.80	
	1	02AUG96	8, .	0	118	70	62	110	68	74	159.00	
	2	09AUG96	15, .	0	118	74	64	110	70	78	161.00	
	3	16AUG96	22, .	0	122	74	64	114	68	76	162.00	
	4	26AUG96	32, .	0	116	74	70	112	70	86	160.20	
	6	03SEP96	40, .	0	118	74	68	112	68	76	161.00	
	7	13SEP96	50, .	0	114	78	68	110	70	76	161.00	
	8	19SEP96	56, .	0	116	76	64	120	80	64	160.50	
	8	27SEP96	64, .	0	118	72	72	110	68	78	161.00	
329.011.00164	SC	15DEC95	-7, .	0	130	90	60	130	80	68	136.50	71.0
	1	28DEC95	7, .	0	120	80	60	118	80	68	134.20	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.011.00164	2	04JAN96	14, .	0	120	80	60	118	78	68	136.70	
	3	11JAN96	21, .	0	118	70	64	118	70	64	137.20	
	4	18JAN96	28, .	0	118	70	64	118	70	68	138.00	
	5	25JAN96	35, .	0	120	80	58	118	78	64	140.50	
329.011.00210	SC	13SEP96	-15, -81	0	108	72	84	110	70	80	113.50	64.2
	BL	27SEP96	-1, -67	0	110	70	80	112	70	84	113.50	
	1	03OCT96	6, -61	0	110	60	70	110	60	70	114.20	
	2	09OCT96	12, -55	0	110	70	80	108	70	88	115.00	
	3	17OCT96	20, -47	0	100	70	72	102	70	76	112.00	
	4	24OCT96	27, -40	0	100	72	76	102	70	80	114.00	
	5	04NOV96	38, -29	0	100	70	80	100	74	86	113.00	
	6	12NOV96	46, -21	0	110	70	84	112	74	86	112.00	
	8	22NOV96	56, -11	0	102	74	80	106	76	86	113.50	
329.011.00285	8	02DEC96	66, -1	0	104	74	80	106	74	80	111.50	
	SC	08MAY96	-10, .	0	110	70	70	100	70	80	184.70	69.5
	BL	17MAY96	-1, .	0	110	70	70	106	70	80	184.70	
	1	27MAY96	10, .	0	110	60	80	110	60	80	185.20	
	2	03JUN96	17, .	0	108	70	80	108	70	84	185.20	
	3	10JUN96	24, .	0	108	68	80	110	70	80	185.00	
	5	21JUN96	35, .	0	104	72	84	110	76	88	184.50	
	6	28JUN96	42, .	0	110	60	80	110	60	84	182.70	
	7	08JUL96	52, .	0	120	60	80	120	60	84	185.50	
329.011.00287	8	18JUL96	62, .	0	118	60	80	114	64	84	184.50	
	8	24JUL96	68, .	0	120	70	88	120	74	88	186.50	
	SC	25JUN96	-8, .	0	104	70	60	104	72	64	121.70	61.0
	BL	02JUL96	-1, .	0	106	70	64	106	74	66	121.70	
	1	09JUL96	7, .	0	110	70	70	110	74	72	124.00	
	2	17JUL96	15, .	0	110	70	76	110	70	80	120.50	
	3	23JUL96	21, .	0	110	70	80	112	70	84	119.20	
	4	30JUL96	28, .	0	110	70	80	112	70	84	120.00	
	5	06AUG96	35, .	0	110	70	80	112	72	84	120.00	
329.011.00287	6	13AUG96	42, .	0	110	70	80	110	70	84	121.50	
	7	20AUG96	49, .	0	106	70	80	110	78	84	119.00	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.011.00287	8	27AUG96	56, .	0	110	70	80	108	72	84	120.20	
329.012.00027	SC	23NOV95	-13, .	0	110	64	68	104	72	80	154.13	71.7
	BL	06DEC95	1, .	0	110	76	88	120	78	92	158.76	
	1	12DEC95	7, .	0	126	72	96	120	86	70	158.32	
	2	19DEC95	14, .	0	110	70	60	110	80	62	156.33	
	3	27DEC95	22, .	0	100	62	72	110	70	100	159.64	
	4	02JAN96	28, .	0	122	66	60	110	52	64	159.64	
329.012.00217	SC	14MAY96	-7, .	0	92	70	76	100	70	80	110.03	61.4
	BL	21MAY96	1, .	0	100	66	60	96	64	84	108.93	
	1	31MAY96	11, .	0	110	70	80	108	74	70	110.69	
	2	07JUN96	18, .	0	110	70	74	100	76	80	111.35	
	3	14JUN96	25, .	0	120	80	70	110	80	76	110.03	
	4	19JUN96	30, .	0	100	60	64	100	70	72	108.49	
329.012.00218	SC	04JUN96	-12, -70	0	100	68	64	104	70	88	118.63	65.7
	BL	14JUN96	-2, -60	0	110	80	80	100	60	100	118.41	
	1	21JUN96	6, -53	0	120	80	80	100	70	88	119.95	
	2	28JUN96	13, -46	0	118	70	80	112	76	92	122.38	
	3	05JUL96	20, -39	0	110	70	76	118	74	80	121.05	
	4	12JUL96	27, -32	0	100	70	72	100	72	80	119.29	
	5	19JUL96	34, -25	0	110	70	72	120	80	72	119.73	
	6	29JUL96	44, -15	0	122	80	76	116	72	82	119.95	
	7	06AUG96	52, -7	0	112	70	80	110	70	76	121.05	
	8	13AUG96	59, 1	0	110	80	72	110	70	76	121.72	
	12	18SEP96	95, 37	0	110	70	72	110	80	80	124.36	
329.012.00224	SC	30AUG96	-17, -83	0	110	80	70	118	76	74	114.66	63.8
	BL	16SEP96	1, -66	0	130	84	86	126	80	82	113.78	
	1	24SEP96	9, -58	0	100	70	72	100	70	100	113.56	
	2	03OCT96	18, -49	0	120	72	80	108	60	90	114.88	
	3	10OCT96	25, -42	0	108	64	68	100	60	84	115.32	
	4	17OCT96	32, -35	0	112	68	74	110	70	86	116.42	
	6	25OCT96	40, -27	0	100	80	80	100	70	82	117.31	
	7	04NOV96	50, -17	0	110	60	72	112	80	72	115.98	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

PAROXETINE - PROTOCOL 329

Appendix E.1

Listing of Vital Sign Values by Treatment Group and Patient
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Week	Visit Date	Relative Days *	Dose (mg)	Sitting Systolic (mmHg)	Sitting Diastolic (mmHg)	Pulse (bpm)	Standing Systolic (mmHg)	Standing Diastolic (mmHg)	Pulse (bpm)	Weight (lbs)	Height (in)
329.012.00224	8	12NOV96	58, -9	0	100	70	68	100	70	88	116.42	
	8	20NOV96	66, -1	0	117	78	80	120	76	100	116.42	
	12	19DEC96	95, 29	0	120	80	80	116	78	84	115.10	
	16	20JAN97	127, 61	0	110	70	88	120	70	92	119.07	
	24	18FEB97	156, 90	0	108	70	78	100	70	86	119.95	
329.012.00225	SC	19NOV96	-7, -71	0	130	78	74	124	76	72	133.40	68.1
	BL	26NOV96	1, -64	0	126	60	72	118	70	92	132.30	
	1	03DEC96	8, -57	0	120	80	80	118	80	90	133.40	
	2	10DEC96	15, -50	0	120	68	64	118	72	68	131.20	
	3	20DEC96	25, -40	0	117	68	72	120	68	80	132.30	
	4	27DEC96	32, -33	0	120	80	86	117	78	90	134.51	
	6	06JAN97	42, -23	0	110	60	80	110	70	76	133.40	
	7	13JAN97	49, -16	0	112	70	76	120	70	92	133.40	
	8	21JAN97	57, -8	0	110	70	64	120	70	72	136.71	
	8	29JAN97	65, 1	0	120	70	64	112	76	96	134.51	
	12	24FEB97	91, 27	0	110	70	68	110	68	78	135.61	
	16	20MAR97	115, 51	0	120	70	82	110	60	88	132.30	
	20	21APR97	147, 83	0	110	64	87	105	62	120	135.61	
	24	26MAY97	182, 118	0	106	64	72	114	64	98	137.37	
	32	30JUN97	217, 153	0	100	70	80	94	70	100	134.51	
	32	30JUL97	247, 183	0	100	62	60	110	64	76	134.95	

* days relative to start of acute phase, days relative to start of continuation phase

More than 14 days after day of last dose.

Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;

Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.2

Listing of Clinically Significant Abnormal Vital Signs by Treatment Group and Parameter
Acute Phase
Intent-to-Treat Population

Treatment	Parameter	Flag	Patient ID	Relative Days *	Value	Baseline Value
PAROXETINE	Diastolic B.P. - Sitting (mmHg)	L	329.005.00299	45	48.00	80.00
	Diastolic B.P. - Standing (mmHg)	L	329.005.00299	45	42.00	80.00
	Pulse - Standing (bpm)	H	329.001.00068	50	124.00	80.00
		L	329.003.00292	15	45.00	80.00
	Systolic B.P. - Standing (mmHg)	L	329.005.00300	43	58.00	88.00
			329.009.00304	43	68.00	121.00
			329.009.00324	29	77.00	131.00
	Weight (lbs)	H	329.005.00004	53	152.90	141.50
			329.009.00201	57	163.80	150.80
		L	329.004.00015	7	107.16	116.87
				14	106.06	116.87
				21	104.96	116.87
				28	102.53	116.87
				35	102.97	116.87
				42	105.18	116.87
				49	105.18	116.87
				58	105.84	116.87
			329.010.00182	32	130.00	140.50
IMIPRAMINE	Diastolic B.P. - Standing (mmHg)	L	329.009.00172	45	47.00	73.00
				58	33.00	73.00
	Pulse - Sitting (bpm)	H	329.002.00056	22	132.00	100.00
			329.006.00040	14	132.00	72.00
			329.009.00172	8	129.00	84.00
			329.009.00264	46	137.00	102.00
	Pulse - Standing (bpm)	H	329.001.00061	14	124.00	72.00
			329.001.00066	14	124.00	80.00
			329.002.00056	29	140.00	102.00
			329.002.00057	15	140.00	89.00
			329.002.00322	57	140.00	89.00
				8	130.00	86.00
			329.003.00073	36	132.00	86.00
				20	132.00	87.00
				35	130.00	87.00

* Days Relative to Start of Acute Phase
Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;
Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.2

Listing of Clinically Significant Abnormal Vital Signs by Treatment Group and Parameter
 Acute Phase
 Intent-to-Treat Population

Treatment	Parameter	Flag	Patient ID	Relative Days *	Value	Baseline Value
IMIPRAMINE	Pulse - Standing (bpm)	H	329.003.00073	42	128.00	87.00
				49	140.00	87.00
			329.006.00040	14	140.00	84.00
			329.008.00159	49	122.00	80.00
			329.008.00273	8	136.00	102.00
			329.009.00195	19	129.00	77.00
				25	125.00	77.00
			329.009.00236	8	121.00	86.00
				22	133.00	86.00
			329.009.00239	35	121.00	74.00
				49	131.00	74.00
			329.009.00262	29	129.00	84.00
				50	121.00	84.00
			329.009.00264	11	140.00	82.00
				18	133.00	82.00
				25	145.00	82.00
				32	137.00	82.00
				41	150.00	82.00
				46	140.00	82.00
				53	148.00	82.00
			329.009.00301	36	126.00	75.00
			329.009.00305	29	132.00	89.00
				50	135.00	89.00
				58	140.00	89.00
			329.009.00325	28	131.00	97.00
	Systolic B.P. - Standing (mmHg)	L	329.002.00322	22	88.00	120.00
			329.009.00172	58	85.00	124.00
	Weight (lbs)	L	329.003.00073	49	128.11	140.00
			329.008.00273	46	140.00	153.00
				56	138.00	153.00
				64	140.00	153.00
			329.009.00262	50	134.50	145.90
PLACEBO	Diastolic B.P. - Sitting (mmHg)	L	329.003.00080	33	48.00	70.00
			329.009.00136	15	48.00	76.00
	Diastolic B.P. - Standing (mmHg)	L	329.009.00306	57	44.00	70.00

* Days Relative to Start of Acute Phase
 Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;
 Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.

Appendix E.2

Listing of Clinically Significant Abnormal Vital Signs by Treatment Group and Parameter
 Acute Phase
 Intent-to-Treat Population

Treatment	Parameter	Flag	Patient ID	Relative Days *	Value	Baseline Value
PLACEBO	Pulse - Standing (bpm)	H	329.005.00005	8	136.00	88.00
	Systolic B.P. - Standing (mmHg)	L	329.002.00060	36	70.00	112.00
			329.009.00136	8	84.00	124.00
			329.009.00197	40	86.00	124.00
	Weight (lbs)	H	329.002.00107	41	179.00	167.00
				51	179.50	167.00
			329.005.00114	22	155.89	145.00
				29	157.00	145.00
				38	157.00	145.00
		L	329.005.00120	51	164.71	152.15
				58	166.04	152.15
			329.002.00323	15	109.00	118.00

* Days Relative to Start of Acute Phase
 Vital Sign Abnormality Criteria: Systolic: L = <90,dec>=30 H = >180,inc>=40; Diastolic: L = <50,dec>=20 H = >105,inc>=30;
 Pulse: L = <50,dec>=30 H = >120,inc>=30; Weight: L = dec>=7% H = inc>=7%.